amiodarone has been researched along with Thyrotoxicosis in 289 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
Thyrotoxicosis: A hypermetabolic syndrome caused by excess THYROID HORMONES which may come from endogenous or exogenous sources. The endogenous source of hormone may be thyroid HYPERPLASIA; THYROID NEOPLASMS; or hormone-producing extrathyroidal tissue. Thyrotoxicosis is characterized by NERVOUSNESS; TACHYCARDIA; FATIGUE; WEIGHT LOSS; heat intolerance; and excessive SWEATING.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Type 2 amiodarone-induced thyrotoxicosis (AIT2) is a form of drug-induced destructive thyroiditis, usually treated with oral glucocorticoids (oGCs)." | 9.34 | Effect of high-dose intravenous glucocorticoid therapy on serum thyroid hormone concentrations in type 2 amiodarone-induced thyrotoxicosis: an exploratory study. ( Bartalena, L; Bogazzi, F; Cappellani, D; Manetti, L; Martino, E; Urbani, C, 2020) |
| "Amiodarone-induced thyrotoxicosis (AIT) may develop long after amiodarone withdrawal." | 9.17 | Amiodarone-induced thyrotoxicosis late after amiodarone withdrawal. ( Hachiya, H; Hirao, K; Isobe, M; Kawabata, M; Nakamura, T; Sasano, T; Sugiyama, K; Tanaka, Y; Yagishita, A, 2013) |
| "Amiodarone-induced thyrotoxicosis (AIT) is a recognized complication of amiodarone treatment with limited management options." | 9.17 | Body mass index and the development of amiodarone-induced thyrotoxicosis in adults with congenital heart disease--a cohort study. ( Ammash, NM; Bahn, RS; Brennan, MD; Nannenga, MR; Stan, MN; Thapa, P; Warnes, CA, 2013) |
| "Amiodarone-induced thyrotoxicosis (AIT) type 2 is self-limiting in nature, but most physicians are reluctant to continue amiodarone." | 9.16 | Treatment of amiodarone-induced thyrotoxicosis type 2: a randomized clinical trial. ( Dullaart, RP; Endert, E; Eskes, SA; Fliers, E; Geskus, RB; Links, TP; Wiersinga, WM, 2012) |
| "Type 2 amiodarone-induced thyrotoxicosis (AIT) is a destructive thyroiditis usually responsive to glucocorticoids." | 9.15 | Continuation of amiodarone delays restoration of euthyroidism in patients with type 2 amiodarone-induced thyrotoxicosis treated with prednisone: a pilot study. ( Bartalena, L; Bogazzi, F; Brogioni, S; Martino, E; Rossi, G; Tomisti, L, 2011) |
| "Amiodarone-induced thyrotoxicosis (AIT) is caused by excessive hormone synthesis and release (AIT I) or a destructive process (AIT II)." | 9.13 | The usefulness of 99mTc-sestaMIBI thyroid scan in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. ( Boi, F; Cocco, MC; Loy, M; Mariotti, S; Piga, M; Serra, A, 2008) |
| "To determine the incidence and predictability of amiodarone-induced thyrotoxicosis (AIT) and hypothyroidism (AIH) in patients with cardiomyopathy." | 9.13 | Incidence and predictability of amiodarone-induced thyrotoxicosis and hypothyroidism. ( Hofmann, A; Holzmannhofer, J; Nawara, C; Ofluoglu, S; Pirich, C; Strohmer, B, 2008) |
| "Amiodarone-induced thyrotoxicosis (AIT) are not uncommon endocrinopathies." | 9.12 | Amiodarone-induced thyrotoxicosis. ( Bricaire, L; Groussin, L; Schubert, L, 2021) |
| "Amiodarone-induced thyrotoxicosis (AIT) resulting from destructive thyroiditis (type 2) is commonly treated with glucocorticoids, but time needed to restore euthyroidism may be unacceptable for patients with underlying cardiac disorders." | 9.12 | Glucocorticoid response in amiodarone-induced thyrotoxicosis resulting from destructive thyroiditis is predicted by thyroid volume and serum free thyroid hormone concentrations. ( Aghini-Lombardi, F; Bartalena, L; Bogazzi, F; Dell'Unto, E; Martino, E; Rossi, G; Tanda, ML; Tomisti, L, 2007) |
| "Amiodarone-induced thyrotoxicosis (AIT) may develop either in apparently normal glands (type II AIT) or in the presence of thyroid abnormalities (type I AIT)." | 9.10 | Preparation with iopanoic acid rapidly controls thyrotoxicosis in patients with amiodarone-induced thyrotoxicosis before thyroidectomy. ( Aghini-Lombardi, F; Bartalena, L; Berti, P; Bogazzi, F; Braverman, LE; Brogioni, S; Cosci, C; Martino, E; Materazzi, G; Miccoli, P; Pinchera, A, 2002) |
| "Amiodarone-induced thyrotoxicosis (AIT) is a complex therapeutic challenge." | 9.10 | A stepwise approach to the treatment of amiodarone-induced thyrotoxicosis. ( Başkal, N; Erdogan, G; Erdogan, MF; Güleç, S; Tutar, E, 2003) |
| "Amiodarone-induced thyrotoxicosis (AIT) may occur either in the presence of underlying thyroid disease (type I AIT) or in apparently normal thyroid glands (type II AIT)." | 9.10 | Treatment of type II amiodarone-induced thyrotoxicosis by either iopanoic acid or glucocorticoids: a prospective, randomized study. ( Aghini-Lombardi, F; Bartalena, L; Bogazzi, F; Braverman, LE; Brogioni, S; Cosci, C; Dell'Unto, E; Grasso, L; Martino, E; Pinchera, A; Rossi, G, 2003) |
| "Amiodarone-induced thyrotoxicosis (AMT) is a life-threatening condition, the appropriate management of which is achieved by identifying its different subtypes." | 9.10 | Thyroid color flow doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis. ( Aghini-Lombardi, F; Bartalena, L; Bogazzi, F; Braverman, LE; Brogioni, S; Ceccarelli, C; Cosci, C; Dell'Unto, E; Martino, E; Pinchera, A, 2003) |
| "Amiodarone, a benzofuranic iodine-rich pan-anti-arrhythmic drug, induces amiodarone-induced thyrotoxicosis (AIT) in 7-15% of patients." | 9.01 | Issues in amiodarone-induced thyrotoxicosis: Update and review of the literature. ( Batisse-Lignier, M; Benichou, T; Dallel, S; Desbiez, F; Maqdasy, S; Montanier, N; Roche, B; Tauveron, I, 2019) |
| "We present three patients treated with amiodarone for atrial fibrillation who developed AIT at least 36 months after beginning the treatment." | 8.87 | [Response to adjuvant therapy with potassium perchlorate in amiodarone-induced thyrotoxicosis: observations on three cases]. ( Arias, N; Boix, E; González, VL; Moreno-Pérez, Ó; Picó, AM; Revert, P; Sánchez-Ortiga, R; Serrano, J, 2011) |
| "We present a patient with a rare combination of amiodarone-induced thyrotoxicosis and Eisenmenger's syndrome." | 8.85 | Surgical management of amiodarone-induced thyrotoxicosis in a patient with Eisenmenger's syndrome: literature review and case report. ( Ahmad, N; Jani, P; Pratap, R; Qayyum, A, 2009) |
| "Amiodarone-induced thyrotoxicosis (AIT) develops in 3% of amiodarone-treated patients in North America." | 8.85 | Amiodarone-induced thyrotoxicosis: a review. ( Houlden, RL; Tsang, W, 2009) |
| "Surgical treatment of amiodarone-associated thyrotoxicosis (AAT) is effective although fewer than 100 cases have been reported world wide." | 8.83 | Total thyroidectomy for amiodarone-associated thyrotoxicosis in patients with severe cardiac disease. ( Gough, IR; Gough, J, 2006) |
| "Amiodarone causes thyrotoxicosis in 3% of US patients who use it." | 8.82 | Amiodarone induced thyrotoxicosis: diagnostic and therapeutic strategies. ( Cabral, JM; Cardenas, GA; Leslie, CA, 2003) |
| "We report a case of amiodarone-induced thyrotoxicosis, and a broad review of the literature." | 8.82 | [Amiodarone-induced thyrotoxicosis: case report and review of the literature]. ( Bianconcini, M; Giannini, AL, 2003) |
| "Amiodarone-induced thyrotoxicosis (AIT) is a well-known complication of amiodarone treatment found in 3% to 12% of patients." | 8.82 | Amiodarone-induced thyrotoxicosis and thyroid cancer: clinical, immunohistochemical, and molecular genetic studies of a case and review of the literature. ( Falciglia, M; Nikiforov, YE; Saad, A; Steward, DL, 2004) |
| "Cardiovascular manifestations of thyrotoxicosis and thyroid dysfunction caused by amiodarone." | 8.82 | [Cardiovascular manifestations of thyrotoxicosis and thyroid dysfunction caused by amiodarone]. ( Barta, K; Lorincz, I; Nagy, E; Simkó, J; Szabó, Z; Varga, E, 2004) |
| "Thyrotoxicosis occurs in up to 3% of people prescribed amiodarone in the UK." | 8.81 | Management of amiodarone-induced thyrotoxicosis. ( el-Houni, A; Jones, IR; Soran, H; Younis, N, 2002) |
| "Pathogenesis, diagnostic procedures and therapy of amiodarone-induced thyrotoxicosis (AIT) and hypothyroidism (AIH) are briefly discussed." | 8.80 | [Therapy of amiodarone-induced thyrotoxicosis and hypothyroidism]. ( Gerber, H; Noth, D, 1999) |
| " The clinical and biochemical response to medical and surgical management of five consecutive Tasmanian patients presenting with severe type-II amiodarone-associated thyrotoxicosis was reviewed." | 8.80 | Refractory amiodarone-associated thyrotoxicosis: an indication for thyroidectomy. ( Burgess, JR; Claxton, S; Donovan, S; Greenaway, TM; Hoffman, L; Loughhead, M; Sinha, SN, 2000) |
| "Amiodarone-induced thyrotoxicosis (AIT) is not an uncommon complication in countries with low iodine intake." | 8.80 | Amiodarone-induced thyrotoxicosis type 2: a case report and review of the literature. ( Benbassat, CA; Blum, I; Cohen, M; Mechlis-Frish, S, 2000) |
| "Amiodarone is the most important drug in the treatment of ventricular arrhythmias and is widely used for atrial fibrillation." | 8.80 | [Amiodarone-induced thyrotoxicosis]. ( Cron, TA; Kaufmann, C; Meier, C; Oberholzer, M; Osswald, S; Staub, JJ, 2000) |
| "Patients with amiodarone-induced thyrotoxicosis (AIT) often receive initial therapy for thyrotoxicosis in several different medical settings before admission to a referral center." | 8.31 | Real-life Data on the Effect of Medical Therapy for Amiodarone-induced Thyrotoxicosis on CV Events and Hospitalizations. ( Bartalena, L; Bogazzi, F; Cappellani, D; Manetti, L; Marconcini, G, 2023) |
| "Possible triggers and genetic markers involved in pathogenesis of amiodarone-induced thyrotoxicosis (AIT) or amiodarone-induced hypothyroidism (AIH) are currently unknown." | 8.31 | DUOX1 Gene Missense Mutation Confers Susceptibility on Type 2 Amiodarone-Induced Thyrotoxicosis. ( Axenova, M; Bestavashvili, A; Biakina, O; Ermolaeva, A; Fadeev, V; Gognieva, D; Kopylov, P; Mitina, Y; Syrkin, A, 2023) |
| "To report cardiac outcomes after total thyroidectomy for amiodarone-induced thyrotoxicosis according to the baseline left ventricular ejection fraction in a tertiary referral center." | 8.31 | Mortality After Total Thyroidectomy for Amiodarone-Induced Thyrotoxicosis According to Left Ventricular Ejection Fraction. ( Caillard, C; Drui, D; Frey, S; Knipping, G; Lande, G; Mahot, P; Mirallié, E; Pattier, S; Volteau, C, 2023) |
| "Fewer than 100 cases of amiodarone-induced thyrotoxicosis (AIT) managed surgically have been reported worldwide." | 8.12 | Early surgery: a favorable prognosticator in amiodarone-induced thyrotoxicosis-a single-center experience with 53 cases. ( Ambrosini, CE; Bakkar, S; Bogazzi, F; Cappellani, D; Catarsi, S; Di Salvo, C; Forfori, F; Materazzi, G; Miccoli, P; Papini, P, 2022) |
| "99m Tc-sestamibi thyroid scintigraphy (STS) can aid in differentiating between types 1 and 2 amiodarone-induced thyrotoxicosis (AIT)." | 8.12 | 99m Tc-Sestamibi Thyroid Scintigraphy in Amiodarone-Induced Thyrotoxicosis : Functional Imaging-Histopathologic Correlation. ( Better, N; Christie, M; Forehan, S; Fourlanos, S; Pattison, DA; Sivaratnam, D; Wang, R; Westcott, J, 2022) |
| "We see an increasing number of patients with amiodarone-induced thyrotoxicosis." | 8.02 | Amiodarone-induced thyrotoxicosis. ( Anfinsen, OG; Lima, K, 2021) |
| "The authors present a case of a 55-year-old gentleman with a medical history of atrial fibrillation on amiodarone who presented with weight loss, palpitations and exertional dyspnoea." | 8.02 | Amiodarone-induced type 2 thyrotoxicosis. ( Abela, A; Fava, S; Mifsud, S; Portelli, D, 2021) |
| "Amiodarone induced thyrotoxicosis (AIT) occurs with considerable incidence and is associated with significant morbidity and mortality." | 8.02 | [AMIODARONE-INDUCED THYROTOXICOSIS - RISK FACTORS AND PREDICTORS OF OUTCOME: A RETROSPECTIVE STUDY]. ( Aker, A; Kassem, S; Khalaili, L; Naoum, I, 2021) |
| "It is not known whether total thyroidectomy is more favorable than medical therapy for patients with amiodarone-induced thyrotoxicosis (AIT)." | 7.96 | Comparison Between Total Thyroidectomy and Medical Therapy for Amiodarone-Induced Thyrotoxicosis. ( Bartalena, L; Bogazzi, F; Cappellani, D; Di Certo, AM; Iervasi, G; Manetti, L; Mantuano, M; Marcocci, C; Marconcini, G; Martino, E; Materazzi, G; Morganti, R; Papini, P; Pingitore, A; Scattina, I; Tomisti, L; Urbani, C, 2020) |
| "A patient with underlying Hashimoto's thyroiditis developed amiodarone-induced thyrotoxicosis type 1 that was successfully treated using methimazole in combination with potassium iodide." | 7.96 | Successful Treatment of Amiodarone-induced Thyrotoxicosis Type 1 in Combination with Methimazole and Potassium Iodide in a Patient with Hashimoto's Thyroiditis. ( Hirose, T; Ikehara, K; Katoh, D; Kumashiro, N; Tsuboi, K; Uchino, H; Yoshino, H, 2020) |
| "BACKGROUND Amiodarone-induced thyrotoxicosis can be refractory to medical treatment seldom requiring surgical intervention." | 7.96 | Surgical Treatment of Amiodarone-Induced Thyrotoxicosis in an Adult with Congenital Heart Disease: An Anesthetists Perspective. ( Al-Halabi, E; El-Asmar, JM; Naja, AS, 2020) |
| "Amiodarone-induced thyrotoxicosis (AIT) affects up to 3% of treated patients." | 7.91 | Pulsed intravenous methylprednisolone combined with oral steroids as a treatment for poorly responsive type 2 amiodarone-induced thyrotoxicosis. ( Campi, I; Fugazzola, L; Groppelli, A; Parati, G; Perego, GB; Persani, L; Ravogli, A, 2019) |
| " The objectives of this study were to evaluate the risk of ATD-related agranulocytosis in patients with amiodarone-induced thyrotoxicosis (AIT), and to compare it with the agranulocytosis risk in patients with thyrotoxicosis due to other etiologies treated with ATDs." | 7.91 | Increased Risk of Antithyroid Drug Agranulocytosis Associated with Amiodarone-Induced Thyrotoxicosis: A Population-Based Cohort Study. ( Gershinsky, M; Gronich, N; Lavi, I; Saliba, W; Shapira, C, 2019) |
| "We describe a case of amiodarone-induced thyrotoxicosis (AIT) with cardiopulmonary arrest (CPA) in a 49-year-old woman." | 7.88 | Amiodarone-induced Thyrotoxicosis with Cardiopulmonary Arrest. ( Hasegawa, N; Inoue, K; Kakuta, Y; Kondo, T; Kowase, S; Miki, K; Nishikawa, T; Omura, M; Saito, J; Sugisawa, C; Tsurutani, Y, 2018) |
| "Amiodarone-induced thyrotoxicosis is a common complication of long-term amiodarone treatment." | 7.88 | "White Thyroid" on Unenhanced Computed Tomography in Amiodarone-Induced Thyrotoxicosis Type 2. ( Braeckman, A; De Vroe, C; Delanote, J; Duytschaever, M; Ghekiere, J; Pyfferoen, L; Tavernier, R; Van den Bruel, A, 2018) |
| "Distinguishing between amiodarone-induced thyrotoxicosis (AIT) caused by excessive hormone synthesis (AIT-1) or by a destructive process (AIT-2) has important therapeutic implications, but is still difficult and debated." | 7.88 | Amiodarone-Induced Thyrotoxicosis: Differential Diagnosis Using 99mTc-SestaMIBI and Target-to-Background Ratio (TBR). ( Barollo, S; Bertazza, L; Bodanza, V; Cavedon, E; Cecchin, D; Censi, S; Gusella, S; Manso, J; Mian, C; Watutantrige-Fernando, S, 2018) |
| "Iodine-induced thyrotoxicosis, which raises several diagnostic and therapeutical challenges, is often overlooked." | 7.83 | Iodine-induced hyperthyroidism as combination of different etiologies: an overlooked entity in the elderly. ( Cascio, C; Foppiani, L; Lo Pinto, G, 2016) |
| "Amiodarone is a potent antiarrhythmic agent, indicated for the treatment of refractory arrhythmias, which may lead to thyrotoxicosis." | 7.83 | Total Thyroidectomy for Amiodarone-induced Thyrotoxicosis in the Hyperthyroid State. ( Christ, ER; Fahrner, R; Fuhrer, J; Kaderli, RM; Martinelli, M; Seiler, CA; Stettler, C; Vogt, A, 2016) |
| "It is widely accepted that type 2 amiodarone-induced thyrotoxicosis (AIT) generally occurs in patients with a normal thyroid gland without signs of thyroid autoimmunity." | 7.83 | The presence of anti-thyroglobulin (TgAb) and/or anti-thyroperoxidase antibodies (TPOAb) does not exclude the diagnosis of type 2 amiodarone-induced thyrotoxicosis. ( Bartalena, L; Bogazzi, F; Curzio, O; Latrofa, F; Lupi, I; Manetti, L; Marcocci, C; Martino, E; Rossi, G; Sardella, C; Tomisti, L; Urbani, C, 2016) |
| "Reintroduction of amiodarone in patients with a history of amiodarone-induced thyrotoxicosis (AIT) is rarely used." | 7.83 | Amiodarone-Induced Thyrotoxicosis Recurrence After Amiodarone Reintroduction. ( Auclair, C; Batisse-Lignier, M; Citron, B; Desbiez, F; Lusson, JR; Maqdasy, S; Roche, B; Tauveron, I; Thieblot, P, 2016) |
| "Amiodarone-induced thyrotoxicosis (AIT) type I describes inducement of clinical hyperthyroidism by excessive thyroidal iodine in the setting of latent Graves disease, and therapy differs from that used for AIT type II." | 7.83 | 99mTc Sestamibi Thyroid Scan in Amiodarone-Induced Thyrotoxicosis Type I. ( Lee, H; Patel, NR; Tamara, LA, 2016) |
| "Amiodarone is an antiarrhythmic drug that is frequently used to control atrial fibrillation (AF)." | 7.83 | Safety and efficacy of early radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation complicated with amiodarone-induced thyrotoxicosis. ( Cai, S; Feng, W; Sun, L; Wang, M; Zhao, Q, 2016) |
| "Amiodarone-induced thyrotoxicosis (AIT) is caused by excessive hormone synthesis and release (AIT I), a destructive thyroiditis (AIT II), or a combination of both (AIT Ind)." | 7.81 | Quantitative assessment of thyroid-to-background ratio improves the interobserver reliability of technetium-99m sestamibi thyroid scintigraphy for investigation of amiodarone-induced thyrotoxicosis. ( Better, N; Forehan, S; Gunawardana, D; Lichtenstein, M; Pattison, DA; Sivaratnam, D; Toh, HB; Westcott, J, 2015) |
| "The development of amiodarone-induced thyrotoxicosis (AIT) can threaten the hemodynamic stability of adult patients with congenital heart disease (CHD)." | 7.80 | Amiodarone-induced thyrotoxicosis in adults with congenital heart disease--clinical presentation and response to therapy. ( Bahn, RS; Brennan, MD; Sathananthan, M; Stan, MN; Thapa, P; Warnes, CA, 2014) |
| "Amiodarone is associated with thyroid dysfunction and life-threatening thyrotoxicosis." | 7.80 | Preoperative therapeutic apheresis for severe medically refractory amiodarone-induced thyrotoxicosis: a case report. ( Ariano, RE; Dostmohamed, H; Houston, DS; Katz, P; Knoll, C; Lewis, B; Schacter, I; Yamamoto, J; Zarychanski, R, 2014) |
| "Considering the different pathogenic mechanisms of the two main forms of amiodarone-induced thyrotoxicosis (AIT), we ascertained whether this results in a different onset time as well." | 7.80 | The onset time of amiodarone-induced thyrotoxicosis (AIT) depends on AIT type. ( Bartalena, L; Bogazzi, F; Martino, E; Rossi, G; Tomisti, L, 2014) |
| " He was diagnosed with atrial fibrillation 2 years previously and started on amiodarone and warfarin." | 7.80 | Amiodarone-induced thyrotoxicosis: type 1 or type 2? ( Khan, A; Puttanna, A; Raskauskiene, D, 2014) |
| "The treatment of amiodarone-induced thyrotoxicosis (AIT) still remains a clinical challenge, requiring the cooperation of both endocrinologists and cardiologists." | 7.80 | Radioiodine therapy in patients with type II amiodarone-induced thyrotoxicosis. ( Czarnywojtek, A; Kobylecka, M; Królicki, L; Kunikowska, J; Miechowicz, I; Płazińska, M; Rewers, A; Ruchała, M; Stangierski, A; Waligórska-Stachura, J; Warmuz-Stangierska, I; Woliński, K, 2014) |
| " Amiodarone, the drug of choice for arrhythmia treatment in such patients, can cause a number of complications, including amiodarone induced thyrotoxicosis (AIT)." | 7.79 | Amiodarone-induced thyrotoxicosis in a case of Eisenmenger's syndrome. ( Czarnywojtek, A; Fichna, M; Florek, E; Greberska, W; Guzik, P; Kwiecinska, B; Lodyga, M; Ruchała, M; Waśko, R; Woliński, K; Zgorzalewicz-Stachowiak, M, 2013) |
| "To report a case of amiodarone-induced thyrotoxicosis (AIT) concomitant with thyroid cancer in multinodular goiter (MNG)." | 7.78 | Amiodarone-induced thyrotoxicosis with thyroid papillary cancer in multinodular goiter: case report. ( Akamizu, T; Inaba, H; Kobayashi, S; Komatsu, M; Suzuki, S; Takeda, T, 2012) |
| " Here we describe a Caucasian woman who developed a bronchiolitis obliterans organizing pneumonia (BOOP)-like interstitial pneumonia after PTU administration for amiodarone-induced thyrotoxicosis." | 7.78 | Propylthiouracil-induced interstitial pneumonia in a Caucasian woman with amiodarone-induced thyrotoxicosis. ( Brigante, G; Diazzi, C; Rochira, V; Rossi, G, 2012) |
| "We prospectively collected cases of amiodarone-associated thyrotoxicosis requiring thyroidectomy due to failure of antithyroid treatment, despite amiodarone discontinuation." | 7.78 | Total thyroidectomy for amiodarone-associated thyrotoxicosis: should surgery always be delayed for pre-operative medical preparation? ( Duverger, V; Merat, S; Perrier, E; Pierret, C; Pons, Y; Tourtier, JP, 2012) |
| "Patients with amiodarone-induced thyrotoxicosis (AIT) and left ventricular (LV) systolic dysfunction have a high mortality rate." | 7.78 | Total thyroidectomy in patients with amiodarone-induced thyrotoxicosis and severe left ventricular systolic dysfunction. ( Bartalena, L; Bogazzi, F; De Napoli, L; Marchello, A; Mariotti, R; Martino, E; Materazzi, G; Miccoli, P; Moretti, M; Rossi, G; Tomisti, L, 2012) |
| "Amiodarone (AM)-induced thyrotoxicosis (AIT) is a condition with uncertainties from the diagnostic and therapeutic standpoints." | 7.77 | Importance of (99)mTc-sestaMIBI thyroid scan in a case of amiodarone-induced thyrotoxicosis. ( Braga, DC; Carvalho, D; Fernandes, H; Matos, MJ; Pereira, J; Souto, SB, 2011) |
| "The identification of the different subtypes of amiodarone-induced thyrotoxicosis (AIT) may provide a rational basis for the choice of the appropriate medical treatment." | 7.76 | Amiodarone-induced thyrotoxicosis in children and adolescents is a possible outcome in patients with low iodine intake. ( Atalay, S; Berberoğlu, M; Hacihamdioğlu, B; Oçal, G; Savaş Erdeve, S; Siklar, Z; Tutar, E, 2010) |
| "Amiodarone-induced thyrotoxicosis (AIT) is a clinical condition that is notoriously difficult to manage; the relative risk of adverse cardiovascular events in these patients compared with euthyroid patients is largely unknown." | 7.75 | Amiodarone-induced thyrotoxicosis is a predictor of adverse cardiovascular outcome. ( Chow, WH; Fan, K; Jim, MH; Lee, CH; Mok, M; Shea, YF; Siu, CW; Tse, HF; Yiu, KH; Yuen, M, 2009) |
| "A 64-year-old female with atrial fibrillation and nodular goiter progressed to overt thyrotoxicosis after receiving therapy with amiodarone 200 mg/day for less than 12 weeks." | 7.75 | Amiodarone-induced thyrotoxicosis in a patient with autonomously functioning nodular goiter. ( Hsiao, SH; Huang, SM; Hung, HC; Liang, YL; Ou, HY; Peng, SL; Wu, TJ, 2009) |
| "Type 2 amiodarone-induced thyrotoxicosis (AIT) is a destructive thyroiditis usually responsive to glucocorticoids; however, recent surveys showed that many expert thyroidologists worldwide use thionamides for type 2 AIT patients." | 7.75 | Glucocorticoids are preferable to thionamides as first-line treatment for amiodarone-induced thyrotoxicosis due to destructive thyroiditis: a matched retrospective cohort study. ( Bartalena, L; Bogazzi, F; Dell'Unto, E; Martino, E; Pepe, P; Rossi, G; Tomisti, L, 2009) |
| "Amiodarone-induced thyrotoxicosis (AIT) is usually classified into two types: type 1, in which a high iodine content triggers the autonomous production of thyroid hormone; and type 2, in which destructive thyroiditis causes the release of preformed thyroid hormone." | 7.74 | Radioactive iodine in the treatment of type-2 amiodarone-induced thyrotoxicosis. ( Anil, C; Demirag, NG; Demirer, AN; Gencoglu, A; Gursoy, A; Tutuncu, NB, 2008) |
| "We describe the effects of iopanoic acid on daily levels of free triiodothyronine (FT(3)) and free thyroxine (FT(4)) in a patient with progressive type II amiodarone-induced thyrotoxicosis (AIT) who was undergoing thyroidectomy." | 7.74 | Pharmacodynamic effect of iopanoic acid on free T(3) and T(4) levels in amiodarone-induced thyrotoxicosis. ( Falciglia, M; Matrka, L; Nikiforov, Y; Steward, D, 2008) |
| "Amiodarone-induced thyrotoxicosis is a life-threatening condition." | 7.74 | Combination of minimally invasive thyroid surgery and local anesthesia associated to iopanoic acid for patients with amiodarone-induced thyrotoxicosis and severe cardiac disorders: a pilot study. ( Ambrosini, CE; Berti, P; Bogazzi, F; Martino, E; Materazzi, G; Miccoli, P, 2007) |
| "To evaluate the usefulness of Doppler parameters in the differentiation between the two types of amiodarone-associated thyrotoxicosis (AAT)." | 7.74 | Differentiation between the two types of amiodarone-associated thyrotoxicosis using duplex and amplitude Doppler sonography. ( Cerri, GG; Chammas, MC; Farage, L; Jorge, PT; Macedo, TA; Santos, VA; Souza, LP; Watanabe, T, 2007) |
| "Two main forms of amiodarone-induced thyrotoxicosis (AIT) exist." | 7.74 | Proportion of type 1 and type 2 amiodarone-induced thyrotoxicosis has changed over a 27-year period in Italy. ( Aghini-Lombardi, F; Bartalena, L; Bogazzi, F; Dell'Unto, E; Grasso, L; Macchia, E; Martino, E; Pepe, P; Pinchera, A; Rossi, G; Tanda, ML; Tomisti, L, 2007) |
| "This study sought to determine the clinical course and predictors of long-term outcome in patients with documented amiodarone-induced thyrotoxicosis (AIT)." | 7.74 | Amiodarone-induced thyrotoxicosis: clinical course and predictors of outcome. ( Ammann, P; Bilz, S; Conen, D; Kaufmann, C; Melly, L; Muller, B; Osswald, S; Schaer, B; Sticherling, C, 2007) |
| "Amiodarone-induced thyrotoxicosis (AIT) may be caused by excessive thyroidal hormone synthesis and release (type 1) or by a destructive process (type 2)." | 7.74 | Color-flow Doppler sonography in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. ( Cianchetti, ME; Loy, M; Mariotti, S; Melis, A; Perra, E; Piga, M; Pinna, G; Serra, A, 2007) |
| "Amiodarone-induced thyrotoxicosis (AIT) with features consistent with both AIT type I (in which thyroid antibodies and nodular goiter are present) and AIT type II (which is not responsive to thionamide therapy and eventually leads to permanent hypothyroidism)." | 7.74 | Treatment of amiodarone-associated thyrotoxicosis. ( Franklyn, JA; Gammage, MD, 2007) |
| "We report the case of a 60 year old female patient on continuous systemic anticoagulation therapy with coumarin due to mechanical aortic valve replacement and a more than 3 years lasting amiodarone therapy due to severe ventricular extrasystoles suffering from amiodarone induced thyrotoxicosis (AIT)." | 7.74 | Impact of thyroid metabolism on the course of INR levels in a patient with systemic anticoagulation suffering from amiodarone-induced thyrotoxicosis. ( Biersack, HJ; Brockmann, H; Bucerius, J; Ezziddin, S; Palmedo, H, 2007) |
| "Amiodarone causes changes in thyroid function tests in about 15-20% of patients, inducing either hypothyroidism or thyrotoxicosis." | 7.74 | [Difficult treatment of amiodarone-induced thyrotoxicosis: a case report]. ( Carmena, R; Catalá, M; Lorente, R; Martínez-Hervás, S; Ortega, J; Pedro, T; Real, JT, 2007) |
| "To investigate how North American thyroidologists assess and treat amiodarone-induced thyrotoxicosis (AIT) and to compare the results with those of the same questionnaire-based survey previously carried out among European thyroidologists." | 7.74 | Diagnosis and management of amiodarone-induced thyrotoxicosis: similarities and differences between North American and European thyroidologists. ( Bartalena, L; Bogazzi, F; Braverman, LE; Lai, A; Liparulo, L; Martino, E; Piantanida, E; Sassi, L; Tanda, ML; Wiersinga, WM, 2008) |
| " Two were cases of type I amiodarone-induced thyrotoxicosis (AIT) treated with methimazole." | 7.74 | Differential diagnosis and appropriate treatment of four thyrotoxic patients with Graves' disease required to take amiodarone due to life-threatening arrhythmia. ( Kasanuki, H; Kodama, H; Obara, T; Omi, Y; Sato, K; Seki, T; Shiga, T; Takano, K; Yamada, E; Yamazaki, K, 2008) |
| "Amiodarone-induced thyrotoxicosis (AIT) type 1 occurs in subjects with an underlying thyroid disease, whereas type 2 AIT is a form of destructive thyroiditis." | 7.73 | Amiodarone-induced thyrotoxicosis due to destructive thyroiditis: therapeutic recommendations. ( Dietlein, M; Schicha, H, 2005) |
| " Administration of amiodarone for atrial fibrillation led to the development of hyperthyroidism." | 7.73 | Amiodarone-induced hyperthyroidism in a patient with functioning papillary carcinoma of the thyroid and extensive hepatic metastases. ( Mackie, GC; Shulkin, BL, 2005) |
| "Amiodarone is a powerful antiarrhythmic drug; however, its use may be complicated by thyrotoxicosis." | 7.73 | Continuation of amiodarone therapy despite type II amiodarone-induced thyrotoxicosis. ( Bertagna, X; Bertherat, J; Duboc, D; Guignat, L; Meune, C; Mouly, S; Thomopoulos, P; Uzan, L; Weber, S, 2006) |
| "Among the amiodarone-induced thyroid dysfunctions, thyrotoxicosis is the most troublesome and with the highest rate of morbidity and mortality." | 7.73 | [Use of lithium carbonate for the treatment of amiodarone-induced thyrotoxicosis]. ( Boeving, A; Carvalho, GA; Cubas, ER; Graf, H; Santos, CM, 2005) |
| "Amiodarone-induced thyrotoxicosis (AIT) is a challenging management problem, since patients treated with amiodarone invariably have underlying heart disease." | 7.73 | Amiodarone-induced thyrotoxicosis: left ventricular dysfunction is associated with increased mortality. ( Diamond, T; Lewis, M; O'Sullivan, AJ, 2006) |
| "Although there are two types of amiodarone-induced thyrotoxicosis (AIT), only type II AIT has been seen at our institution in Japan so far." | 7.73 | Mild and short recurrence of type II amiodarone-induced thyrotoxicosis in three patients receiving amiodarone continuously for more than 10 years. ( Hagiwara, N; Kasanuki, H; Matsuda, N; Onoda, N; Sato, K; Shiga, T; Takano, K, 2006) |
| " Most respondents lived in iodine-sufficient areas and observed that amiodarone-induced hypothyroidism (AIH) is more common than AIT." | 7.73 | Management of amiodarone-induced thyrotoxicosis in Latin America: an electronic survey. ( Albino, CC; Bartalena, L; Diehl, LA; Graf, H; Martino, E; Romaldini, JH; Wiersinga, WM, 2006) |
| "Two main forms of amiodarone- induced thyrotoxicosis (AIT) exist: type 1 AIT is a condition of true hyperthyroidism developing in patients with pre-existing thyroid disorders, and usually requires thyroid ablative treatment." | 7.73 | Long-term outcome of thyroid function after amiodarone-induced thyrotoxicosis, as compared to subacute thyroiditis. ( Aghini-Lombardi, F; Bartalena, L; Bogazzi, F; Cosci, C; Dell'Unto, E; Martino, E; Pinchera, A; Sardella, C; Tanda, ML; Tomisti, L, 2006) |
| "Amiodarone was required in 10 cases of recurrent symptomatic paroxysmal atrial fibrillation (AF) and in 5 cases of ventricular tachycardia (VT) (M = 12, F = 3, mean age: 63 +/- 14)." | 7.72 | Radioiodine ablation of the thyroid to prevent recurrence of amiodarone-induced thyrotoxicosis in patients with resistant tachyarrhythmias. ( Arlot, S; Delonca, J; Hermida, JS; Jarry, G; Moullart, V; Rey, JL; Schvartz, C; Tcheng, E, 2004) |
| "Thyrotoxicosis is a well-documented and studied complication of treatment with amiodarone, but little has been written about the risks and treatment of recurrent thyrotoxicosis upon re-exposure to amiodarone." | 7.72 | Can amiodarone be restarted after amiodarone-induced thyrotoxicosis? ( Braverman, LE; Cooper, DS; Kloos, RT; Ladenson, PW; Ryan, LE, 2004) |
| "To determine how expert European thyroidologists assess and treat amiodarone-induced thyrotoxicosis (AIT)." | 7.72 | Diagnosis and management of amiodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association. ( Bartalena, L; Bogazzi, F; Lai, A; Martino, E; Piantanida, E; Tanda, ML; Wiersinga, WM, 2004) |
| "Amiodarone-associated thyrotoxicosis (AAT) is often poorly tolerated owing to underlying cardiac disease, and it is frequently refractory to conventional medical treatment." | 7.72 | Surgical management of amiodarone-associated thyrotoxicosis: Mayo Clinic experience. ( Brennan, MD; Farley, DR; Grant, CS; Houghton, SG; Thompson, GB; van Heerden, JA, 2004) |
| "Amiodarone-induced thyrotoxicosis is a life-threatening problem that is very effectively managed by total thyroidectomy, although often many of these patients are considered "too unfit" for anaesthesia." | 7.71 | Anaesthesia for amiodarone-induced thyrotoxicosis: a case review. ( Delbridge, L; Robinson, B; Sutherland, J, 2001) |
| "For a patient with idiopathic dilated cardiomyopathy, an implantable defibrillator, and amiodarone induced thyrotoxicosis associated with ventricular fibrillation storm." | 7.71 | Electrical storm due to amiodarone induced thyrotoxicosis in a young adult with dilated cardiomyopathy: thyroidectomy as the treatment of choice. ( Manios, EG; Marketou, ME; Simantirakis, EN; Vardas, PE, 2001) |
| "Current thinking is that amiodarone-induced thyrotoxicosis (AIT) might be either iodine-induced thyrotoxicosis in latent hyperthyroidism (Type 1) or destructive thyroiditis (Type 2), and also that colour-flow Doppler sonography (CFDS) of the thyroid and serum interleukin 6 (IL-6) are tools that can classify AIT and direct treatment." | 7.71 | Clinical experience of amiodarone-induced thyrotoxicosis over a 3-year period: role of colour-flow Doppler sonography. ( Bennet, WM; Eaton, SE; Euinton, HA; Newman, CM; Weetman, AP, 2002) |
| "Amiodarone-induced thyrotoxicosis (AIT) is a difficult management problem about which there are little published data." | 7.71 | Successful treatment of amiodarone-induced thyrotoxicosis. ( Franklyn, JA; Gammage, MD; Osman, F; Sheppard, MC, 2002) |
| "Amiodarone-induced thyrotoxicosis (AIT) may develop either in apparently normal thyroid glands (Type II AIT) or in the presence of sub-clinical thyroid abnormalities (either autonomous goiter or latent Graves' disease; Type I AIT)." | 7.71 | Iopanoic acid rapidly controls type I amiodarone-induced thyrotoxicosis prior to thyroidectomy. ( Aghini-Lombardi, F; Bartalena, L; Basolo, F; Bogazzi, F; Braverman, LE; Cosci, C; Lupi, I; Martino, E; Miccoli, P; Pinchera, A; Santini, F; Tanda, ML, 2002) |
| "Amiodarone-associated thyrotoxicosis, often clinically mild and resolutive after amiodarone discontinuation or under medical therapy, is sometimes drug unresponsive and not uncommonly follows a dramatic, even fatal course." | 7.70 | Surgical management of amiodarone-associated thyrotoxicosis: too risky or too effective? ( Defechereux, T; Hamoir, E; Hennen, G; Joris, J; Meurisse, M; Vivario, J, 1998) |
| "Since amiodarone was first marketed in 1992 in Japan, the incidence of amiodarone-induced thyrotoxicosis (AIT) has been increasing." | 7.70 | Amiodarone-induced thyrotoxicosis associated with thyrotropin receptor antibody. ( Demura, H; Kanaji, Y; Kasanuki, H; Ohnishi, S; Sato, K; Yamazaki, K, 1998) |
| "Amiodarone may induce hyper- or hypothyroidism." | 7.70 | High prevalence of thyroid dysfunction in adult patients with beta-thalassemia major submitted to amiodarone treatment. ( Balestrieri, A; Lai, ME; Loviselli, A; Mandas, A; Mariotti, S; Martino, E; Murenu, S; Sau, F; Vacquer, S; Valentino, L, 1999) |
| "A patient with amiodarone-induced thyrotoxicosis and autonomous nodule was treated with percutaneous ethanol injection (PEI) in 8 sessions." | 7.69 | Percutaneous ethanol injection therapy of autonomous nodule and amiodarone-induced thyrotoxicosis. ( Caraccio, N; Casolaro, A; Del Guerra, P; Franchi, F; Monzani, F; Pucci, E, 1994) |
| "Treatment with the antiarrhythmic agent amiodarone results in alterations in thyroid hormone metabolism, and can induce either hypothyroidism or hyperthyroidism (amiodarone-associated thyrotoxicosis, AAT)." | 7.69 | Nongoitrous (type I) amiodarone-associated thyrotoxicosis: evidence of follicular disruption in vitro and in vivo. ( Bahn, RS; Brennan, MD; Carney, JA; Erickson, DZ, 1995) |
| "Amiodarone induced thyrotoxicosis (AIT) occurs most frequently in euthyroid patients with nodular goiter or Graves' disease due to release of iodine from this iodine rich drug." | 7.69 | Thyroid ultrasonography in patients with a previous episode of amiodarone induced thyrotoxicosis. ( Bianconi, L; Braverman, LE; De Chiara, F; Gardini, E; Minelli, R; Roti, E; Salvi, M; Tosi, C, 1994) |
| "Two patients with amiodarone-induced thyrotoxicosis were treated successfully with potassium perchlorate and carbimazole while treatment with amiodarone was continued." | 7.69 | Two cases of amiodarone-induced thyrotoxicosis successfully treated with a short course of antithyroid drugs while amiodarone was continued. ( Düren, DR; Trip, MD; Wiersinga, WM, 1994) |
| "Amiodarone, an iodine-rich cardiac drug, may induce thyrotoxicosis (AIT), which can occur in patients with preexisting thyroid abnormalities and in subjects with apparently normal thyroid glands." | 7.69 | Serum interleukin-6 in amiodarone-induced thyrotoxicosis. ( Aghini-Lombardi, F; Bartalena, L; Braverman, LE; Brogioni, S; Grasso, L; Martino, E, 1994) |
| "Amiodarone-induced thyrotoxicosis (AIT) occurs in both abnormal (type I) and apparently normal (type II) thyroid glands due to iodine-induced excessive thyroid hormone synthesis in patients with nodular goiter or latent Graves' disease (type I) or to a thyroid-destructive process caused by amiodarone or iodine (type II)." | 7.69 | Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study. ( Bartalena, L; Bogazzi, F; Brogioni, S; Burelli, A; Grasso, L; Martino, E, 1996) |
| "Amiodarone-induced thyrotoxicosis occurs in 2-12." | 7.69 | Ultrastructural evidence of thyroid damage in amiodarone-induced thyrotoxicosis. ( Bernasconi, R; Boldorini, R; Cappiello, E; Piraneo, S; Raggi, U; Tosoni, A, 1995) |
| "We describe a patient who was treated with amiodarone for ventricular arrhythmia based on arrhythmogenic right ventricular dysplasia and who subsequently developed severe amiodarone-induced thyrotoxicosis." | 7.69 | A case of amiodarone-induced thyrotoxicosis successfully treated with prednisolone. ( Hayashi, K; Kondoh, J; Numaguchi, Y; Sassa, H; Sone, T; Suzuki, T; Tsuboi, H, 1997) |
| "We report a case of amiodarone-induced thyrotoxicosis, diagnosed with a systematic laboratory investigation in a 64-year-old patient, for haematuria." | 7.69 | [Amiodarone-induced thyrotoxicosis cured by thyroidectomy]. ( Guerin-Robardey, AM; Le Cosquer, P; Ossart, M, 1996) |
| "We conclude that lithium is a useful and safe medication for treatment of iodine-induced thyrotoxicosis caused by amiodarone." | 7.69 | Lithium treatment in amiodarone-induced thyrotoxicosis. ( Adawi, F; Baron, E; Dickstein, G; Ish-Shalom, S; Kaplan, J; Shechner, C, 1997) |
| "Amiodarone-induced thyrotoxicosis (AIT) occurs both in abnormal thyroid glands (nodular goiter, latent Graves' disease) (type I AIT) or in apparently normal thyroid glands (type II AIT)." | 7.69 | Color flow Doppler sonography rapidly differentiates type I and type II amiodarone-induced thyrotoxicosis. ( Bartalena, L; Bartolozzi, C; Bogazzi, F; Brogioni, S; Burelli, A; Martino, E; Mazzeo, S; Vitti, P, 1997) |
| "The present report illustrates the clinical and biochemical outcome in two amiodarone iodine-induced thyrotoxicosis (AIIT) patients submitted to plasmapheresis." | 7.68 | Treatment of amiodarone iodine-induced thyrotoxicosis with plasmapheresis and methimazole. ( Aghini-Lombardi, F; Braverman, LE; Fosella, PV; Grasso, L; Mariotti, S; Martino, E; Pinchera, A, 1993) |
| "Amiodarone-induced thyrotoxicosis (AIT) is a rare disorder that is frequently refractory to conventional pharmacologic therapy." | 7.68 | Amiodarone-induced thyrotoxicosis: clinical presentation and expanded indications for thyroidectomy. ( Esselstyn, CB; Kinney, W; McHenry, CR; Mulligan, DC, 1993) |
| "In a patient chronically treated with amiodarone, subclinical iodine-induced hypothyroidism occurred as a result of excess iodine released from the amiodarone molecule." | 7.68 | Subclinical hypothyroidism, overt thyrotoxicosis and subclinical hypothyroidism: the subsequent phases of thyroid function in a patient chronically treated with amiodarone. ( Bianconi, L; Gardini, E; Minelli, R; Roti, E; Salvi, M, 1992) |
| "Amiodarone-induced thyrotoxicosis (AIT) occurs most frequently in patients with underlying thyroid disease and is generally believed to be due to the iodine contamination of amiodarone and iodine released by the metabolism of the drug." | 7.68 | Iodine-induced subclinical hypothyroidism in euthyroid subjects with a previous episode of amiodarone-induced thyrotoxicosis. ( Bianconi, L; Braverman, LE; Gardini, E; Gavaruzzi, G; Minelli, R; Neri, TM; Roti, E; Ugolotti, G, 1992) |
| "We report four cases of life-threatening amiodarone iodine-induced thyrotoxicosis." | 7.68 | Life-threatening thyrotoxicosis induced by amiodarone in patients with benign heart disease. ( Georges, JL; Lenormand, ME; Normand, JP; Schwob, J, 1992) |
| "To determine the incidence and predictability and to elucidate the pathogenesis of amiodarone-induced thyrotoxicosis (AIT) and hypothyroidism (AIH)." | 7.68 | Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. ( Plomp, TA; Trip, MD; Wiersinga, W, 1991) |
| "Amiodarone-induced thyrotoxicosis (AIT) is generally believed to result from increased hormonal synthesis related to the iodine overload." | 7.68 | Amiodarone-induced thyrotoxicosis suggestive of thyroid damage. ( Brohet, C; De Nayer, P; Gangji, D; Lambert, M; Unger, J, 1990) |
| "Amiodarone hydrochloride, an iodine-rich drug used in the treatment of tachyarrhythmias, is responsible for the development of thyrotoxicosis in approximately 10% of patients who reside in areas of moderate iodine deficiency." | 7.68 | Thyroidectomy for amiodarone-induced thyrotoxicosis. ( Abend, SL; Braverman, LE; Farwell, AP; Huang, SK; Patwardhan, NA, 1990) |
| "Treatment of amiodarone iodine-induced thyrotoxicosis is often unsuccessful." | 7.67 | Rapid effectiveness of prednisone and thionamides combined therapy in severe amiodarone iodine-induced thyrotoxicosis. Comparison of two groups of patients with apparently normal thyroid glands. ( Barbier, Y; Bornet, H; Broussolle, C; Ducottet, X; Martin, C; Noel, G; Orgiazzi, J, 1989) |
| "We describe a case of amiodarone-induced thyrotoxicosis following heart valve replacement in a patient with a multinodular goitre." | 7.67 | Anaplastic carcinoma of the thyroid in a patient receiving radio-iodine therapy for amiodarone-induced thyrotoxicosis. ( Bridges, AB; Davies, RR; McNeill, GP; Newton, RW, 1989) |
| "Treatment of amiodarone-induced thyrotoxicosis (AIT) with thionamide, lithium or radioactive iodine is ineffective." | 7.67 | Dexamethasone treatment of amiodarone-induced thyrotoxicosis (AIT) with or without persistent administration of the drug. ( Bernard, R; Bonnyns, M; Bourdoux, P; Demaret, B; Renard, M; Sterling, I, 1989) |
| "Amiodarone, a iodine-rich drug widely used in the treatment of tachyarrhythmias, represents one of the most common sources of iodine-induced thyrotoxicosis." | 7.67 | Amiodarone: a common source of iodine-induced thyrotoxicosis. ( Aghini-Lombardi, F; Bartalena, L; Braverman, L; Mariotti, S; Martino, E; Pinchera, A, 1987) |
| "Amiodarone iodine induced thyrotoxicosis occurs frequently in patients residing in areas of mild iodine deficiency and in patients with preexisting goiter." | 7.67 | Treatment of amiodarone associated thyrotoxicosis by simultaneous administration of potassium perchlorate and methimazole. ( Aghini-Lombardi, F; Baschieri, L; Braverman, LE; Lenziardi, M; Mariotti, S; Martino, E; Pinchera, A, 1986) |
| "A 41-year-old male patient developed amiodarone-induced thyrotoxicosis after 29 months of treatment with amiodarone." | 7.67 | Suppression of thyroglobulin secretion in amiodarone iodine-induced thyrotoxicosis. ( Weissel, M, 1988) |
| "A rare case of amiodarone-iodine-induced thyrotoxicosis (AIIT) associated with nonthyroidal illness is reported." | 7.67 | Diagnosis of amiodarone-iodine-induced thyrotoxicosis(AIIT) associated with severe nonthyroidal illness. ( Balestrieri, A; Balzano, S; Bartalena, L; Cherchi, A; Martino, E; Ruscazio, M; Sau, F, 1987) |
| "Amiodarone, an iodine containing drug, may induce thyrotoxicosis by an uncertain mechanism." | 7.67 | Is humoral thyroid autoimmunity relevant in amiodarone iodine-induced thyrotoxicosis (AIIT)? ( Aghini-Lombardi, F; Antonelli, A; Baschieri, L; Concetti, R; Fenzi, GF; Lenziardi, M; Macchia, E; Martino, E; Pinchera, A, 1986) |
| "Amiodarone is a common anti-arrhythmic agent mostly used to treat and prevent different kinds of arrhythmia with several considerable side effects, most commonly on the thyroid gland." | 7.01 | Prevalence of amiodarone-induced hypothyroidism; A systematic review and meta-analysis. ( Bondariyan, N; Heidarpour, M; Mohammadi, K; Rezvanian, H; Shafie, D; Vakhshoori, M, 2023) |
| "Diagnosis of thyrotoxicosis is easy, based on the finding of increased free thyroid hormone concentrations and suppressed TSH levels." | 6.46 | Approach to the patient with amiodarone-induced thyrotoxicosis. ( Bartalena, L; Bogazzi, F; Martino, E, 2010) |
| "Amiodarone can cause thyroid dysfunction in patients with or without previous thyroid disease." | 6.42 | Surgical management of amiodarone-induced thyrotoxicosis. ( Fan, CY; Franzese, CB; Stack, BC, 2003) |
| "Amiodarone is an effective drug and its withdrawal may have significant impact on a patient's already fragile cardiac status." | 6.42 | Management of amiodarone-induced thyrotoxicosis. ( Gilbey, SG; Rajeswaran, C; Shelton, RJ, 2003) |
| "Treating amiodarone-induced thyrotoxicosis (AIT) may include traditional antithyroid agents, glucocorticoids, and surgery." | 6.42 | Treating amiodarone-induced thyrotoxicosis with radioactive iodine. ( Iskandar, SB; Jordan, RM; Peiris, AN; Richard, MJ, 2004) |
| "Amiodarone is a class 3 antiarrhythmic drug which may be associated with thyroid dysfunction." | 5.62 | Resistant type 2 amiodarone-induced thyrotoxicosis responsive to cholestyramine as an adjunctive therapy. ( Ali, A; Mandal, S; Maryam, M; Rummaan, A; Saeed, T, 2021) |
| "Amiodarone is widely used in treating atrial and ventricular arrhythmias; however, due to its high iodine concentration, the chronic use of the drug can induce thyroid disorders." | 5.62 | Amiodarone-Induced Thyrotoxicosis - Literature Review & Clinical Update. ( Campagnolo, MT; Martins, LCB; Scanavacca, MI; Souza, LVF, 2021) |
| "Amiodarone is a widely used anti-arrhythmic drug." | 5.40 | An audit of amiodarone-induced thyrotoxicosis--do anti-thyroid drugs alone provide adequate treatment? ( Inder, WJ; Kaye, G; Patel, N; Sullivan, C, 2014) |
| "Transient hypothyroidism was observed in only two patients (5%) with AIH, though was not observed in TMNG." | 5.35 | Radioiodine therapy in patients with amiodarone-induced thyrotoxicosis (AIT). ( Bartkowiak, Z; Czarnywojtek, A; Czepczynski, R; Florek, E; Ruchala, M; Sowinski, J; Szczepanek, E; Wasko, R; Zamyslowska, H; Zgorzalewicz-Stachowiak, M, 2009) |
| "Type 2 amiodarone-induced thyrotoxicosis (AIT2) is a form of drug-induced destructive thyroiditis, usually treated with oral glucocorticoids (oGCs)." | 5.34 | Effect of high-dose intravenous glucocorticoid therapy on serum thyroid hormone concentrations in type 2 amiodarone-induced thyrotoxicosis: an exploratory study. ( Bartalena, L; Bogazzi, F; Cappellani, D; Manetti, L; Martino, E; Urbani, C, 2020) |
| "Examining the course of cardiac arrhythmias (CA) in developed TT has established that this condition gives rise to their recurrence." | 5.32 | [The specific features of thyrotoxicosis and euthyroid hyperthyroxinemia developed due to the use of cordarone]. ( Bakalov, SA; Domogadskiĭ, SP; Golitsyn, SP; Kolesnikova, GS; Masenko, VP; Molashenko, NV; Platonova, NM; Serdiuk, SE; Sviridenko, NIu, 2004) |
| "Thyrotoxicosis is less common than hypothyroidism." | 5.31 | Amiodarone-induced thyrotoxicosis presenting as hypokalemic periodic paralysis. ( Akinwande, AO; Ganti, AK; Laroia, ST; Newman, W; Zaw, KM, 2002) |
| "Amiodarone is an iodine-rich drug used in the treatment of resistant cardiac arrhythmias." | 5.29 | Thyrotoxicosis followed by hypothyroidism in patients treated with amiodarone. A possible consequence of a destructive process in the thyroid. ( Bianconi, L; Braverman, LE; Gardini, E; Minelli, R; Roti, E, 1993) |
| "Amiodarone is an antiarrhythmic drug, frequently used in cardiology, which may produce secondary effects on the thyroid function." | 5.29 | [Subtotal thyroidectomy. A treatment to keep in mind in amiodarone-induced thyrotoxicosis]. ( Alonso Ruiz, F; Altozano Gómez, JC; Alvarez Suárez-Bárcenas, JM; Díaz Pérez de Madrid, J; García Andoaín, JM; García Guerrero, JJ; López Mínguez, JR; Morales Pérez, F; Redondo Méndez, A, 1996) |
| "Treatment with amiodarone was continued; however, therapy with L-thyroxin was initiated, followed by a complete regression of the goiter." | 5.28 | Goiter and hypothyroidism during re-treatment with amiodarone in a patient who previously experienced amiodarone-induced thyrotoxicosis. ( Ish-Shalom, S; Kaplan, J, 1991) |
| "Amiodarone-induced thyrotoxicosis (AIT) may develop long after amiodarone withdrawal." | 5.17 | Amiodarone-induced thyrotoxicosis late after amiodarone withdrawal. ( Hachiya, H; Hirao, K; Isobe, M; Kawabata, M; Nakamura, T; Sasano, T; Sugiyama, K; Tanaka, Y; Yagishita, A, 2013) |
| "Amiodarone-induced thyrotoxicosis (AIT) is a recognized complication of amiodarone treatment with limited management options." | 5.17 | Body mass index and the development of amiodarone-induced thyrotoxicosis in adults with congenital heart disease--a cohort study. ( Ammash, NM; Bahn, RS; Brennan, MD; Nannenga, MR; Stan, MN; Thapa, P; Warnes, CA, 2013) |
| "Amiodarone-induced thyrotoxicosis (AIT) type 2 is self-limiting in nature, but most physicians are reluctant to continue amiodarone." | 5.16 | Treatment of amiodarone-induced thyrotoxicosis type 2: a randomized clinical trial. ( Dullaart, RP; Endert, E; Eskes, SA; Fliers, E; Geskus, RB; Links, TP; Wiersinga, WM, 2012) |
| "Amiodarone-induced thyrotoxicosis (AIT) is caused by excessive hormone synthesis and release (AIT I) or a destructive process (AIT II)." | 5.13 | The usefulness of 99mTc-sestaMIBI thyroid scan in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. ( Boi, F; Cocco, MC; Loy, M; Mariotti, S; Piga, M; Serra, A, 2008) |
| "To determine the incidence and predictability of amiodarone-induced thyrotoxicosis (AIT) and hypothyroidism (AIH) in patients with cardiomyopathy." | 5.13 | Incidence and predictability of amiodarone-induced thyrotoxicosis and hypothyroidism. ( Hofmann, A; Holzmannhofer, J; Nawara, C; Ofluoglu, S; Pirich, C; Strohmer, B, 2008) |
| "Amiodarone-induced thyrotoxicosis (AIT) are not uncommon endocrinopathies." | 5.12 | Amiodarone-induced thyrotoxicosis. ( Bricaire, L; Groussin, L; Schubert, L, 2021) |
| "Amiodarone-induced thyrotoxicosis (AIT) resulting from destructive thyroiditis (type 2) is commonly treated with glucocorticoids, but time needed to restore euthyroidism may be unacceptable for patients with underlying cardiac disorders." | 5.12 | Glucocorticoid response in amiodarone-induced thyrotoxicosis resulting from destructive thyroiditis is predicted by thyroid volume and serum free thyroid hormone concentrations. ( Aghini-Lombardi, F; Bartalena, L; Bogazzi, F; Dell'Unto, E; Martino, E; Rossi, G; Tanda, ML; Tomisti, L, 2007) |
| "Amiodarone-induced thyrotoxicosis (AIT) may develop either in apparently normal glands (type II AIT) or in the presence of thyroid abnormalities (type I AIT)." | 5.10 | Preparation with iopanoic acid rapidly controls thyrotoxicosis in patients with amiodarone-induced thyrotoxicosis before thyroidectomy. ( Aghini-Lombardi, F; Bartalena, L; Berti, P; Bogazzi, F; Braverman, LE; Brogioni, S; Cosci, C; Martino, E; Materazzi, G; Miccoli, P; Pinchera, A, 2002) |
| "Amiodarone-induced thyrotoxicosis (AIT) is a complex therapeutic challenge." | 5.10 | A stepwise approach to the treatment of amiodarone-induced thyrotoxicosis. ( Başkal, N; Erdogan, G; Erdogan, MF; Güleç, S; Tutar, E, 2003) |
| "Amiodarone-induced thyrotoxicosis (AIT) may occur either in the presence of underlying thyroid disease (type I AIT) or in apparently normal thyroid glands (type II AIT)." | 5.10 | Treatment of type II amiodarone-induced thyrotoxicosis by either iopanoic acid or glucocorticoids: a prospective, randomized study. ( Aghini-Lombardi, F; Bartalena, L; Bogazzi, F; Braverman, LE; Brogioni, S; Cosci, C; Dell'Unto, E; Grasso, L; Martino, E; Pinchera, A; Rossi, G, 2003) |
| "Amiodarone, a benzofuranic iodine-rich pan-anti-arrhythmic drug, induces amiodarone-induced thyrotoxicosis (AIT) in 7-15% of patients." | 5.01 | Issues in amiodarone-induced thyrotoxicosis: Update and review of the literature. ( Batisse-Lignier, M; Benichou, T; Dallel, S; Desbiez, F; Maqdasy, S; Montanier, N; Roche, B; Tauveron, I, 2019) |
| "We reported six patients in the age range from two weeks to 14 years, with complex congenital cardiac diseases and severe arrhythmias, who developed amiodarone-induced thyroid dysfunctions: thyrotoxicosis or hypothyroidism or both together." | 5.01 | Amiodarone-induced thyroid dysfunction in the developmental period: prenatally, in childhood, and adolescence - case reports and a review of the literature. ( Furtak, A; Januś, D; Kalicka-Kasperczyk, A; Kordon, Z; Rudziński, A; Starzyk, JB; Wędrychowicz, A; Wójcik, M, 2019) |
| "We made a review of available publications in PUBMED referring the amiodaroneinduced thyroid pathology, focusing on the differential diagnosis, made by nuclear medicine tests, of hypothyroidism (AIH) and hyperthyroidism expressed as: type I amiodarone induced thyrotoxicosis (AIT I), type II amiodarone induced thyrotoxicosis (AIT II), and less frequently as a mixt form, type III amiodarone induced thyrotoxicosis (AIT III)." | 4.95 | The Role of Radiopharmaceuticals in Amiodarone-Induced Thyroid Pathology. ( Irimie, A; Piciu, D, 2017) |
| "The off-label use of OCAs was reviewed for the management of neonatal and adult Graves' disease, subacute thyroiditis, amiodarone-induced thyroiditis (AIT), exogenous hyperthyroidism, toxic multinodular goiter (TMNG), thyrotropinoma, thyrotoxicosis during pregnancy, rapid pre-operative control of hyperthyroidism, and thyroid storm." | 4.90 | Review of oral cholecystographic agents for the management of hyperthyroidism. ( Kim, TY; Martinez, DS; Tyer, NM, 2014) |
| "We present three patients treated with amiodarone for atrial fibrillation who developed AIT at least 36 months after beginning the treatment." | 4.87 | [Response to adjuvant therapy with potassium perchlorate in amiodarone-induced thyrotoxicosis: observations on three cases]. ( Arias, N; Boix, E; González, VL; Moreno-Pérez, Ó; Picó, AM; Revert, P; Sánchez-Ortiga, R; Serrano, J, 2011) |
| "We present a patient with a rare combination of amiodarone-induced thyrotoxicosis and Eisenmenger's syndrome." | 4.85 | Surgical management of amiodarone-induced thyrotoxicosis in a patient with Eisenmenger's syndrome: literature review and case report. ( Ahmad, N; Jani, P; Pratap, R; Qayyum, A, 2009) |
| "Amiodarone-induced thyrotoxicosis (AIT) develops in 3% of amiodarone-treated patients in North America." | 4.85 | Amiodarone-induced thyrotoxicosis: a review. ( Houlden, RL; Tsang, W, 2009) |
| " More recently, it has been suggested that rhTSH is useful for treatment of multinodular goiter and amiodarone-induced thyrotoxicosis, as well as for diagnosis of congenital hypothyroidism." | 4.84 | Recombinant human thyrotropin in the management of thyroid disorders. ( Graf, H; Paz-Filho, GJ, 2008) |
| "Surgical treatment of amiodarone-associated thyrotoxicosis (AAT) is effective although fewer than 100 cases have been reported world wide." | 4.83 | Total thyroidectomy for amiodarone-associated thyrotoxicosis in patients with severe cardiac disease. ( Gough, IR; Gough, J, 2006) |
| "Amiodarone causes thyrotoxicosis in 3% of US patients who use it." | 4.82 | Amiodarone induced thyrotoxicosis: diagnostic and therapeutic strategies. ( Cabral, JM; Cardenas, GA; Leslie, CA, 2003) |
| "We report a case of amiodarone-induced thyrotoxicosis, and a broad review of the literature." | 4.82 | [Amiodarone-induced thyrotoxicosis: case report and review of the literature]. ( Bianconcini, M; Giannini, AL, 2003) |
| "Many patients with cardiac arrhythmias require concomitant therapy with warfarin and amiodarone." | 4.82 | Complex drug-drug-disease interactions between amiodarone, warfarin, and the thyroid gland. ( Ezra, D; Farfel, Z; Halkin, H; Kurnik, D; Loebstein, R; Olchovsky, D, 2004) |
| "Amiodarone-induced thyrotoxicosis (AIT) is a well-known complication of amiodarone treatment found in 3% to 12% of patients." | 4.82 | Amiodarone-induced thyrotoxicosis and thyroid cancer: clinical, immunohistochemical, and molecular genetic studies of a case and review of the literature. ( Falciglia, M; Nikiforov, YE; Saad, A; Steward, DL, 2004) |
| " Treatment with amiodarone may lead to changes in thyroid tests results and to development of hypothyroidism or thyrotoxicosis." | 4.82 | [Thyroid and cardiovascular disorders]. ( Gajek, J; Zyśko, D, 2004) |
| "Cardiovascular manifestations of thyrotoxicosis and thyroid dysfunction caused by amiodarone." | 4.82 | [Cardiovascular manifestations of thyrotoxicosis and thyroid dysfunction caused by amiodarone]. ( Barta, K; Lorincz, I; Nagy, E; Simkó, J; Szabó, Z; Varga, E, 2004) |
| "Pathogenesis, diagnostic procedures and therapy of amiodarone-induced thyrotoxicosis (AIT) and hypothyroidism (AIH) are briefly discussed." | 4.80 | [Therapy of amiodarone-induced thyrotoxicosis and hypothyroidism]. ( Gerber, H; Noth, D, 1999) |
| " The clinical and biochemical response to medical and surgical management of five consecutive Tasmanian patients presenting with severe type-II amiodarone-associated thyrotoxicosis was reviewed." | 4.80 | Refractory amiodarone-associated thyrotoxicosis: an indication for thyroidectomy. ( Burgess, JR; Claxton, S; Donovan, S; Greenaway, TM; Hoffman, L; Loughhead, M; Sinha, SN, 2000) |
| "Amiodarone is the most important drug in the treatment of ventricular arrhythmias and is widely used for atrial fibrillation." | 4.80 | [Amiodarone-induced thyrotoxicosis]. ( Cron, TA; Kaufmann, C; Meier, C; Oberholzer, M; Osswald, S; Staub, JJ, 2000) |
| "Patients with amiodarone-induced thyrotoxicosis (AIT) often receive initial therapy for thyrotoxicosis in several different medical settings before admission to a referral center." | 4.31 | Real-life Data on the Effect of Medical Therapy for Amiodarone-induced Thyrotoxicosis on CV Events and Hospitalizations. ( Bartalena, L; Bogazzi, F; Cappellani, D; Manetti, L; Marconcini, G, 2023) |
| "To report cardiac outcomes after total thyroidectomy for amiodarone-induced thyrotoxicosis according to the baseline left ventricular ejection fraction in a tertiary referral center." | 4.31 | Mortality After Total Thyroidectomy for Amiodarone-Induced Thyrotoxicosis According to Left Ventricular Ejection Fraction. ( Caillard, C; Drui, D; Frey, S; Knipping, G; Lande, G; Mahot, P; Mirallié, E; Pattier, S; Volteau, C, 2023) |
| "99m Tc-sestamibi thyroid scintigraphy (STS) can aid in differentiating between types 1 and 2 amiodarone-induced thyrotoxicosis (AIT)." | 4.12 | 99m Tc-Sestamibi Thyroid Scintigraphy in Amiodarone-Induced Thyrotoxicosis : Functional Imaging-Histopathologic Correlation. ( Better, N; Christie, M; Forehan, S; Fourlanos, S; Pattison, DA; Sivaratnam, D; Wang, R; Westcott, J, 2022) |
| " Ultrasound has a role in the investigation of Graves' disease, subacute thyroiditis, gestational thyrotoxicosis, postpartum thyroiditis, amiodarone thyrotoxicosis and goiter with or without adenoma, but adenomas are usually investigated by endocrine surgeons in Sweden." | 4.12 | [Thyroid ultrasound and its role in the investigation of thyroid disease]. ( Almquist, M; Koutouridou, E; Lantz, M; Mijovic, Z; Pellby, D; Planck, T; Tsoumani, K, 2022) |
| "We see an increasing number of patients with amiodarone-induced thyrotoxicosis." | 4.02 | Amiodarone-induced thyrotoxicosis. ( Anfinsen, OG; Lima, K, 2021) |
| "The authors present a case of a 55-year-old gentleman with a medical history of atrial fibrillation on amiodarone who presented with weight loss, palpitations and exertional dyspnoea." | 4.02 | Amiodarone-induced type 2 thyrotoxicosis. ( Abela, A; Fava, S; Mifsud, S; Portelli, D, 2021) |
| "It is not known whether total thyroidectomy is more favorable than medical therapy for patients with amiodarone-induced thyrotoxicosis (AIT)." | 3.96 | Comparison Between Total Thyroidectomy and Medical Therapy for Amiodarone-Induced Thyrotoxicosis. ( Bartalena, L; Bogazzi, F; Cappellani, D; Di Certo, AM; Iervasi, G; Manetti, L; Mantuano, M; Marcocci, C; Marconcini, G; Martino, E; Materazzi, G; Morganti, R; Papini, P; Pingitore, A; Scattina, I; Tomisti, L; Urbani, C, 2020) |
| "A patient with underlying Hashimoto's thyroiditis developed amiodarone-induced thyrotoxicosis type 1 that was successfully treated using methimazole in combination with potassium iodide." | 3.96 | Successful Treatment of Amiodarone-induced Thyrotoxicosis Type 1 in Combination with Methimazole and Potassium Iodide in a Patient with Hashimoto's Thyroiditis. ( Hirose, T; Ikehara, K; Katoh, D; Kumashiro, N; Tsuboi, K; Uchino, H; Yoshino, H, 2020) |
| "BACKGROUND Amiodarone-induced thyrotoxicosis can be refractory to medical treatment seldom requiring surgical intervention." | 3.96 | Surgical Treatment of Amiodarone-Induced Thyrotoxicosis in an Adult with Congenital Heart Disease: An Anesthetists Perspective. ( Al-Halabi, E; El-Asmar, JM; Naja, AS, 2020) |
| "Patients with amiodarone-induced thyrotoxicosis (AIT) and severely reduced left ventricular ejection fraction (LVEF) have a high mortality rate that may be reduced by total thyroidectomy." | 3.96 | Duration of Exposure to Thyrotoxicosis Increases Mortality of Compromised AIT Patients: the Role of Early Thyroidectomy. ( Bartalena, L; Bogazzi, F; Cappellani, D; Cosentino, G; Di Certo, AM; Manetti, L; Marconcini, G; Martino, E; Materazzi, G; Morganti, R; Papini, P; Tanda, ML; Urbani, C, 2020) |
| "Amiodarone-induced thyrotoxicosis (AIT) affects up to 3% of treated patients." | 3.91 | Pulsed intravenous methylprednisolone combined with oral steroids as a treatment for poorly responsive type 2 amiodarone-induced thyrotoxicosis. ( Campi, I; Fugazzola, L; Groppelli, A; Parati, G; Perego, GB; Persani, L; Ravogli, A, 2019) |
| " The objectives of this study were to evaluate the risk of ATD-related agranulocytosis in patients with amiodarone-induced thyrotoxicosis (AIT), and to compare it with the agranulocytosis risk in patients with thyrotoxicosis due to other etiologies treated with ATDs." | 3.91 | Increased Risk of Antithyroid Drug Agranulocytosis Associated with Amiodarone-Induced Thyrotoxicosis: A Population-Based Cohort Study. ( Gershinsky, M; Gronich, N; Lavi, I; Saliba, W; Shapira, C, 2019) |
| "We describe a case of amiodarone-induced thyrotoxicosis (AIT) with cardiopulmonary arrest (CPA) in a 49-year-old woman." | 3.88 | Amiodarone-induced Thyrotoxicosis with Cardiopulmonary Arrest. ( Hasegawa, N; Inoue, K; Kakuta, Y; Kondo, T; Kowase, S; Miki, K; Nishikawa, T; Omura, M; Saito, J; Sugisawa, C; Tsurutani, Y, 2018) |
| "Distinguishing between amiodarone-induced thyrotoxicosis (AIT) caused by excessive hormone synthesis (AIT-1) or by a destructive process (AIT-2) has important therapeutic implications, but is still difficult and debated." | 3.88 | Amiodarone-Induced Thyrotoxicosis: Differential Diagnosis Using 99mTc-SestaMIBI and Target-to-Background Ratio (TBR). ( Barollo, S; Bertazza, L; Bodanza, V; Cavedon, E; Cecchin, D; Censi, S; Gusella, S; Manso, J; Mian, C; Watutantrige-Fernando, S, 2018) |
| "Amiodarone is used for the maintenance of sinus rhythm in patients with arrhythmias, but thyroid dysfunction (amiodarone-induced thyrotoxicosis (AIT) or amiodarone-induced hypothyroidism (AIH)) is a common adverse effect." | 3.85 | The clinical value of regular thyroid function tests during amiodarone treatment. ( Benjamens, S; Dullaart, RPF; Links, TP; Rienstra, M; Sluiter, WJ; van Gelder, IC, 2017) |
| "Amiodarone-induced thyrotoxicosis (AIT) is caused by amiodarone as a side effect of cardiovascular disease treatment." | 3.85 | Evaluation of ( Wang, J; Zhang, R, 2017) |
| "Iodine-induced thyrotoxicosis, which raises several diagnostic and therapeutical challenges, is often overlooked." | 3.83 | Iodine-induced hyperthyroidism as combination of different etiologies: an overlooked entity in the elderly. ( Cascio, C; Foppiani, L; Lo Pinto, G, 2016) |
| "Reintroduction of amiodarone in patients with a history of amiodarone-induced thyrotoxicosis (AIT) is rarely used." | 3.83 | Amiodarone-Induced Thyrotoxicosis Recurrence After Amiodarone Reintroduction. ( Auclair, C; Batisse-Lignier, M; Citron, B; Desbiez, F; Lusson, JR; Maqdasy, S; Roche, B; Tauveron, I; Thieblot, P, 2016) |
| "Amiodarone-induced thyrotoxicosis (AIT) type I describes inducement of clinical hyperthyroidism by excessive thyroidal iodine in the setting of latent Graves disease, and therapy differs from that used for AIT type II." | 3.83 | 99mTc Sestamibi Thyroid Scan in Amiodarone-Induced Thyrotoxicosis Type I. ( Lee, H; Patel, NR; Tamara, LA, 2016) |
| "Amiodarone is an antiarrhythmic drug that is frequently used to control atrial fibrillation (AF)." | 3.83 | Safety and efficacy of early radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation complicated with amiodarone-induced thyrotoxicosis. ( Cai, S; Feng, W; Sun, L; Wang, M; Zhao, Q, 2016) |
| "Amiodarone-induced thyrotoxicosis (AIT) is caused by excessive hormone synthesis and release (AIT I), a destructive thyroiditis (AIT II), or a combination of both (AIT Ind)." | 3.81 | Quantitative assessment of thyroid-to-background ratio improves the interobserver reliability of technetium-99m sestamibi thyroid scintigraphy for investigation of amiodarone-induced thyrotoxicosis. ( Better, N; Forehan, S; Gunawardana, D; Lichtenstein, M; Pattison, DA; Sivaratnam, D; Toh, HB; Westcott, J, 2015) |
| "The development of amiodarone-induced thyrotoxicosis (AIT) can threaten the hemodynamic stability of adult patients with congenital heart disease (CHD)." | 3.80 | Amiodarone-induced thyrotoxicosis in adults with congenital heart disease--clinical presentation and response to therapy. ( Bahn, RS; Brennan, MD; Sathananthan, M; Stan, MN; Thapa, P; Warnes, CA, 2014) |
| "Amiodarone is associated with thyroid dysfunction and life-threatening thyrotoxicosis." | 3.80 | Preoperative therapeutic apheresis for severe medically refractory amiodarone-induced thyrotoxicosis: a case report. ( Ariano, RE; Dostmohamed, H; Houston, DS; Katz, P; Knoll, C; Lewis, B; Schacter, I; Yamamoto, J; Zarychanski, R, 2014) |
| "Incidence and risk factors of amiodarone-induced thyrotoxicosis (AIT) and amiodarone-induced hypothyroidism (AIH) were assessed." | 3.80 | Amiodarone-induced thyroid dysfunction in Taiwan: a retrospective cohort study. ( Chang, JW; Chang, SL; Chen, PJ; Chen, SA; Huang, CJ; Huang, DF; Jap, TS; Lin, LY, 2014) |
| " He was diagnosed with atrial fibrillation 2 years previously and started on amiodarone and warfarin." | 3.80 | Amiodarone-induced thyrotoxicosis: type 1 or type 2? ( Khan, A; Puttanna, A; Raskauskiene, D, 2014) |
| " A year later, he developed thyrotoxicosis, presumably secondary to amiodarone administered for ventricular fibrillation." | 3.79 | Thyrotoxicosis-facilitated bridge to recovery with a continuous-flow left ventricular assist device. ( Frazier, OH; Letsou, GV; Reverdin, S, 2013) |
| " Amiodarone, the drug of choice for arrhythmia treatment in such patients, can cause a number of complications, including amiodarone induced thyrotoxicosis (AIT)." | 3.79 | Amiodarone-induced thyrotoxicosis in a case of Eisenmenger's syndrome. ( Czarnywojtek, A; Fichna, M; Florek, E; Greberska, W; Guzik, P; Kwiecinska, B; Lodyga, M; Ruchała, M; Waśko, R; Woliński, K; Zgorzalewicz-Stachowiak, M, 2013) |
| "To report a case of amiodarone-induced thyrotoxicosis (AIT) concomitant with thyroid cancer in multinodular goiter (MNG)." | 3.78 | Amiodarone-induced thyrotoxicosis with thyroid papillary cancer in multinodular goiter: case report. ( Akamizu, T; Inaba, H; Kobayashi, S; Komatsu, M; Suzuki, S; Takeda, T, 2012) |
| " Here we describe a Caucasian woman who developed a bronchiolitis obliterans organizing pneumonia (BOOP)-like interstitial pneumonia after PTU administration for amiodarone-induced thyrotoxicosis." | 3.78 | Propylthiouracil-induced interstitial pneumonia in a Caucasian woman with amiodarone-induced thyrotoxicosis. ( Brigante, G; Diazzi, C; Rochira, V; Rossi, G, 2012) |
| "We prospectively collected cases of amiodarone-associated thyrotoxicosis requiring thyroidectomy due to failure of antithyroid treatment, despite amiodarone discontinuation." | 3.78 | Total thyroidectomy for amiodarone-associated thyrotoxicosis: should surgery always be delayed for pre-operative medical preparation? ( Duverger, V; Merat, S; Perrier, E; Pierret, C; Pons, Y; Tourtier, JP, 2012) |
| "Patients with amiodarone-induced thyrotoxicosis (AIT) and left ventricular (LV) systolic dysfunction have a high mortality rate." | 3.78 | Total thyroidectomy in patients with amiodarone-induced thyrotoxicosis and severe left ventricular systolic dysfunction. ( Bartalena, L; Bogazzi, F; De Napoli, L; Marchello, A; Mariotti, R; Martino, E; Materazzi, G; Miccoli, P; Moretti, M; Rossi, G; Tomisti, L, 2012) |
| "We included 303 consecutive patients with amiodarone therapy for cardiac arrhythmias (260 with atrial fibrillation and 43 with ventricular arrhythmias)." | 3.77 | Determinants and outcome of amiodarone-associated thyroid dysfunction. ( Ahmed, S; Links, TP; Van Gelder, IC; Van Veldhuisen, DJ; Wiesfeld, AC, 2011) |
| "Amiodarone (AM)-induced thyrotoxicosis (AIT) is a condition with uncertainties from the diagnostic and therapeutic standpoints." | 3.77 | Importance of (99)mTc-sestaMIBI thyroid scan in a case of amiodarone-induced thyrotoxicosis. ( Braga, DC; Carvalho, D; Fernandes, H; Matos, MJ; Pereira, J; Souto, SB, 2011) |
| "The identification of the different subtypes of amiodarone-induced thyrotoxicosis (AIT) may provide a rational basis for the choice of the appropriate medical treatment." | 3.76 | Amiodarone-induced thyrotoxicosis in children and adolescents is a possible outcome in patients with low iodine intake. ( Atalay, S; Berberoğlu, M; Hacihamdioğlu, B; Oçal, G; Savaş Erdeve, S; Siklar, Z; Tutar, E, 2010) |
| "Amiodarone-induced thyrotoxicosis (AIT) should be included in differential diagnoses of thyrotoxicosis in presence of a suggestive drug history." | 3.76 | [A rare cause of thyreotoxicosis]. ( Fend, F; Kurth, R; Müssig, K; Sauer-Schulz, A; Schnauder, G; Teichmann, R, 2010) |
| "Amiodarone-induced thyrotoxicosis (AIT) is a clinical condition that is notoriously difficult to manage; the relative risk of adverse cardiovascular events in these patients compared with euthyroid patients is largely unknown." | 3.75 | Amiodarone-induced thyrotoxicosis is a predictor of adverse cardiovascular outcome. ( Chow, WH; Fan, K; Jim, MH; Lee, CH; Mok, M; Shea, YF; Siu, CW; Tse, HF; Yiu, KH; Yuen, M, 2009) |
| "A 64-year-old female with atrial fibrillation and nodular goiter progressed to overt thyrotoxicosis after receiving therapy with amiodarone 200 mg/day for less than 12 weeks." | 3.75 | Amiodarone-induced thyrotoxicosis in a patient with autonomously functioning nodular goiter. ( Hsiao, SH; Huang, SM; Hung, HC; Liang, YL; Ou, HY; Peng, SL; Wu, TJ, 2009) |
| "Type 2 amiodarone-induced thyrotoxicosis (AIT) is a destructive thyroiditis usually responsive to glucocorticoids; however, recent surveys showed that many expert thyroidologists worldwide use thionamides for type 2 AIT patients." | 3.75 | Glucocorticoids are preferable to thionamides as first-line treatment for amiodarone-induced thyrotoxicosis due to destructive thyroiditis: a matched retrospective cohort study. ( Bartalena, L; Bogazzi, F; Dell'Unto, E; Martino, E; Pepe, P; Rossi, G; Tomisti, L, 2009) |
| "We describe the effects of iopanoic acid on daily levels of free triiodothyronine (FT(3)) and free thyroxine (FT(4)) in a patient with progressive type II amiodarone-induced thyrotoxicosis (AIT) who was undergoing thyroidectomy." | 3.74 | Pharmacodynamic effect of iopanoic acid on free T(3) and T(4) levels in amiodarone-induced thyrotoxicosis. ( Falciglia, M; Matrka, L; Nikiforov, Y; Steward, D, 2008) |
| "Amiodarone-induced thyrotoxicosis is a life-threatening condition." | 3.74 | Combination of minimally invasive thyroid surgery and local anesthesia associated to iopanoic acid for patients with amiodarone-induced thyrotoxicosis and severe cardiac disorders: a pilot study. ( Ambrosini, CE; Berti, P; Bogazzi, F; Martino, E; Materazzi, G; Miccoli, P, 2007) |
| "Twelve patients--7 men and 5 women, aged 63 to 82 years--presented with drug-induced fulminant thyrotoxicosis following 1 to 12 months of amiodarone treatment (11 patients, mean 7 months) and after a 6 months course of interferon-alpha treatment (one patient)." | 3.74 | Drug-induced thyrotoxicosis: the surgical option. ( Lorberboym, M; Schachter, P, 2007) |
| "To evaluate the usefulness of Doppler parameters in the differentiation between the two types of amiodarone-associated thyrotoxicosis (AAT)." | 3.74 | Differentiation between the two types of amiodarone-associated thyrotoxicosis using duplex and amplitude Doppler sonography. ( Cerri, GG; Chammas, MC; Farage, L; Jorge, PT; Macedo, TA; Santos, VA; Souza, LP; Watanabe, T, 2007) |
| "This study sought to determine the clinical course and predictors of long-term outcome in patients with documented amiodarone-induced thyrotoxicosis (AIT)." | 3.74 | Amiodarone-induced thyrotoxicosis: clinical course and predictors of outcome. ( Ammann, P; Bilz, S; Conen, D; Kaufmann, C; Melly, L; Muller, B; Osswald, S; Schaer, B; Sticherling, C, 2007) |
| "Amiodarone-induced thyrotoxicosis (AIT) may be caused by excessive thyroidal hormone synthesis and release (type 1) or by a destructive process (type 2)." | 3.74 | Color-flow Doppler sonography in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. ( Cianchetti, ME; Loy, M; Mariotti, S; Melis, A; Perra, E; Piga, M; Pinna, G; Serra, A, 2007) |
| "Amiodarone-induced thyrotoxicosis (AIT) with features consistent with both AIT type I (in which thyroid antibodies and nodular goiter are present) and AIT type II (which is not responsive to thionamide therapy and eventually leads to permanent hypothyroidism)." | 3.74 | Treatment of amiodarone-associated thyrotoxicosis. ( Franklyn, JA; Gammage, MD, 2007) |
| "We report the case of a 60 year old female patient on continuous systemic anticoagulation therapy with coumarin due to mechanical aortic valve replacement and a more than 3 years lasting amiodarone therapy due to severe ventricular extrasystoles suffering from amiodarone induced thyrotoxicosis (AIT)." | 3.74 | Impact of thyroid metabolism on the course of INR levels in a patient with systemic anticoagulation suffering from amiodarone-induced thyrotoxicosis. ( Biersack, HJ; Brockmann, H; Bucerius, J; Ezziddin, S; Palmedo, H, 2007) |
| " Two were cases of type I amiodarone-induced thyrotoxicosis (AIT) treated with methimazole." | 3.74 | Differential diagnosis and appropriate treatment of four thyrotoxic patients with Graves' disease required to take amiodarone due to life-threatening arrhythmia. ( Kasanuki, H; Kodama, H; Obara, T; Omi, Y; Sato, K; Seki, T; Shiga, T; Takano, K; Yamada, E; Yamazaki, K, 2008) |
| "Relationship between amiodarone-associated thyroid dysfunction and antiarrhythmic activity of amiodarone was studied in 27 patients (13 with hypothyroidism, 8 with hyperthyroidism, 6 with euthyroid hyperthyroxinemia)." | 3.73 | [Thyroid dysfunction in long-term amiodarone administration. Correlation of the antiarrhythmic activity of amiodarone with its effect on thyroid function]. ( Bakalov, SA; Golitsyn, SP; Molashenko, NV; Platonova, NM; Serdiuk, SE; Sitina, VK; Sviridenko, NIu, 2005) |
| "Amiodarone-induced thyrotoxicosis (AIT) type 1 occurs in subjects with an underlying thyroid disease, whereas type 2 AIT is a form of destructive thyroiditis." | 3.73 | Amiodarone-induced thyrotoxicosis due to destructive thyroiditis: therapeutic recommendations. ( Dietlein, M; Schicha, H, 2005) |
| " Administration of amiodarone for atrial fibrillation led to the development of hyperthyroidism." | 3.73 | Amiodarone-induced hyperthyroidism in a patient with functioning papillary carcinoma of the thyroid and extensive hepatic metastases. ( Mackie, GC; Shulkin, BL, 2005) |
| "In this report we discuss a patient with predominant right heart failure and pulmonary hypertension, caused by thyrotoxicosis due to Graves disease, which deteriorated to asystole, due to amiodarone administration for rapid atrial fibrillation." | 3.73 | Pulmonary hypertension and predominant right heart failure in thyrotoxicosis. ( Goldin, Y; Justo, D; Nimrod, A; Paran, Y, 2006) |
| "Amiodarone is a powerful antiarrhythmic drug; however, its use may be complicated by thyrotoxicosis." | 3.73 | Continuation of amiodarone therapy despite type II amiodarone-induced thyrotoxicosis. ( Bertagna, X; Bertherat, J; Duboc, D; Guignat, L; Meune, C; Mouly, S; Thomopoulos, P; Uzan, L; Weber, S, 2006) |
| "Among the amiodarone-induced thyroid dysfunctions, thyrotoxicosis is the most troublesome and with the highest rate of morbidity and mortality." | 3.73 | [Use of lithium carbonate for the treatment of amiodarone-induced thyrotoxicosis]. ( Boeving, A; Carvalho, GA; Cubas, ER; Graf, H; Santos, CM, 2005) |
| "Amiodarone-induced thyrotoxicosis (AIT) is a challenging management problem, since patients treated with amiodarone invariably have underlying heart disease." | 3.73 | Amiodarone-induced thyrotoxicosis: left ventricular dysfunction is associated with increased mortality. ( Diamond, T; Lewis, M; O'Sullivan, AJ, 2006) |
| "Although there are two types of amiodarone-induced thyrotoxicosis (AIT), only type II AIT has been seen at our institution in Japan so far." | 3.73 | Mild and short recurrence of type II amiodarone-induced thyrotoxicosis in three patients receiving amiodarone continuously for more than 10 years. ( Hagiwara, N; Kasanuki, H; Matsuda, N; Onoda, N; Sato, K; Shiga, T; Takano, K, 2006) |
| " Most respondents lived in iodine-sufficient areas and observed that amiodarone-induced hypothyroidism (AIH) is more common than AIT." | 3.73 | Management of amiodarone-induced thyrotoxicosis in Latin America: an electronic survey. ( Albino, CC; Bartalena, L; Diehl, LA; Graf, H; Martino, E; Romaldini, JH; Wiersinga, WM, 2006) |
| "Two main forms of amiodarone- induced thyrotoxicosis (AIT) exist: type 1 AIT is a condition of true hyperthyroidism developing in patients with pre-existing thyroid disorders, and usually requires thyroid ablative treatment." | 3.73 | Long-term outcome of thyroid function after amiodarone-induced thyrotoxicosis, as compared to subacute thyroiditis. ( Aghini-Lombardi, F; Bartalena, L; Bogazzi, F; Cosci, C; Dell'Unto, E; Martino, E; Pinchera, A; Sardella, C; Tanda, ML; Tomisti, L, 2006) |
| "Eleven patients developed amiodarone- induced thyrotoxicosis (AIT), ten developed amiodarone-induced hypothyroidism (AIH) and one patient first developed AIT, followed by AIH." | 3.72 | Differential diagnosis and clinical course of amiodarone-induced thyroid dysfunction. ( Acu, B; Alyan, O; Arda, K; Demirkan, D; Ozdemir, O; Soylu, M, 2003) |
| " This study was intended to determine whether CRP levels could differentiate between inflammatory and noninflammatory thyroid conditions, especially between type II inflammatory amiodarone-induced thyrotoxicosis (AIT) and type I iodine-induced AIT." | 3.72 | The prevalence of elevated serum C-reactive protein levels in inflammatory and noninflammatory thyroid disease. ( Bogazzi, F; Braverman, LE; Brogioni, S; Lazarus, JH; Martino, E; Pardini, E; Parkes, AB; Pearce, EN; Pellegrini, G; Pinchera, A, 2003) |
| "Amiodarone was required in 10 cases of recurrent symptomatic paroxysmal atrial fibrillation (AF) and in 5 cases of ventricular tachycardia (VT) (M = 12, F = 3, mean age: 63 +/- 14)." | 3.72 | Radioiodine ablation of the thyroid to prevent recurrence of amiodarone-induced thyrotoxicosis in patients with resistant tachyarrhythmias. ( Arlot, S; Delonca, J; Hermida, JS; Jarry, G; Moullart, V; Rey, JL; Schvartz, C; Tcheng, E, 2004) |
| "Thyrotoxicosis is a well-documented and studied complication of treatment with amiodarone, but little has been written about the risks and treatment of recurrent thyrotoxicosis upon re-exposure to amiodarone." | 3.72 | Can amiodarone be restarted after amiodarone-induced thyrotoxicosis? ( Braverman, LE; Cooper, DS; Kloos, RT; Ladenson, PW; Ryan, LE, 2004) |
| "To determine how expert European thyroidologists assess and treat amiodarone-induced thyrotoxicosis (AIT)." | 3.72 | Diagnosis and management of amiodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association. ( Bartalena, L; Bogazzi, F; Lai, A; Martino, E; Piantanida, E; Tanda, ML; Wiersinga, WM, 2004) |
| "Amiodarone-associated thyrotoxicosis (AAT) is often poorly tolerated owing to underlying cardiac disease, and it is frequently refractory to conventional medical treatment." | 3.72 | Surgical management of amiodarone-associated thyrotoxicosis: Mayo Clinic experience. ( Brennan, MD; Farley, DR; Grant, CS; Houghton, SG; Thompson, GB; van Heerden, JA, 2004) |
| "Amiodarone-induced thyrotoxicosis developed in 31 patients (49." | 3.72 | Amiodarone-induced thyroid dysfunction in cardiac patients from areas with iodine deficiency. ( Barbu, C; Bunghez, R; Coculescu, M; Fica, S; Trifănescu, R; Ursu, H; Vârtej, I, 2004) |
| "Between 1992 and 2000 in the group of the patients before heart transplantation, amiodarone induced thyrotoxicosis occurred in 5 (4 male and 1 female, average age 45." | 3.71 | [Thyrotoxicosis in heart recipients]. ( Biernat, M; Garlicki, M; Plicner, D; Sadowski, J; Skirzyńska, D; Wierzbicki, K; Wysocka, T, 2002) |
| "Of the 347 patients who underwent thyroidectomy, 54 (16%) had thyrotoxicosis, secondary to Graves' disease (32 patients), toxic multinodular goiter (18 patients), thyroiditis (2 patients), or amiodarone (2 patients)." | 3.71 | Thyroidectomy for selected patients with thyrotoxicosis. ( McHenry, CR; Mittendorf, EA, 2001) |
| "Amiodarone-induced thyrotoxicosis is a life-threatening problem that is very effectively managed by total thyroidectomy, although often many of these patients are considered "too unfit" for anaesthesia." | 3.71 | Anaesthesia for amiodarone-induced thyrotoxicosis: a case review. ( Delbridge, L; Robinson, B; Sutherland, J, 2001) |
| "For a patient with idiopathic dilated cardiomyopathy, an implantable defibrillator, and amiodarone induced thyrotoxicosis associated with ventricular fibrillation storm." | 3.71 | Electrical storm due to amiodarone induced thyrotoxicosis in a young adult with dilated cardiomyopathy: thyroidectomy as the treatment of choice. ( Manios, EG; Marketou, ME; Simantirakis, EN; Vardas, PE, 2001) |
| "Current thinking is that amiodarone-induced thyrotoxicosis (AIT) might be either iodine-induced thyrotoxicosis in latent hyperthyroidism (Type 1) or destructive thyroiditis (Type 2), and also that colour-flow Doppler sonography (CFDS) of the thyroid and serum interleukin 6 (IL-6) are tools that can classify AIT and direct treatment." | 3.71 | Clinical experience of amiodarone-induced thyrotoxicosis over a 3-year period: role of colour-flow Doppler sonography. ( Bennet, WM; Eaton, SE; Euinton, HA; Newman, CM; Weetman, AP, 2002) |
| "Amiodarone-induced thyrotoxicosis (AIT) is a difficult management problem about which there are little published data." | 3.71 | Successful treatment of amiodarone-induced thyrotoxicosis. ( Franklyn, JA; Gammage, MD; Osman, F; Sheppard, MC, 2002) |
| "Amiodarone-induced thyrotoxicosis (AIT) may develop either in apparently normal thyroid glands (Type II AIT) or in the presence of sub-clinical thyroid abnormalities (either autonomous goiter or latent Graves' disease; Type I AIT)." | 3.71 | Iopanoic acid rapidly controls type I amiodarone-induced thyrotoxicosis prior to thyroidectomy. ( Aghini-Lombardi, F; Bartalena, L; Basolo, F; Bogazzi, F; Braverman, LE; Cosci, C; Lupi, I; Martino, E; Miccoli, P; Pinchera, A; Santini, F; Tanda, ML, 2002) |
| "Since amiodarone was first marketed in 1992 in Japan, the incidence of amiodarone-induced thyrotoxicosis (AIT) has been increasing." | 3.70 | Amiodarone-induced thyrotoxicosis associated with thyrotropin receptor antibody. ( Demura, H; Kanaji, Y; Kasanuki, H; Ohnishi, S; Sato, K; Yamazaki, K, 1998) |
| "Amiodarone may induce hyper- or hypothyroidism." | 3.70 | High prevalence of thyroid dysfunction in adult patients with beta-thalassemia major submitted to amiodarone treatment. ( Balestrieri, A; Lai, ME; Loviselli, A; Mandas, A; Mariotti, S; Martino, E; Murenu, S; Sau, F; Vacquer, S; Valentino, L, 1999) |
| "Iodine-induced thyrotoxicosis or "jodbasedow phenomenon" has been reported throughout the world since iodine has been administered to treat endemic goitre." | 3.70 | [Iodine-induced hyperthyroidism (iodine-induced Basedow's disease): a current disease picture]. ( Brander, L; Buess, M; Henzen, C, 1999) |
| "A patient with amiodarone-induced thyrotoxicosis and autonomous nodule was treated with percutaneous ethanol injection (PEI) in 8 sessions." | 3.69 | Percutaneous ethanol injection therapy of autonomous nodule and amiodarone-induced thyrotoxicosis. ( Caraccio, N; Casolaro, A; Del Guerra, P; Franchi, F; Monzani, F; Pucci, E, 1994) |
| "Treatment with the antiarrhythmic agent amiodarone results in alterations in thyroid hormone metabolism, and can induce either hypothyroidism or hyperthyroidism (amiodarone-associated thyrotoxicosis, AAT)." | 3.69 | Nongoitrous (type I) amiodarone-associated thyrotoxicosis: evidence of follicular disruption in vitro and in vivo. ( Bahn, RS; Brennan, MD; Carney, JA; Erickson, DZ, 1995) |
| "Two patients with amiodarone-induced thyrotoxicosis were treated successfully with potassium perchlorate and carbimazole while treatment with amiodarone was continued." | 3.69 | Two cases of amiodarone-induced thyrotoxicosis successfully treated with a short course of antithyroid drugs while amiodarone was continued. ( Düren, DR; Trip, MD; Wiersinga, WM, 1994) |
| "Amiodarone, an iodine-rich cardiac drug, may induce thyrotoxicosis (AIT), which can occur in patients with preexisting thyroid abnormalities and in subjects with apparently normal thyroid glands." | 3.69 | Serum interleukin-6 in amiodarone-induced thyrotoxicosis. ( Aghini-Lombardi, F; Bartalena, L; Braverman, LE; Brogioni, S; Grasso, L; Martino, E, 1994) |
| "Amiodarone-induced thyrotoxicosis (AIT) occurs in both abnormal (type I) and apparently normal (type II) thyroid glands due to iodine-induced excessive thyroid hormone synthesis in patients with nodular goiter or latent Graves' disease (type I) or to a thyroid-destructive process caused by amiodarone or iodine (type II)." | 3.69 | Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study. ( Bartalena, L; Bogazzi, F; Brogioni, S; Burelli, A; Grasso, L; Martino, E, 1996) |
| "Amiodarone-induced thyrotoxicosis occurs in 2-12." | 3.69 | Ultrastructural evidence of thyroid damage in amiodarone-induced thyrotoxicosis. ( Bernasconi, R; Boldorini, R; Cappiello, E; Piraneo, S; Raggi, U; Tosoni, A, 1995) |
| "We describe a patient who was treated with amiodarone for ventricular arrhythmia based on arrhythmogenic right ventricular dysplasia and who subsequently developed severe amiodarone-induced thyrotoxicosis." | 3.69 | A case of amiodarone-induced thyrotoxicosis successfully treated with prednisolone. ( Hayashi, K; Kondoh, J; Numaguchi, Y; Sassa, H; Sone, T; Suzuki, T; Tsuboi, H, 1997) |
| "We report a case of amiodarone-induced thyrotoxicosis, diagnosed with a systematic laboratory investigation in a 64-year-old patient, for haematuria." | 3.69 | [Amiodarone-induced thyrotoxicosis cured by thyroidectomy]. ( Guerin-Robardey, AM; Le Cosquer, P; Ossart, M, 1996) |
| "We conclude that lithium is a useful and safe medication for treatment of iodine-induced thyrotoxicosis caused by amiodarone." | 3.69 | Lithium treatment in amiodarone-induced thyrotoxicosis. ( Adawi, F; Baron, E; Dickstein, G; Ish-Shalom, S; Kaplan, J; Shechner, C, 1997) |
| "Amiodarone-induced thyrotoxicosis (AIT) occurs both in abnormal thyroid glands (nodular goiter, latent Graves' disease) (type I AIT) or in apparently normal thyroid glands (type II AIT)." | 3.69 | Color flow Doppler sonography rapidly differentiates type I and type II amiodarone-induced thyrotoxicosis. ( Bartalena, L; Bartolozzi, C; Bogazzi, F; Brogioni, S; Burelli, A; Martino, E; Mazzeo, S; Vitti, P, 1997) |
| "The present report illustrates the clinical and biochemical outcome in two amiodarone iodine-induced thyrotoxicosis (AIIT) patients submitted to plasmapheresis." | 3.68 | Treatment of amiodarone iodine-induced thyrotoxicosis with plasmapheresis and methimazole. ( Aghini-Lombardi, F; Braverman, LE; Fosella, PV; Grasso, L; Mariotti, S; Martino, E; Pinchera, A, 1993) |
| "Amiodarone-induced thyrotoxicosis (AIT) is a rare disorder that is frequently refractory to conventional pharmacologic therapy." | 3.68 | Amiodarone-induced thyrotoxicosis: clinical presentation and expanded indications for thyroidectomy. ( Esselstyn, CB; Kinney, W; McHenry, CR; Mulligan, DC, 1993) |
| "In a patient chronically treated with amiodarone, subclinical iodine-induced hypothyroidism occurred as a result of excess iodine released from the amiodarone molecule." | 3.68 | Subclinical hypothyroidism, overt thyrotoxicosis and subclinical hypothyroidism: the subsequent phases of thyroid function in a patient chronically treated with amiodarone. ( Bianconi, L; Gardini, E; Minelli, R; Roti, E; Salvi, M, 1992) |
| "Amiodarone-induced thyrotoxicosis (AIT) occurs most frequently in patients with underlying thyroid disease and is generally believed to be due to the iodine contamination of amiodarone and iodine released by the metabolism of the drug." | 3.68 | Iodine-induced subclinical hypothyroidism in euthyroid subjects with a previous episode of amiodarone-induced thyrotoxicosis. ( Bianconi, L; Braverman, LE; Gardini, E; Gavaruzzi, G; Minelli, R; Neri, TM; Roti, E; Ugolotti, G, 1992) |
| "We report four cases of life-threatening amiodarone iodine-induced thyrotoxicosis." | 3.68 | Life-threatening thyrotoxicosis induced by amiodarone in patients with benign heart disease. ( Georges, JL; Lenormand, ME; Normand, JP; Schwob, J, 1992) |
| "To determine the incidence and predictability and to elucidate the pathogenesis of amiodarone-induced thyrotoxicosis (AIT) and hypothyroidism (AIH)." | 3.68 | Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. ( Plomp, TA; Trip, MD; Wiersinga, W, 1991) |
| "Amiodarone-induced thyrotoxicosis (AIT) is generally believed to result from increased hormonal synthesis related to the iodine overload." | 3.68 | Amiodarone-induced thyrotoxicosis suggestive of thyroid damage. ( Brohet, C; De Nayer, P; Gangji, D; Lambert, M; Unger, J, 1990) |
| "Treatment of amiodarone iodine-induced thyrotoxicosis is often unsuccessful." | 3.67 | Rapid effectiveness of prednisone and thionamides combined therapy in severe amiodarone iodine-induced thyrotoxicosis. Comparison of two groups of patients with apparently normal thyroid glands. ( Barbier, Y; Bornet, H; Broussolle, C; Ducottet, X; Martin, C; Noel, G; Orgiazzi, J, 1989) |
| "We describe a case of amiodarone-induced thyrotoxicosis following heart valve replacement in a patient with a multinodular goitre." | 3.67 | Anaplastic carcinoma of the thyroid in a patient receiving radio-iodine therapy for amiodarone-induced thyrotoxicosis. ( Bridges, AB; Davies, RR; McNeill, GP; Newton, RW, 1989) |
| "Treatment of amiodarone-induced thyrotoxicosis (AIT) with thionamide, lithium or radioactive iodine is ineffective." | 3.67 | Dexamethasone treatment of amiodarone-induced thyrotoxicosis (AIT) with or without persistent administration of the drug. ( Bernard, R; Bonnyns, M; Bourdoux, P; Demaret, B; Renard, M; Sterling, I, 1989) |
| "Amiodarone, a iodine-rich drug widely used in the treatment of tachyarrhythmias, represents one of the most common sources of iodine-induced thyrotoxicosis." | 3.67 | Amiodarone: a common source of iodine-induced thyrotoxicosis. ( Aghini-Lombardi, F; Bartalena, L; Braverman, L; Mariotti, S; Martino, E; Pinchera, A, 1987) |
| "Amiodarone iodine induced thyrotoxicosis occurs frequently in patients residing in areas of mild iodine deficiency and in patients with preexisting goiter." | 3.67 | Treatment of amiodarone associated thyrotoxicosis by simultaneous administration of potassium perchlorate and methimazole. ( Aghini-Lombardi, F; Baschieri, L; Braverman, LE; Lenziardi, M; Mariotti, S; Martino, E; Pinchera, A, 1986) |
| "A 41-year-old male patient developed amiodarone-induced thyrotoxicosis after 29 months of treatment with amiodarone." | 3.67 | Suppression of thyroglobulin secretion in amiodarone iodine-induced thyrotoxicosis. ( Weissel, M, 1988) |
| "A rare case of amiodarone-iodine-induced thyrotoxicosis (AIIT) associated with nonthyroidal illness is reported." | 3.67 | Diagnosis of amiodarone-iodine-induced thyrotoxicosis(AIIT) associated with severe nonthyroidal illness. ( Balestrieri, A; Balzano, S; Bartalena, L; Cherchi, A; Martino, E; Ruscazio, M; Sau, F, 1987) |
| "Amiodarone is a common anti-arrhythmic agent mostly used to treat and prevent different kinds of arrhythmia with several considerable side effects, most commonly on the thyroid gland." | 3.01 | Prevalence of amiodarone-induced hypothyroidism; A systematic review and meta-analysis. ( Bondariyan, N; Heidarpour, M; Mohammadi, K; Rezvanian, H; Shafie, D; Vakhshoori, M, 2023) |
| "Amiodarone may cause amiodarone-induced hypothyroidism (AIH) or amiodarone-induced thyrotoxicosis (AIT)." | 2.82 | AMIODARONE AND THYROID DYSFUNCTION. ( Alfirević, M; Bakula, M; Marić, N; Medić, F; Mucić, K, 2022) |
| "Amiodarone is an antiarrhythmic drug frequently used in everyday clinical practice." | 2.53 | [Clinical procedure in amiodarone-induced thyroid dysfunction]. ( Cygankiewicz, I; Kosmalski, M; Michalak, R; Ptaszyński, P; Różycka-Kosmalska, M; Wranicz, JK; Zieleniewski, W, 2016) |
| "Hyperthyroidism is characterised by increased thyroid hormone synthesis and secretion from the thyroid gland, whereas thyrotoxicosis refers to the clinical syndrome of excess circulating thyroid hormones, irrespective of the source." | 2.53 | Hyperthyroidism. ( Braverman, LE; De Leo, S; Lee, SY, 2016) |
| "Amiodarone is an effective medication for the treatment of cardiac arrhythmias." | 2.52 | Amiodarone-induced thyroid dysfunction. ( Danzi, S; Klein, I, 2015) |
| "Amiodarone can cause both hypothyroidism (AIH, amiodarone-induced hypothyroidism) and thyrotoxicosis (AIT, amiodarone-induced thyrotoxicosis)." | 2.52 | Amiodarone and the thyroid. ( Bartalena, L; Bednarczuk, T; Hubalewska-Dydejczyk, A; Jabrocka-Hybel, A; Kamiński, G; Kostecka-Matyja, M; Pach, D; Ruchała, M, 2015) |
| " Of all the antiarrhythmic drugs hitherto used, AM has the most adverse effects on the thyroid gland." | 2.48 | [Effect of amiodarone on the thyroid function and safety of the therapy--what's new]. ( Czarnywojtek, A; Florek, E; Hen, K; Ruchała, M; Stangierski, A; Warmuz-Stangierska, I; Zdanowska, J, 2012) |
| "Amiodarone is a structural analogue of thyroid hormone, and some of its anti-arrhythmic actions and toxicity are attributable to its interaction with nuclear receptors of thyroid hormones." | 2.48 | [Amiodarone and thyroid dysfunction]. ( Bruno, OD; Rizzo, LF, 2012) |
| "Thyrotoxicosis is a common disorder, especially in women." | 2.48 | Thyrotoxicosis. ( Boelaert, K; Franklyn, JA, 2012) |
| "Amiodarone is a benzofuran derivative approved for the treatment of cardiac arrhythmias." | 2.46 | Effects of amiodarone therapy on thyroid function. ( Cohen-Lehman, J; Dahl, P; Danzi, S; Klein, I, 2010) |
| "Amiodarone treatment affects thyroid status in about the half of patients." | 2.46 | [Amiodarone-induced thyroid gland dysfunctions]. ( Caglayan, E; Dietlein, M; Er, F; Erdmann, E; Gassanov, N, 2010) |
| "Diagnosis of thyrotoxicosis is easy, based on the finding of increased free thyroid hormone concentrations and suppressed TSH levels." | 2.46 | Approach to the patient with amiodarone-induced thyrotoxicosis. ( Bartalena, L; Bogazzi, F; Martino, E, 2010) |
| "Amiodarone is a potent antiarrhythmic drug associated with thyroid dysfunction." | 2.46 | Amiodarone and thyroid dysfunction. ( Padmanabhan, H, 2010) |
| "Amiodarone has been used widely for treating resistant tachyarrhythmias in the past three decades." | 2.45 | Benzofuran derivatives and the thyroid. ( Han, TS; Vanderpump, MP; Williams, GR, 2009) |
| "Amiodarone is a frequently used antiarrhythmic drug with a high antiarrhythmic potency." | 2.44 | [Thyroid and treatment with amiodarone diagnosis, therapy and clinical management]. ( Mikosch, P, 2008) |
| "Thyrotoxicosis is associated with increased cardiovascular morbidity and mortality, primarily due to heart failure and thromboembolism." | 2.43 | Thyrotoxicosis and the cardiovascular system. ( Brandle, M; Cattaneo, F; Roffi, M, 2005) |
| "Thyrotoxicosis is associated with increased cardiovascular morbidity and mortality, primarily due to heart failure and thromboembolism." | 2.42 | Thyrotoxicosis and the cardiovascular system: subtle but serious effects. ( Cattaneo, F; Roffi, M; Topol, EJ, 2003) |
| "Amiodarone can cause thyroid dysfunction in patients with or without previous thyroid disease." | 2.42 | Surgical management of amiodarone-induced thyrotoxicosis. ( Fan, CY; Franzese, CB; Stack, BC, 2003) |
| "Amiodarone is an iodine-rich drug." | 2.42 | [Amiodarone and the thyroid gland]. ( Bednarek-Tupikowska, G; Bugajski, J; Filus, A; Kuliczkowska, J, 2004) |
| "Amiodarone is an iodine-rich drug widely used for the management of cardiac arrhythmias." | 2.42 | [Amiodarone and the thyroid]. ( Jesus, AM; Maciel, LM; Pavan, R, 2004) |
| "Thyrotoxicosis is the clinical syndrome that results when tissues are exposed to high levels of circulating thyroid hormones." | 2.41 | Iatrogenic thyrotoxicosis: causal circumstances, pathophysiology, and principles of treatment-review of the literature. ( Defechereux, T; Degauque, C; Fumal, I; Gollogly, L; Hamoir, E; Meurisse, M, 2000) |
| "Reports of dilated cardiomyopathy associated with Graves' disease and evidence for TSH-receptors in the human myocardium suggest a relationship between these two diseases." | 2.41 | [Hyperthyroidism and heart]. ( Weissel, M, 2001) |
| "Thyrotoxicosis is a well defined clinical entity, determined by an increase of plasma levels of thyroid hormones (T3 and T4)." | 2.41 | [The management of thyrotoxicosis: a schematic approach]. ( Carapezzi, C; Corsello, SM; Papi, G, 2002) |
| " After approximately 30 days, the perchlorate dosage can be tapered or stopped, continuing with thionamides alone." | 2.40 | Perchlorate and the thyroid gland. ( Wolff, J, 1998) |
| "Amiodarone is a class 3 antiarrhythmic drug which may be associated with thyroid dysfunction." | 1.62 | Resistant type 2 amiodarone-induced thyrotoxicosis responsive to cholestyramine as an adjunctive therapy. ( Ali, A; Mandal, S; Maryam, M; Rummaan, A; Saeed, T, 2021) |
| "Amiodarone induced thyrotoxicosis is a complex condition marked by two different pathophysiological mechanisms with different treatments." | 1.43 | [Iodine excess induced thyroid dysfunction]. ( Egloff, M; Philippe, J, 2016) |
| "Amiodarone is a widely used anti-arrhythmic drug." | 1.40 | An audit of amiodarone-induced thyrotoxicosis--do anti-thyroid drugs alone provide adequate treatment? ( Inder, WJ; Kaye, G; Patel, N; Sullivan, C, 2014) |
| "Amiodarone is a benzofuranic iodine-rich antiarrhythmic drug used in the treatment of severe tachyarrhythmias, especially ventricular." | 1.39 | [Amiodarone treatment and thyroid disorders]. ( Fraczek, MM; Łacka, K, 2013) |
| "Transient hypothyroidism was observed in only two patients (5%) with AIH, though was not observed in TMNG." | 1.35 | Radioiodine therapy in patients with amiodarone-induced thyrotoxicosis (AIT). ( Bartkowiak, Z; Czarnywojtek, A; Czepczynski, R; Florek, E; Ruchala, M; Sowinski, J; Szczepanek, E; Wasko, R; Zamyslowska, H; Zgorzalewicz-Stachowiak, M, 2009) |
| "To analyze occurrence of thyroid dysfunction due to regular long-term intake of amiodaron (for one year), to search for predictors of amiodaron-induced hypothyroidism and thyrotoxicosis." | 1.33 | [Incidence and predictors of thyroid dysfunction caused by long-term intake of amiodaron]. ( Bakalov, SA; Golitsyn, SP; Molashenko, NV; Platonova, NM; Serdiuk, SE; Sviridenko, NIu, 2005) |
| "Amiodarone is a widely used anti-arrythmic drug with considerable potential to cause thyroid dysfunction because of its 35% iodine content." | 1.33 | [The effects of amiodaron on the thyroid function]. ( Kucharczyk, A; Kucharczyk, P; Michałkiewicz, D, 2006) |
| "Examining the course of cardiac arrhythmias (CA) in developed TT has established that this condition gives rise to their recurrence." | 1.32 | [The specific features of thyrotoxicosis and euthyroid hyperthyroxinemia developed due to the use of cordarone]. ( Bakalov, SA; Domogadskiĭ, SP; Golitsyn, SP; Kolesnikova, GS; Masenko, VP; Molashenko, NV; Platonova, NM; Serdiuk, SE; Sviridenko, NIu, 2004) |
| "Thyrotoxicosis is less common than hypothyroidism." | 1.31 | Amiodarone-induced thyrotoxicosis presenting as hypokalemic periodic paralysis. ( Akinwande, AO; Ganti, AK; Laroia, ST; Newman, W; Zaw, KM, 2002) |
| "Amiodarone is an iodine-rich drug used in the treatment of resistant cardiac arrhythmias." | 1.29 | Thyrotoxicosis followed by hypothyroidism in patients treated with amiodarone. A possible consequence of a destructive process in the thyroid. ( Bianconi, L; Braverman, LE; Gardini, E; Minelli, R; Roti, E, 1993) |
| "Amiodarone is an antiarrhythmic drug, frequently used in cardiology, which may produce secondary effects on the thyroid function." | 1.29 | [Subtotal thyroidectomy. A treatment to keep in mind in amiodarone-induced thyrotoxicosis]. ( Alonso Ruiz, F; Altozano Gómez, JC; Alvarez Suárez-Bárcenas, JM; Díaz Pérez de Madrid, J; García Andoaín, JM; García Guerrero, JJ; López Mínguez, JR; Morales Pérez, F; Redondo Méndez, A, 1996) |
| "Treatment with amiodarone was continued; however, therapy with L-thyroxin was initiated, followed by a complete regression of the goiter." | 1.28 | Goiter and hypothyroidism during re-treatment with amiodarone in a patient who previously experienced amiodarone-induced thyrotoxicosis. ( Ish-Shalom, S; Kaplan, J, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (6.57) | 18.7374 |
| 1990's | 51 (17.65) | 18.2507 |
| 2000's | 115 (39.79) | 29.6817 |
| 2010's | 77 (26.64) | 24.3611 |
| 2020's | 27 (9.34) | 2.80 |
| Authors | Studies |
|---|---|
| Rummaan, A | 1 |
| Maryam, M | 1 |
| Ali, A | 1 |
| Mandal, S | 1 |
| Saeed, T | 1 |
| Anfinsen, OG | 1 |
| Lima, K | 1 |
| Souza, LVF | 1 |
| Campagnolo, MT | 1 |
| Martins, LCB | 1 |
| Scanavacca, MI | 1 |
| Mohammadi, K | 1 |
| Shafie, D | 1 |
| Vakhshoori, M | 1 |
| Bondariyan, N | 1 |
| Rezvanian, H | 1 |
| Heidarpour, M | 1 |
| Cappellani, D | 8 |
| Torregrossa, L | 2 |
| Papini, P | 4 |
| Poma, AM | 1 |
| Ambrosini, E | 1 |
| De Napoli, L | 2 |
| Materazzi, G | 7 |
| Basolo, F | 3 |
| Bogazzi, F | 33 |
| Bakkar, S | 1 |
| Forfori, F | 1 |
| Di Salvo, C | 1 |
| Catarsi, S | 1 |
| Ambrosini, CE | 2 |
| Miccoli, P | 5 |
| Wang, R | 1 |
| Better, N | 2 |
| Sivaratnam, D | 2 |
| Westcott, J | 2 |
| Forehan, S | 2 |
| Christie, M | 1 |
| Pattison, DA | 2 |
| Fourlanos, S | 1 |
| Lantz, M | 1 |
| Almquist, M | 1 |
| Koutouridou, E | 1 |
| Pellby, D | 1 |
| Planck, T | 1 |
| Tsoumani, K | 1 |
| Mijovic, Z | 1 |
| Marconcini, G | 4 |
| Manetti, L | 7 |
| Bartalena, L | 32 |
| Medić, F | 1 |
| Bakula, M | 2 |
| Alfirević, M | 1 |
| Mucić, K | 1 |
| Marić, N | 1 |
| Biakina, O | 1 |
| Mitina, Y | 1 |
| Gognieva, D | 1 |
| Axenova, M | 1 |
| Ermolaeva, A | 1 |
| Bestavashvili, A | 1 |
| Fadeev, V | 1 |
| Syrkin, A | 1 |
| Kopylov, P | 1 |
| Piscopo, N | 1 |
| Soler, SF | 1 |
| Mifsud, S | 2 |
| Vella, S | 1 |
| Frey, S | 1 |
| Caillard, C | 1 |
| Mahot, P | 1 |
| Pattier, S | 1 |
| Volteau, C | 1 |
| Knipping, G | 1 |
| Lande, G | 1 |
| Drui, D | 1 |
| Mirallié, E | 1 |
| Zheng, B | 1 |
| Wang, N | 1 |
| Wu, T | 1 |
| Yin, T | 1 |
| Tan, L | 1 |
| Xu, W | 1 |
| Ren, J | 1 |
| Jhawar, N | 1 |
| Chirila, R | 1 |
| Campi, I | 1 |
| Perego, GB | 1 |
| Ravogli, A | 1 |
| Groppelli, A | 1 |
| Parati, G | 1 |
| Persani, L | 1 |
| Fugazzola, L | 1 |
| Pingitore, A | 1 |
| Tomisti, L | 11 |
| Mantuano, M | 1 |
| Di Certo, AM | 3 |
| Scattina, I | 1 |
| Urbani, C | 5 |
| Morganti, R | 2 |
| Marcocci, C | 2 |
| Iervasi, G | 2 |
| Martino, E | 39 |
| Katoh, D | 1 |
| Yoshino, H | 1 |
| Ikehara, K | 1 |
| Kumashiro, N | 1 |
| Uchino, H | 1 |
| Tsuboi, K | 1 |
| Hirose, T | 1 |
| El-Asmar, JM | 1 |
| Naja, AS | 1 |
| Al-Halabi, E | 1 |
| Schubert, L | 1 |
| Bricaire, L | 1 |
| Groussin, L | 1 |
| Donckier, JE | 1 |
| Bertrand, C | 1 |
| Tanda, ML | 10 |
| Cosentino, G | 2 |
| Portelli, D | 1 |
| Abela, A | 1 |
| Fava, S | 1 |
| Ganesan, K | 1 |
| Bradley, B | 1 |
| Jones, DW | 1 |
| Solomon, DS | 1 |
| De Marco, G | 1 |
| Ferrarini, E | 1 |
| Mattiello, A | 1 |
| Agretti, P | 1 |
| Tonacchera, M | 1 |
| Khalaili, L | 1 |
| Aker, A | 1 |
| Naoum, I | 1 |
| Kassem, S | 1 |
| Di Bello, V | 1 |
| Benjamens, S | 1 |
| Dullaart, RPF | 1 |
| Sluiter, WJ | 1 |
| Rienstra, M | 1 |
| van Gelder, IC | 2 |
| Links, TP | 3 |
| Irimie, A | 1 |
| Piciu, D | 1 |
| Inoue, K | 1 |
| Saito, J | 1 |
| Kondo, T | 1 |
| Miki, K | 1 |
| Sugisawa, C | 1 |
| Tsurutani, Y | 1 |
| Hasegawa, N | 1 |
| Kowase, S | 1 |
| Kakuta, Y | 1 |
| Omura, M | 1 |
| Nishikawa, T | 1 |
| Yamato, M | 1 |
| Wada, K | 1 |
| Hayashi, T | 1 |
| Fujimoto, M | 1 |
| Hosomi, K | 1 |
| Oita, A | 1 |
| Takada, M | 1 |
| Elnaggar, MN | 1 |
| Jbeili, K | 1 |
| Nik-Hussin, N | 1 |
| Kozhippally, M | 1 |
| Pappachan, JM | 1 |
| Van den Bruel, A | 1 |
| Delanote, J | 1 |
| Braeckman, A | 1 |
| De Vroe, C | 1 |
| Pyfferoen, L | 1 |
| Ghekiere, J | 1 |
| Duytschaever, M | 1 |
| Tavernier, R | 1 |
| Censi, S | 1 |
| Bodanza, V | 1 |
| Manso, J | 1 |
| Gusella, S | 1 |
| Watutantrige-Fernando, S | 1 |
| Cavedon, E | 1 |
| Barollo, S | 1 |
| Bertazza, L | 1 |
| Cecchin, D | 1 |
| Mian, C | 1 |
| Maqdasy, S | 3 |
| Benichou, T | 1 |
| Dallel, S | 1 |
| Roche, B | 2 |
| Desbiez, F | 2 |
| Montanier, N | 1 |
| Batisse-Lignier, M | 3 |
| Tauveron, I | 3 |
| Gershinsky, M | 1 |
| Saliba, W | 1 |
| Lavi, I | 1 |
| Shapira, C | 1 |
| Gronich, N | 1 |
| Jamieson, A | 1 |
| Furtak, A | 1 |
| Wędrychowicz, A | 1 |
| Kalicka-Kasperczyk, A | 1 |
| Januś, D | 1 |
| Wójcik, M | 1 |
| Kordon, Z | 1 |
| Rudziński, A | 1 |
| Starzyk, JB | 1 |
| Hen, K | 1 |
| Czarnywojtek, A | 4 |
| Stangierski, A | 2 |
| Warmuz-Stangierska, I | 2 |
| Zdanowska, J | 1 |
| Florek, E | 3 |
| Ruchała, M | 4 |
| Letsou, GV | 1 |
| Reverdin, S | 1 |
| Frazier, OH | 1 |
| Mateo Gavira, I | 1 |
| Vilchez López, F | 1 |
| Larrán Escandón, L | 1 |
| Roldán Caballero, P | 1 |
| Aguilar Diosdado, M | 1 |
| Palermo-Garófalo, C | 1 |
| Martínez, JH | 1 |
| Silva, F | 1 |
| González, E | 1 |
| Torres, O | 1 |
| Figueroa, J | 1 |
| González, J | 1 |
| de Lourdes, MM | 1 |
| Łacka, K | 1 |
| Fraczek, MM | 1 |
| Stan, MN | 2 |
| Sathananthan, M | 1 |
| Warnes, CA | 2 |
| Brennan, MD | 6 |
| Thapa, P | 2 |
| Bahn, RS | 3 |
| Yagishita, A | 1 |
| Hachiya, H | 1 |
| Kawabata, M | 1 |
| Nakamura, T | 1 |
| Sugiyama, K | 1 |
| Tanaka, Y | 1 |
| Sasano, T | 1 |
| Isobe, M | 1 |
| Hirao, K | 1 |
| Danzi, S | 3 |
| Klein, I | 3 |
| Shinohara, T | 2 |
| Takahashi, N | 1 |
| Yamamoto, J | 1 |
| Dostmohamed, H | 1 |
| Schacter, I | 1 |
| Ariano, RE | 1 |
| Houston, DS | 1 |
| Lewis, B | 1 |
| Knoll, C | 1 |
| Katz, P | 1 |
| Zarychanski, R | 1 |
| Huang, CJ | 1 |
| Chen, PJ | 1 |
| Chang, JW | 1 |
| Huang, DF | 1 |
| Chang, SL | 1 |
| Chen, SA | 1 |
| Jap, TS | 1 |
| Lin, LY | 1 |
| Woliński, K | 2 |
| Waśko, R | 2 |
| Zgorzalewicz-Stachowiak, M | 2 |
| Fichna, M | 1 |
| Greberska, W | 1 |
| Guzik, P | 1 |
| Lodyga, M | 1 |
| Kwiecinska, B | 1 |
| Patel, N | 1 |
| Inder, WJ | 1 |
| Sullivan, C | 1 |
| Kaye, G | 1 |
| Rohrhoff, NJ | 1 |
| McNeill, DB | 1 |
| Boggan, JC | 1 |
| Rossi, G | 9 |
| Tyer, NM | 1 |
| Kim, TY | 1 |
| Martinez, DS | 1 |
| Olsen, JS | 1 |
| Carlé, A | 1 |
| Thomsen, HH | 1 |
| Hudzik, B | 1 |
| Zubelewicz-Szkodzinska, B | 1 |
| Khan, A | 1 |
| Puttanna, A | 1 |
| Raskauskiene, D | 1 |
| Płazińska, M | 1 |
| Kobylecka, M | 1 |
| Kunikowska, J | 1 |
| Miechowicz, I | 1 |
| Waligórska-Stachura, J | 1 |
| Rewers, A | 1 |
| Królicki, L | 1 |
| Lichtenstein, M | 1 |
| Toh, HB | 1 |
| Gunawardana, D | 1 |
| Jabrocka-Hybel, A | 1 |
| Bednarczuk, T | 1 |
| Pach, D | 1 |
| Kamiński, G | 1 |
| Kostecka-Matyja, M | 1 |
| Hubalewska-Dydejczyk, A | 1 |
| Takeuchi, D | 1 |
| Honda, K | 1 |
| Inai, K | 1 |
| Toyohara, K | 1 |
| Nakanishi, T | 1 |
| Foppiani, L | 1 |
| Cascio, C | 1 |
| Lo Pinto, G | 1 |
| Kaderli, RM | 1 |
| Fahrner, R | 1 |
| Christ, ER | 1 |
| Stettler, C | 1 |
| Fuhrer, J | 1 |
| Martinelli, M | 1 |
| Vogt, A | 1 |
| Seiler, CA | 1 |
| Latrofa, F | 1 |
| Sardella, C | 2 |
| Lupi, I | 2 |
| Curzio, O | 1 |
| Auclair, C | 1 |
| Citron, B | 1 |
| Thieblot, P | 1 |
| Lusson, JR | 1 |
| Różycka-Kosmalska, M | 1 |
| Michalak, R | 1 |
| Kosmalski, M | 1 |
| Ptaszyński, P | 1 |
| Wranicz, JK | 1 |
| Zieleniewski, W | 1 |
| Cygankiewicz, I | 1 |
| Sbrana, F | 1 |
| Genovesi, D | 1 |
| Catapano, GA | 1 |
| Panchetti, L | 1 |
| Bottoni, A | 1 |
| Ünal, E | 1 |
| Perkin, P | 1 |
| Konca Değertekin, C | 1 |
| Ergül, G | 1 |
| De Leo, S | 1 |
| Lee, SY | 1 |
| Braverman, LE | 17 |
| Patel, NR | 1 |
| Tamara, LA | 1 |
| Lee, H | 1 |
| Egloff, M | 1 |
| Philippe, J | 1 |
| Wang, M | 1 |
| Cai, S | 1 |
| Sun, L | 1 |
| Zhao, Q | 1 |
| Feng, W | 1 |
| Wang, J | 1 |
| Zhang, R | 1 |
| Seymour, M | 1 |
| Morton, A | 1 |
| Gursoy, A | 1 |
| Tutuncu, NB | 1 |
| Gencoglu, A | 1 |
| Anil, C | 1 |
| Demirer, AN | 1 |
| Demirag, NG | 1 |
| Kurt, IH | 1 |
| Yigit, T | 1 |
| Karademir, BM | 1 |
| Piga, M | 3 |
| Cocco, MC | 1 |
| Serra, A | 3 |
| Boi, F | 2 |
| Loy, M | 2 |
| Mariotti, S | 7 |
| Han, TS | 1 |
| Williams, GR | 1 |
| Vanderpump, MP | 2 |
| Dahl, P | 2 |
| Albino, CC | 2 |
| Paz-Filho, G | 1 |
| Graf, H | 4 |
| Nadkarni, PJ | 1 |
| Sharma, M | 1 |
| Zinsmeister, B | 1 |
| Wartofsky, L | 2 |
| Burman, KD | 2 |
| Hofmann, A | 1 |
| Nawara, C | 1 |
| Ofluoglu, S | 1 |
| Holzmannhofer, J | 1 |
| Strohmer, B | 1 |
| Pirich, C | 1 |
| Paz-Filho, GJ | 1 |
| Yiu, KH | 1 |
| Jim, MH | 1 |
| Siu, CW | 1 |
| Lee, CH | 1 |
| Yuen, M | 1 |
| Mok, M | 1 |
| Shea, YF | 1 |
| Fan, K | 1 |
| Tse, HF | 1 |
| Chow, WH | 1 |
| Pratap, R | 1 |
| Qayyum, A | 1 |
| Ahmad, N | 1 |
| Jani, P | 1 |
| Matrka, L | 1 |
| Steward, D | 1 |
| Falciglia, M | 2 |
| Nikiforov, Y | 1 |
| Liang, YL | 1 |
| Huang, SM | 1 |
| Peng, SL | 1 |
| Hsiao, SH | 1 |
| Hung, HC | 1 |
| Ou, HY | 1 |
| Wu, TJ | 1 |
| Ceccarelli, C | 2 |
| Tsang, W | 1 |
| Houlden, RL | 1 |
| Dell'Unto, E | 6 |
| Pepe, P | 2 |
| Czepczynski, R | 1 |
| Ruchala, M | 1 |
| Szczepanek, E | 1 |
| Zamyslowska, H | 1 |
| Bartkowiak, Z | 1 |
| Sowinski, J | 1 |
| Cohen-Lehman, J | 1 |
| Eskes, SA | 2 |
| Wiersinga, WM | 6 |
| Gómez, JJ | 1 |
| Pomar, MD | 1 |
| Casariego, AV | 1 |
| Rodríguez, IC | 1 |
| Gassanov, N | 1 |
| Dietlein, M | 2 |
| Caglayan, E | 1 |
| Erdmann, E | 1 |
| Er, F | 1 |
| Hacihamdioğlu, B | 1 |
| Berberoğlu, M | 1 |
| Siklar, Z | 1 |
| Savaş Erdeve, S | 1 |
| Oçal, G | 1 |
| Tutar, E | 3 |
| Atalay, S | 1 |
| Padmanabhan, H | 1 |
| Sauer-Schulz, A | 1 |
| Müssig, K | 1 |
| Kurth, R | 1 |
| Fend, F | 1 |
| Teichmann, R | 1 |
| Schnauder, G | 1 |
| Wong, WY | 1 |
| Lee, KF | 1 |
| Lee, KM | 1 |
| Fung, TT | 1 |
| Tavares, AB | 1 |
| Paula, SK | 1 |
| Vaisman, M | 1 |
| Teixeira, Pde F | 1 |
| Arias, N | 1 |
| Moreno-Pérez, Ó | 1 |
| Boix, E | 1 |
| Serrano, J | 1 |
| Revert, P | 1 |
| González, VL | 1 |
| Sánchez-Ortiga, R | 1 |
| Picó, AM | 1 |
| Ahmed, S | 1 |
| Wiesfeld, AC | 1 |
| Van Veldhuisen, DJ | 1 |
| Brogioni, S | 9 |
| Inaba, H | 1 |
| Suzuki, S | 1 |
| Takeda, T | 1 |
| Kobayashi, S | 1 |
| Akamizu, T | 1 |
| Komatsu, M | 1 |
| Endert, E | 1 |
| Fliers, E | 1 |
| Geskus, RB | 1 |
| Dullaart, RP | 1 |
| Souto, SB | 1 |
| Fernandes, H | 1 |
| Matos, MJ | 1 |
| Braga, DC | 1 |
| Pereira, J | 1 |
| Carvalho, D | 1 |
| Rizzo, LF | 1 |
| Bruno, OD | 1 |
| Diazzi, C | 1 |
| Brigante, G | 1 |
| Rochira, V | 1 |
| Zosin, I | 1 |
| Balaş, M | 1 |
| Erdogan, HI | 1 |
| Gul, EE | 1 |
| Gok, H | 1 |
| Nikus, KC | 1 |
| Ammash, NM | 1 |
| Nannenga, MR | 1 |
| Franklyn, JA | 4 |
| Boelaert, K | 1 |
| Raghavan, RP | 1 |
| Taylor, PN | 1 |
| Bhake, R | 1 |
| Vaidya, B | 1 |
| Dayan, CM | 1 |
| Bradley, K | 1 |
| Mete, O | 1 |
| Asa, SL | 1 |
| Pierret, C | 1 |
| Tourtier, JP | 1 |
| Pons, Y | 1 |
| Merat, S | 1 |
| Duverger, V | 1 |
| Perrier, E | 1 |
| Marchello, A | 1 |
| Moretti, M | 1 |
| Mariotti, R | 1 |
| Taniyama, M | 1 |
| Otsuka, F | 1 |
| Kimura, Y | 1 |
| Williams, M | 1 |
| Lo Gerfo, P | 1 |
| Younis, N | 1 |
| el-Houni, A | 1 |
| Soran, H | 1 |
| Jones, IR | 1 |
| Berti, P | 2 |
| Cosci, C | 5 |
| Aghini-Lombardi, F | 14 |
| Pinchera, A | 12 |
| Gama, R | 1 |
| Skirzyńska, D | 1 |
| Garlicki, M | 1 |
| Plicner, D | 1 |
| Wysocka, T | 1 |
| Wierzbicki, K | 1 |
| Biernat, M | 1 |
| Sadowski, J | 1 |
| Peiris, AN | 2 |
| Laroia, ST | 1 |
| Zaw, KM | 1 |
| Ganti, AK | 1 |
| Newman, W | 1 |
| Akinwande, AO | 1 |
| Roffi, M | 2 |
| Cattaneo, F | 3 |
| Topol, EJ | 1 |
| Erdogan, MF | 2 |
| Güleç, S | 2 |
| Başkal, N | 2 |
| Erdogan, G | 2 |
| Grasso, L | 5 |
| Carlsten, JR | 1 |
| Gopalakrishnan, G | 1 |
| Monchik, J | 1 |
| DeLellis, RA | 1 |
| Cardenas, GA | 1 |
| Cabral, JM | 1 |
| Leslie, CA | 1 |
| Alyan, O | 1 |
| Arda, K | 1 |
| Ozdemir, O | 1 |
| Acu, B | 1 |
| Soylu, M | 1 |
| Demirkan, D | 1 |
| Pearce, EN | 1 |
| Pardini, E | 1 |
| Pellegrini, G | 1 |
| Parkes, AB | 1 |
| Lazarus, JH | 1 |
| Franzese, CB | 1 |
| Fan, CY | 1 |
| Stack, BC | 1 |
| Sidhu, J | 1 |
| Jenkins, D | 1 |
| Bianconcini, M | 1 |
| Giannini, AL | 1 |
| Rajeswaran, C | 1 |
| Shelton, RJ | 1 |
| Gilbey, SG | 1 |
| Hermida, JS | 2 |
| Jarry, G | 2 |
| Tcheng, E | 2 |
| Moullart, V | 2 |
| Arlot, S | 2 |
| Rey, JL | 2 |
| Delonca, J | 2 |
| Schvartz, C | 2 |
| Kurnik, D | 2 |
| Loebstein, R | 2 |
| Farfel, Z | 1 |
| Ezra, D | 1 |
| Halkin, H | 1 |
| Olchovsky, D | 2 |
| Ryan, LE | 1 |
| Cooper, DS | 1 |
| Ladenson, PW | 1 |
| Kloos, RT | 1 |
| Bednarek-Tupikowska, G | 1 |
| Filus, A | 1 |
| Kuliczkowska, J | 1 |
| Bugajski, J | 1 |
| Saad, A | 1 |
| Steward, DL | 1 |
| Nikiforov, YE | 1 |
| Diamond, TH | 1 |
| Rajagopal, R | 1 |
| Ganda, K | 1 |
| Manoharan, A | 1 |
| Luk, A | 1 |
| Piantanida, E | 2 |
| Lai, A | 2 |
| Houghton, SG | 1 |
| Farley, DR | 1 |
| van Heerden, JA | 2 |
| Thompson, GB | 1 |
| Grant, CS | 1 |
| Iskandar, SB | 1 |
| Jordan, RM | 1 |
| Richard, MJ | 1 |
| Zyśko, D | 1 |
| Gajek, J | 1 |
| Pavan, R | 1 |
| Jesus, AM | 1 |
| Maciel, LM | 1 |
| Simkó, J | 1 |
| Barta, K | 1 |
| Szabó, Z | 1 |
| Varga, E | 1 |
| Nagy, E | 1 |
| Lorincz, I | 1 |
| Serdiuk, SE | 3 |
| Bakalov, SA | 3 |
| Golitsyn, SP | 3 |
| Sitina, VK | 1 |
| Molashenko, NV | 3 |
| Platonova, NM | 3 |
| Sviridenko, NIu | 3 |
| Kolesnikova, GS | 1 |
| Masenko, VP | 1 |
| Domogadskiĭ, SP | 1 |
| Schicha, H | 1 |
| Ross, IL | 1 |
| Marshall, D | 1 |
| Okreglicki, A | 1 |
| Isaacs, S | 1 |
| Levitt, NS | 1 |
| Brandle, M | 1 |
| Schuetz, P | 1 |
| Eriksson, U | 1 |
| Christ-Crain, M | 1 |
| Zulewski, H | 1 |
| Miller, B | 1 |
| Sato, K | 6 |
| Trifănescu, R | 1 |
| Fica, S | 1 |
| Barbu, C | 1 |
| Vârtej, I | 1 |
| Ursu, H | 1 |
| Bunghez, R | 1 |
| Coculescu, M | 1 |
| Mackie, GC | 1 |
| Shulkin, BL | 1 |
| Paran, Y | 1 |
| Nimrod, A | 1 |
| Goldin, Y | 1 |
| Justo, D | 1 |
| Uzan, L | 1 |
| Guignat, L | 1 |
| Meune, C | 1 |
| Mouly, S | 1 |
| Weber, S | 1 |
| Bertagna, X | 1 |
| Bertherat, J | 1 |
| Thomopoulos, P | 1 |
| Duboc, D | 1 |
| Boeving, A | 1 |
| Cubas, ER | 1 |
| Santos, CM | 1 |
| Carvalho, GA | 1 |
| O'Sullivan, AJ | 1 |
| Lewis, M | 1 |
| Diamond, T | 1 |
| Porsche, R | 1 |
| Brenner, ZR | 1 |
| Schreiber, DH | 1 |
| DeFreest, MS | 1 |
| Shiga, T | 3 |
| Matsuda, N | 2 |
| Onoda, N | 1 |
| Takano, K | 2 |
| Hagiwara, N | 1 |
| Kasanuki, H | 4 |
| Diehl, LA | 1 |
| Romaldini, JH | 1 |
| Kucharczyk, P | 2 |
| Michałkiewicz, D | 2 |
| Kucharczyk, A | 2 |
| Gough, J | 2 |
| Gough, IR | 2 |
| Lorberboym, M | 1 |
| Schachter, P | 1 |
| Saikia, UK | 1 |
| Saikia, M | 1 |
| Macedo, TA | 1 |
| Chammas, MC | 1 |
| Jorge, PT | 1 |
| Souza, LP | 1 |
| Farage, L | 1 |
| Watanabe, T | 1 |
| Santos, VA | 1 |
| Cerri, GG | 1 |
| Rehman, Hu | 1 |
| Macchia, E | 2 |
| Conen, D | 1 |
| Melly, L | 1 |
| Kaufmann, C | 2 |
| Bilz, S | 1 |
| Ammann, P | 1 |
| Schaer, B | 1 |
| Sticherling, C | 1 |
| Muller, B | 1 |
| Osswald, S | 2 |
| Perra, E | 1 |
| Melis, A | 1 |
| Cianchetti, ME | 1 |
| Pinna, G | 1 |
| Gammage, MD | 2 |
| Bucerius, J | 1 |
| Ezziddin, S | 1 |
| Brockmann, H | 1 |
| Palmedo, H | 1 |
| Biersack, HJ | 1 |
| Pedro, T | 1 |
| Martínez-Hervás, S | 1 |
| Lorente, R | 1 |
| Catalá, M | 1 |
| Ortega, J | 1 |
| Real, JT | 1 |
| Carmena, R | 1 |
| Mikosch, P | 1 |
| Fideler, FJ | 1 |
| Dieterich, HJ | 1 |
| Schroeder, TH | 1 |
| Liparulo, L | 1 |
| Sassi, L | 1 |
| Omi, Y | 1 |
| Kodama, H | 1 |
| Obara, T | 1 |
| Yamazaki, K | 2 |
| Yamada, E | 1 |
| Seki, T | 1 |
| Monzani, F | 1 |
| Del Guerra, P | 1 |
| Caraccio, N | 1 |
| Casolaro, A | 1 |
| Pucci, E | 1 |
| Franchi, F | 1 |
| Erickson, DZ | 1 |
| Carney, JA | 3 |
| García Gil, D | 1 |
| Escobar Jiménez, L | 1 |
| Piñero Gálvez, C | 1 |
| Girón González, JA | 1 |
| Roti, E | 4 |
| Bianconi, L | 4 |
| De Chiara, F | 1 |
| Minelli, R | 4 |
| Tosi, C | 1 |
| Gardini, E | 4 |
| Salvi, M | 2 |
| Trip, MD | 2 |
| Düren, DR | 1 |
| Fosella, PV | 1 |
| Unger, J | 6 |
| Mulligan, DC | 1 |
| McHenry, CR | 2 |
| Kinney, W | 1 |
| Esselstyn, CB | 1 |
| Lambert, M | 2 |
| Jonckheer, MH | 1 |
| Denayer, P | 1 |
| López Mínguez, JR | 1 |
| Díaz Pérez de Madrid, J | 1 |
| García Andoaín, JM | 1 |
| García Guerrero, JJ | 1 |
| Morales Pérez, F | 1 |
| Alvarez Suárez-Bárcenas, JM | 1 |
| Altozano Gómez, JC | 1 |
| Redondo Méndez, A | 1 |
| Alonso Ruiz, F | 1 |
| Burelli, A | 2 |
| Cappiello, E | 1 |
| Boldorini, R | 1 |
| Tosoni, A | 1 |
| Piraneo, S | 1 |
| Bernasconi, R | 1 |
| Raggi, U | 1 |
| Hayashi, K | 1 |
| Sone, T | 1 |
| Suzuki, T | 1 |
| Numaguchi, Y | 1 |
| Kondoh, J | 1 |
| Tsuboi, H | 1 |
| Sassa, H | 1 |
| Le Cosquer, P | 1 |
| Guerin-Robardey, AM | 1 |
| Ossart, M | 1 |
| Dickstein, G | 1 |
| Shechner, C | 1 |
| Adawi, F | 1 |
| Kaplan, J | 2 |
| Baron, E | 1 |
| Ish-Shalom, S | 2 |
| Tavackoli, S | 1 |
| Stouffer, GA | 1 |
| Sheahan, RG | 1 |
| Mazzeo, S | 1 |
| Vitti, P | 1 |
| Bartolozzi, C | 1 |
| Isidro, ML | 1 |
| Argüeso, R | 1 |
| Cordido, F | 1 |
| Newman, CM | 2 |
| Price, A | 1 |
| Davies, DW | 1 |
| Gray, TA | 1 |
| Weetman, AP | 2 |
| Wolff, J | 1 |
| Hamoir, E | 2 |
| Meurisse, M | 2 |
| Defechereux, T | 2 |
| Joris, J | 1 |
| Vivario, J | 1 |
| Hennen, G | 1 |
| Choudhury, RP | 1 |
| MacDermot, J | 1 |
| Kanaji, Y | 1 |
| Ohnishi, S | 2 |
| Demura, H | 1 |
| Woeber, KA | 1 |
| Warner, I | 1 |
| Sousa, J | 2 |
| Rocha, V | 2 |
| Silvestre, I | 2 |
| Pereira, EV | 2 |
| Alacatrão, M | 1 |
| Ferreira, FF | 2 |
| Raposo, F | 2 |
| Alcatrão, M | 1 |
| Modlinska, A | 1 |
| Sworczak, K | 1 |
| Loviselli, A | 1 |
| Murenu, S | 1 |
| Sau, F | 2 |
| Valentino, L | 1 |
| Mandas, A | 1 |
| Vacquer, S | 1 |
| Balestrieri, A | 2 |
| Lai, ME | 1 |
| Lahera Vargas, M | 1 |
| de Luis Román, D | 1 |
| Hervilla Ezquerra, S | 1 |
| Maldonado Castro, G | 1 |
| Zurita Sepúlveda, P | 1 |
| Ligtenberg, J | 1 |
| Tulleken, J | 1 |
| Zijlstra, J | 1 |
| Henzen, C | 1 |
| Buess, M | 1 |
| Brander, L | 1 |
| Gerber, H | 1 |
| Noth, D | 1 |
| Miyakawa, M | 1 |
| Eto, M | 1 |
| Inaba, T | 1 |
| Vandergheynst, F | 1 |
| Liénart, F | 1 |
| Ducobu, J | 1 |
| Findlay, PF | 1 |
| Seymour, DG | 1 |
| Gough, I | 1 |
| Meyer-Witting, M | 1 |
| Claxton, S | 1 |
| Sinha, SN | 1 |
| Donovan, S | 1 |
| Greenaway, TM | 1 |
| Hoffman, L | 1 |
| Loughhead, M | 1 |
| Burgess, JR | 1 |
| Güldal, M | 1 |
| Gollogly, L | 1 |
| Degauque, C | 1 |
| Fumal, I | 1 |
| Benbassat, CA | 1 |
| Mechlis-Frish, S | 1 |
| Cohen, M | 1 |
| Blum, I | 1 |
| Cron, TA | 1 |
| Meier, C | 1 |
| Staub, JJ | 1 |
| Oberholzer, M | 1 |
| Mittendorf, EA | 1 |
| Daniels, GH | 1 |
| Sutherland, J | 1 |
| Robinson, B | 1 |
| Delbridge, L | 1 |
| Weissel, M | 2 |
| Gasperi, M | 1 |
| Sandhu, RS | 1 |
| Davies, PH | 2 |
| Marketou, ME | 1 |
| Simantirakis, EN | 1 |
| Manios, EG | 1 |
| Vardas, PE | 1 |
| Eaton, SE | 1 |
| Euinton, HA | 1 |
| Bennet, WM | 1 |
| Osman, F | 1 |
| Sheppard, MC | 2 |
| Santini, F | 1 |
| Papi, G | 1 |
| Carapezzi, C | 1 |
| Corsello, SM | 1 |
| Gavaruzzi, G | 1 |
| Ugolotti, G | 1 |
| Neri, TM | 1 |
| Peche, R | 1 |
| Abramowicz, M | 1 |
| Georges, JL | 1 |
| Normand, JP | 1 |
| Lenormand, ME | 1 |
| Schwob, J | 1 |
| Mercer, M | 1 |
| Zykova, TA | 1 |
| Miroliubova, OA | 1 |
| Kyrkalova, NE | 1 |
| Mileĭko, OS | 1 |
| Tkachev, AV | 1 |
| Wiersinga, W | 1 |
| Plomp, TA | 1 |
| Uzzan, B | 1 |
| Pussard, E | 1 |
| Leon, A | 1 |
| Bekhechi, D | 1 |
| Krivitzky, A | 1 |
| Modigliani, E | 1 |
| Perret, G | 1 |
| Vassy, R | 1 |
| Berdeaux, A | 1 |
| Giudicelli, JF | 1 |
| Chow, CC | 1 |
| Cockram, CS | 1 |
| De Nayer, P | 1 |
| Brohet, C | 1 |
| Gangji, D | 1 |
| Farwell, AP | 1 |
| Abend, SL | 1 |
| Huang, SK | 1 |
| Patwardhan, NA | 1 |
| Salamon, E | 1 |
| Rowe, RC | 1 |
| Faiman, C | 1 |
| Broussolle, C | 1 |
| Ducottet, X | 1 |
| Martin, C | 1 |
| Barbier, Y | 1 |
| Bornet, H | 1 |
| Noel, G | 1 |
| Orgiazzi, J | 1 |
| Bridges, AB | 1 |
| Davies, RR | 1 |
| Newton, RW | 1 |
| McNeill, GP | 1 |
| Bonnyns, M | 1 |
| Sterling, I | 1 |
| Renard, M | 1 |
| Bernard, R | 1 |
| Demaret, B | 1 |
| Bourdoux, P | 1 |
| Segers, O | 1 |
| Dal Fabbro, S | 1 |
| Dalle Mule, I | 1 |
| Bridda, A | 1 |
| Braverman, L | 1 |
| Lenziardi, M | 2 |
| Baschieri, L | 2 |
| López Navidad, A | 1 |
| Farrerons, J | 1 |
| García Ameijeiras, A | 1 |
| Balzano, S | 1 |
| Ruscazio, M | 1 |
| Cherchi, A | 1 |
| Miaskiewicz, SL | 1 |
| Amico, JA | 1 |
| Follansbee, WP | 1 |
| Levey, GS | 1 |
| Bambini, G | 1 |
| Rosner, W | 1 |
| Khan, MS | 1 |
| Safran, M | 1 |
| Antonelli, A | 1 |
| Concetti, R | 1 |
| Fenzi, GF | 1 |
| Mechlis, S | 1 |
| Lubin, E | 1 |
| Laor, J | 1 |
| Margaliot, M | 1 |
| Strasberg, B | 1 |
| Smyrk, TC | 1 |
| Goellner, JR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid-Related Upper Lid Retraction With and Without Proptosis[NCT04976816] | Phase 2/Phase 3 | 92 participants (Actual) | Interventional | 2021-12-01 | Completed | ||
| A Multi-center, Open Label, Randomised Parallel- Group Study to Compare the Efficacy of Cholestyramine Plus Standard Treatment Versus Prednisolone Plus Standard Treatment Versus Standard Treatment Alone in Treatment of Overt Hyperthyroidism[NCT03303053] | Phase 3 | 135 participants (Anticipated) | Interventional | 2017-05-11 | Recruiting | ||
| A Randomized, Open-label, Parallel-group Study to Explore the Efficacy of High-intensity Focused Ultrasound (HIFU) Versus Fixed-dose Radioiodine-131 in the Treatment of Relapsed Graves' Disease[NCT03013257] | 240 participants (Actual) | Interventional | 2017-04-25 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
77 reviews available for amiodarone and Thyrotoxicosis
| Article | Year |
|---|---|
Prevalence of amiodarone-induced hypothyroidism; A systematic review and meta-analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Female; Humans; Hypo | 2023 |
AMIODARONE AND THYROID DYSFUNCTION.
Topics: Amiodarone; Humans; Hypothyroidism; Iodine; Thyroiditis; Thyrotoxicosis; Thyroxine | 2022 |
Amiodarone-induced thyrotoxicosis.
Topics: Amiodarone; Anti-Arrhythmia Agents; History, 21st Century; Hypothyroidism; Practice Guidelines as To | 2021 |
A Case Report on Type 2 Amiodarone Induced Thyrotoxicosis and Hypercalcemia.
Topics: Amiodarone; Anti-Arrhythmia Agents; Follow-Up Studies; Heart Failure; Humans; Hypercalcemia; Male; M | 2021 |
[Amiodarone-induced thyrotoxicosis].
Topics: Amiodarone; Anti-Arrhythmia Agents; Humans; Hypothyroidism; Thyroid Gland; Thyrotoxicosis | 2017 |
The Role of Radiopharmaceuticals in Amiodarone-Induced Thyroid Pathology.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Biomarkers; Diagnosis, Differential; Early | 2017 |
Amiodarone-Induced Thyroid Dysfunction: A Clinical Update.
Topics: Amiodarone; Anti-Arrhythmia Agents; Chest Pain; Coronary Artery Disease; Humans; Male; Middle Aged; | 2018 |
Issues in amiodarone-induced thyrotoxicosis: Update and review of the literature.
Topics: Amiodarone; Anti-Arrhythmia Agents; Humans; Recurrence; Risk Factors; Tachycardia; Thioamides; Thyro | 2019 |
[Challenges in the management of amiodarone-induced thyrotoxicosis].
Topics: Amiodarone; Anti-Arrhythmia Agents; Endocrinology; Humans; Thyroid Function Tests; Thyroidectomy; Th | 2018 |
Amiodarone-induced thyroid dysfunction in the developmental period: prenatally, in childhood, and adolescence - case reports and a review of the literature.
Topics: Adolescent; Amiodarone; Anti-Arrhythmia Agents; Child; Child, Preschool; Female; Humans; Hypothyroid | 2019 |
[Effect of amiodarone on the thyroid function and safety of the therapy--what's new].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Causality; Comorbidity; Dronedarone; Human | 2012 |
The cardiology and endocrinology connection between amiodarone and thyrotoxicosis: case report and review of the literature.
Topics: Aged; Amiodarone; Cardiology; Endocrinology; Female; Humans; Thyrotoxicosis | 2013 |
Amiodarone-induced thyroid dysfunction.
Topics: Amiodarone; Anti-Arrhythmia Agents; Female; Humans; Hypothyroidism; Male; Middle Aged; Thyroid Funct | 2015 |
Review of oral cholecystographic agents for the management of hyperthyroidism.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Female; Goiter, Nodular; Humans; Hyperthyroidism; Neoplas | 2014 |
[Every sixth patient in amiodarone treatment develops thyrotoxicosis or hypothyreosis].
Topics: Amiodarone; Anti-Arrhythmia Agents; Dronedarone; Drug Prescriptions; Humans; Hypothyroidism; Risk Fa | 2014 |
Amiodarone and the thyroid.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Female; Glucocorticoids; Humans; Hypothyroidism; Male; Mid | 2015 |
[Clinical procedure in amiodarone-induced thyroid dysfunction].
Topics: Amiodarone; Anti-Arrhythmia Agents; Humans; Hypothyroidism; Risk Factors; Thyroid Diseases; Thyroid | 2016 |
Hyperthyroidism.
Topics: Adrenergic beta-Antagonists; Amiodarone; Antithyroid Agents; Diagnosis, Differential; Drug Administr | 2016 |
Amiodarone-induced thyrotoxicosis: something new to refine the initial diagnosis?
Topics: Amiodarone; Anti-Arrhythmia Agents; Heart Diseases; Humans; Thyrotoxicosis | 2008 |
Benzofuran derivatives and the thyroid.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Benzofurans; Dronedarone; Humans; Hypothyroidism; Recep | 2009 |
Thyrotoxic cardiac disease.
Topics: Adrenergic Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiomyopathy, Di | 2008 |
Amiodarone-induced thyrotoxicosis. A review.
Topics: Amiodarone; Anti-Arrhythmia Agents; Humans; Interleukin-6; Iodine; Iodine Radioisotopes; Iopanoic Ac | 2008 |
Recombinant human thyrotropin in the management of thyroid disorders.
Topics: Amiodarone; Clinical Trials as Topic; Goiter; Humans; Iodine Radioisotopes; Neoplasm Metastasis; Rec | 2008 |
Surgical management of amiodarone-induced thyrotoxicosis in a patient with Eisenmenger's syndrome: literature review and case report.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Eisenmenger Complex; Humans; Male; Risk Factors; Thyroide | 2009 |
Amiodarone-induced thyrotoxicosis: a review.
Topics: Amiodarone; Anti-Arrhythmia Agents; Goiter, Nodular; Graves Disease; Humans; Thyroiditis, Subacute; | 2009 |
Effects of amiodarone therapy on thyroid function.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Dronedarone; Humans; Hypothyroidism; Iodine; Thyroid Di | 2010 |
Amiodarone and thyroid.
Topics: Amiodarone; Anti-Arrhythmia Agents; Dronedarone; Female; Humans; Hypothyroidism; Male; Pregnancy; Pr | 2009 |
[Amiodarone-induced thyroid gland dysfunctions].
Topics: Amiodarone; Anti-Arrhythmia Agents; Drug Interactions; Follow-Up Studies; Half-Life; Humans; Hyperth | 2010 |
Approach to the patient with amiodarone-induced thyrotoxicosis.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biomarkers; Humans; Iodine Radioisoto | 2010 |
Amiodarone and thyroid dysfunction.
Topics: Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Continuity of Patient Care; Glucocorticoids; | 2010 |
[Response to adjuvant therapy with potassium perchlorate in amiodarone-induced thyrotoxicosis: observations on three cases].
Topics: Acenocoumarol; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Algorithms; Amiodarone; Atrial | 2011 |
[Amiodarone and thyroid dysfunction].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Hypothyroidism; Iodine | 2012 |
Thyrotoxicosis.
Topics: Agranulocytosis; Amiodarone; Antithyroid Agents; Atrial Fibrillation; Autoimmune Diseases; Child; Ex | 2012 |
Thyroidectomy using local anesthesia in critically ill patients with amiodarone-induced thyrotoxicosis: a review and description of the technique.
Topics: Adult; Aged; Amiodarone; Anesthesia, Local; Anti-Arrhythmia Agents; Humans; Middle Aged; Risk Factor | 2002 |
Management of amiodarone-induced thyrotoxicosis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Humans; Thyrotoxicosis | 2002 |
Thyrotoxicosis and the cardiovascular system: subtle but serious effects.
Topics: Adrenergic beta-Antagonists; Amiodarone; Antithyroid Agents; Calcium Channel Blockers; Cardiovascula | 2003 |
Amiodarone induced thyrotoxicosis: diagnostic and therapeutic strategies.
Topics: Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Humans; Iodine; Practice Guidelines as Topic | 2003 |
Surgical management of amiodarone-induced thyrotoxicosis.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiomyopathies; Female; Humans; M | 2003 |
[Amiodarone-induced thyrotoxicosis: case report and review of the literature].
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Cardiomyopathy, Hypertrophic, Familia | 2003 |
Management of amiodarone-induced thyrotoxicosis.
Topics: Adrenal Cortex Hormones; Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Humans; Thyroid Gla | 2003 |
Complex drug-drug-disease interactions between amiodarone, warfarin, and the thyroid gland.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Arrhythmias, Cardiac; Drug Interactions; | 2004 |
[Amiodarone and the thyroid gland].
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Antithyroid Agents; Female; Glucocorticoids; Humans; Hy | 2004 |
Amiodarone-induced thyrotoxicosis and thyroid cancer: clinical, immunohistochemical, and molecular genetic studies of a case and review of the literature.
Topics: Amiodarone; Anti-Arrhythmia Agents; Carcinoma, Papillary, Follicular; Humans; Immunohistochemistry; | 2004 |
Treating amiodarone-induced thyrotoxicosis with radioactive iodine.
Topics: Aged; Amiodarone; Follow-Up Studies; Humans; Iodine Radioisotopes; Male; Risk Assessment; Severity o | 2004 |
[Thyroid and cardiovascular disorders].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiovascular Diseases; Coronary Artery B | 2004 |
[Amiodarone and the thyroid].
Topics: Amiodarone; Anti-Arrhythmia Agents; Humans; Thyrotoxicosis | 2004 |
[Cardiovascular manifestations of thyrotoxicosis and thyroid dysfunction caused by amiodarone].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Diseases; Heart Failure; Hum | 2004 |
Thyrotoxicosis and the cardiovascular system.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiovascula | 2005 |
[Drug (amiodarone)-induced thyroid disease].
Topics: Amiodarone; Hormone Replacement Therapy; Humans; Hypothyroidism; Perchlorates; Prednisolone; Thyroto | 2005 |
Amiodarone-induced thyroid dysfunction.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Critical Care; Diagnosis, Differentia | 2006 |
[Amiodarone-induced thyrotoxicosis].
Topics: Amiodarone; Anti-Arrhythmia Agents; Diagnosis, Differential; Humans; Thyrotoxicosis | 2006 |
Total thyroidectomy for amiodarone-associated thyrotoxicosis in patients with severe cardiac disease.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Hu | 2006 |
[Drugs affecting thyroid--part II].
Topics: Amiodarone; Anti-Arrhythmia Agents; Female; Humans; Hypothyroidism; Iodine; Lithium; Male; Thyroid F | 2006 |
Drug-induced thyroid disorders.
Topics: Amiodarone; Dexamethasone; Enzyme Inhibitors; Humans; Hypothyroidism; Interferon-alpha; Lithium Comp | 2006 |
[Thyroid and treatment with amiodarone diagnosis, therapy and clinical management].
Topics: Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Female; Follow-Up Studies; Humans; Hyperthyr | 2008 |
[Amiodarone and thyroid: pharmacologic and toxic effects].
Topics: Amiodarone; Drug Monitoring; Humans; Hypothyroidism; Thyroid Gland; Thyroid Hormones; Thyrotoxicosis | 1996 |
Amiodarone-induced thyrotoxicosis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Diagnosis, Differential; Humans; Male; Middle Aged; Thyroid Func | 1997 |
Amiodarone and the thyroid: a practical guide to the management of thyroid dysfunction induced by amiodarone therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Protocols; Humans; Hypothyroidism; Thyroid Function Tes | 1998 |
Perchlorate and the thyroid gland.
Topics: Amiodarone; Animals; Enzyme Inhibitors; Humans; Hypothyroidism; Iodide Peroxidase; Iodides; Kinetics | 1998 |
[Amiodarone and the thyroid gland].
Topics: Amiodarone; Animals; Dose-Response Relationship, Drug; Humans; Thyroid Diseases; Thyroid Gland; Thyr | 1998 |
[Amiodarone and the thyroid].
Topics: Amiodarone; Anti-Arrhythmia Agents; Humans; Hypothyroidism; Iodine; Thyroid Gland; Thyrotoxicosis | 1999 |
[Therapy of amiodarone-induced thyrotoxicosis and hypothyroidism].
Topics: Algorithms; Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Contraindications; Hormone Repla | 1999 |
[Amiodarone and thyroid disorders--prospective study and review of the literature].
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Female; Humans; Hypothyroidism; | 1999 |
Surgery and anaesthesia for amiodarone-associated thyrotoxicosis.
Topics: Amiodarone; Anesthesia; Anti-Arrhythmia Agents; Humans; Thyroidectomy; Thyrotoxicosis | 2000 |
Refractory amiodarone-associated thyrotoxicosis: an indication for thyroidectomy.
Topics: Acute Disease; Aged; Amiodarone; Anti-Arrhythmia Agents; Humans; Male; Middle Aged; Tasmania; Thyroi | 2000 |
HLA-B40-, HLA-Cw3-, and HLA-DR5-associated susceptibility to amiodarone-induced thyroid dysfunction.
Topics: Amiodarone; Anti-Arrhythmia Agents; HLA Antigens; HLA-B Antigens; HLA-B40 Antigen; HLA-C Antigens; H | 2000 |
Iatrogenic thyrotoxicosis: causal circumstances, pathophysiology, and principles of treatment-review of the literature.
Topics: Amiodarone; Animals; Cytokines; Female; Humans; Iatrogenic Disease; Iodides; Iodine Radioisotopes; L | 2000 |
Amiodarone-induced thyrotoxicosis type 2: a case report and review of the literature.
Topics: Amiodarone; Anti-Arrhythmia Agents; Humans; Male; Middle Aged; Thyroid Hormones; Thyrotoxicosis | 2000 |
[Amiodarone-induced thyrotoxicosis].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Thyrotoxicosis | 2000 |
Amiodarone-induced thyrotoxicosis.
Topics: Aged; Amiodarone; Animals; Drug Therapy, Combination; Humans; Male; Thyroidectomy; Thyrotoxicosis | 2001 |
[Hyperthyroidism and heart].
Topics: Amiodarone; Angina Pectoris; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopathy, Dilated; D | 2001 |
The various effects of amiodarone on thyroid function.
Topics: Amiodarone; Female; Humans; Hypothyroidism; Male; Pregnancy; Thyroid Diseases; Thyroid Gland; Thyrot | 2001 |
Amiodarone induced thyroid dysfunction: pathophysiology, diagnosis and management.
Topics: Amiodarone; Anti-Arrhythmia Agents; Humans; Hypothyroidism; Thyroid Function Tests; Thyroid Gland; T | 2001 |
Iodine effects on the thyroid gland: biochemical and clinical aspects.
Topics: Amiodarone; Autoimmune Diseases; Contrast Media; Humans; Hyperthyroidism; Iodides; Iodine; Iodine Ra | 2000 |
[The management of thyrotoxicosis: a schematic approach].
Topics: Adenoma; Adrenal Cortex Hormones; Adult; Aged; Amiodarone; Antithyroid Agents; Cardiovascular Diseas | 2002 |
Failure to respond to dexamethasone with fatal consequences, after initial response to multidrug treatment in a case of amiodarone-associated thyrotoxicosis.
Topics: Amiodarone; Angina, Unstable; Death, Sudden; Dexamethasone; Humans; Hyperthyroidism; Male; Middle Ag | 1992 |
Thyroid disorders induced by lithium and amiodarone: an overview.
Topics: Amiodarone; Animals; Goiter; Humans; Hypothyroidism; Lithium; Thyroid Diseases; Thyroid Hormones; Th | 1990 |
12 trials available for amiodarone and Thyrotoxicosis
| Article | Year |
|---|---|
Effect of high-dose intravenous glucocorticoid therapy on serum thyroid hormone concentrations in type 2 amiodarone-induced thyrotoxicosis: an exploratory study.
Topics: Administration, Intravenous; Adult; Aged; Amiodarone; Dose-Response Relationship, Drug; Female; Gluc | 2020 |
Amiodarone-induced thyrotoxicosis late after amiodarone withdrawal.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; | 2013 |
The usefulness of 99mTc-sestaMIBI thyroid scan in the differential diagnosis and management of amiodarone-induced thyrotoxicosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; | 2008 |
Incidence and predictability of amiodarone-induced thyrotoxicosis and hypothyroidism.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Austria; Female; Humans; Hypothyroidism; Incidence; Male; | 2008 |
Continuation of amiodarone delays restoration of euthyroidism in patients with type 2 amiodarone-induced thyrotoxicosis treated with prednisone: a pilot study.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Cohort Studies; Female; Glucocorticoids | 2011 |
Treatment of amiodarone-induced thyrotoxicosis type 2: a randomized clinical trial.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Endocrine Disruptors; Feasibili | 2012 |
Body mass index and the development of amiodarone-induced thyrotoxicosis in adults with congenital heart disease--a cohort study.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Body Mass Index; Cohort Studies; Databases, Factual; Fema | 2013 |
Preparation with iopanoic acid rapidly controls thyrotoxicosis in patients with amiodarone-induced thyrotoxicosis before thyroidectomy.
Topics: Aged; Aged, 80 and over; Amiodarone; Contrast Media; Enzyme Inhibitors; Female; Humans; Hyperthyroid | 2002 |
A stepwise approach to the treatment of amiodarone-induced thyrotoxicosis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Antibodies; Antithyroid Agents; Female | 2003 |
Treatment of type II amiodarone-induced thyrotoxicosis by either iopanoic acid or glucocorticoids: a prospective, randomized study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Enzyme Inhibitors; Female; Glucocorticoids; Humans; Iodide | 2003 |
Thyroid color flow doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Cross-Over Studies; Diagnosis, D | 2003 |
Glucocorticoid response in amiodarone-induced thyrotoxicosis resulting from destructive thyroiditis is predicted by thyroid volume and serum free thyroid hormone concentrations.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Cohort Studies; Female; Follow-U | 2007 |
200 other studies available for amiodarone and Thyrotoxicosis
| Article | Year |
|---|---|
Resistant type 2 amiodarone-induced thyrotoxicosis responsive to cholestyramine as an adjunctive therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cholestyramine Resin; Humans; Thyrotoxicosis | 2021 |
Amiodarone-induced thyrotoxicosis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Heart Failure; Humans; Thyroidectomy; Thyrotoxicosis | 2021 |
Amiodarone-Induced Thyrotoxicosis - Literature Review & Clinical Update.
Topics: Amiodarone; Anti-Arrhythmia Agents; Humans; Iodine Radioisotopes; Stroke Volume; Thyrotoxicosis; Ven | 2021 |
Salvage total thyroidectomy for amiodarone-induced thyrotoxicosis in a SARS-CoV-2 positive patient: results of the viral genome research on the pathology sample of this destructive thyroiditis.
Topics: Amiodarone; COVID-19; Genome, Viral; Humans; Hyperthyroidism; SARS-CoV-2; Thyroidectomy; Thyroiditis | 2022 |
Early surgery: a favorable prognosticator in amiodarone-induced thyrotoxicosis-a single-center experience with 53 cases.
Topics: Amiodarone; Anti-Arrhythmia Agents; Female; Humans; Male; Middle Aged; Retrospective Studies; Thyroi | 2022 |
99m Tc-Sestamibi Thyroid Scintigraphy in Amiodarone-Induced Thyrotoxicosis : Functional Imaging-Histopathologic Correlation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Humans; Hyperthyroidism; Male; Radionuclide Imaging; Technetium | 2022 |
[Thyroid ultrasound and its role in the investigation of thyroid disease].
Topics: Amiodarone; Female; Graves Disease; Humans; Thyroid Diseases; Thyrotoxicosis | 2022 |
Real-life Data on the Effect of Medical Therapy for Amiodarone-induced Thyrotoxicosis on CV Events and Hospitalizations.
Topics: Amiodarone; Anti-Arrhythmia Agents; Hospitalization; Humans; Hyperthyroidism; Prospective Studies; T | 2023 |
DUOX1 Gene Missense Mutation Confers Susceptibility on Type 2 Amiodarone-Induced Thyrotoxicosis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Dual Oxidases; Genetic Markers; Humans; Mutation, Missense; Thyr | 2023 |
Type 2 amiodarone-induced thyrotoxicosis in a patient with positive thyroid-stimulating hormone-receptor antibodies.
Topics: Amiodarone; Humans; Thyrotoxicosis; Thyrotropin | 2023 |
Mortality After Total Thyroidectomy for Amiodarone-Induced Thyrotoxicosis According to Left Ventricular Ejection Fraction.
Topics: Amiodarone; Anti-Arrhythmia Agents; Humans; Hyperthyroidism; Retrospective Studies; Stroke Volume; T | 2023 |
Effects of thermal ablation on thyroid function in patients with thyrotoxicosis.
Topics: Amiodarone; Humans; Thyrotoxicosis | 2023 |
How do I diagnose and treat my patient's amiodarone-induced thyrotoxicosis?
Topics: Amiodarone; Anti-Arrhythmia Agents; Humans; Thyrotoxicosis | 2023 |
Pulsed intravenous methylprednisolone combined with oral steroids as a treatment for poorly responsive type 2 amiodarone-induced thyrotoxicosis.
Topics: Administration, Intravenous; Aged; Amiodarone; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Hum | 2019 |
Comparison Between Total Thyroidectomy and Medical Therapy for Amiodarone-Induced Thyrotoxicosis.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Cohort Studies; Female; Glucocorticoids; | 2020 |
Successful Treatment of Amiodarone-induced Thyrotoxicosis Type 1 in Combination with Methimazole and Potassium Iodide in a Patient with Hashimoto's Thyroiditis.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Female; Hashimoto Disease; Humans; Me | 2020 |
Surgical Treatment of Amiodarone-Induced Thyrotoxicosis in an Adult with Congenital Heart Disease: An Anesthetists Perspective.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Heart Defects, Congenital; Humans; Male; Thyroidectomy; T | 2020 |
Response to the Letter to the Editor: "Comparison Between Total Thyroidectomy and Medical Therapy for Amiodarone-Induced Thyrotoxicosis".
Topics: Amiodarone; Humans; Iatrogenic Disease; Thyroidectomy; Thyrotoxicosis | 2020 |
Letter to the Editor: " Comparison Between Total Thyroidectomy and Medical Therapy for Amiodarone-Induced Thyrotoxicosis ".
Topics: Amiodarone; Humans; Iatrogenic Disease; Thyroidectomy; Thyrotoxicosis | 2020 |
Duration of Exposure to Thyrotoxicosis Increases Mortality of Compromised AIT Patients: the Role of Early Thyroidectomy.
Topics: Aged; Amiodarone; Cohort Studies; Disease Progression; Early Medical Intervention; Female; Humans; M | 2020 |
Amiodarone-induced type 2 thyrotoxicosis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Male; Middle Aged; Thyrotoxicosis | 2021 |
Identification of Two Different Phenotypes of Patients with Amiodarone-Induced Thyrotoxicosis and Positive Thyrotropin Receptor Antibody Tests.
Topics: Adult; Aged; Amiodarone; Animals; Autoantibodies; Biomarkers; CHO Cells; Cricetulus; Diagnosis, Diff | 2021 |
[AMIODARONE-INDUCED THYROTOXICOSIS - RISK FACTORS AND PREDICTORS OF OUTCOME: A RETROSPECTIVE STUDY].
Topics: Amiodarone; Anti-Arrhythmia Agents; Humans; Retrospective Studies; Risk Factors; Thyrotoxicosis | 2021 |
The clinical value of regular thyroid function tests during amiodarone treatment.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Follow-Up Studies; Hu | 2017 |
Amiodarone-induced Thyrotoxicosis with Cardiopulmonary Arrest.
Topics: Amiodarone; Anti-Arrhythmia Agents; Female; Heart Arrest; Humans; Middle Aged; Tachycardia, Ventricu | 2018 |
Association between Serum Amiodarone and N-Desethylamiodarone Concentrations and Development of Thyroid Dysfunction.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Female; Humans; Hypothyroidism; | 2018 |
"White Thyroid" on Unenhanced Computed Tomography in Amiodarone-Induced Thyrotoxicosis Type 2.
Topics: Aged; Aged, 80 and over; Amiodarone; Contrast Media; Cross-Sectional Studies; Female; Humans; Male; | 2018 |
Amiodarone-Induced Thyrotoxicosis: Differential Diagnosis Using 99mTc-SestaMIBI and Target-to-Background Ratio (TBR).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Diagnosis, Differential; Female; Humans; Male; Middle Aged | 2018 |
Increased Risk of Antithyroid Drug Agranulocytosis Associated with Amiodarone-Induced Thyrotoxicosis: A Population-Based Cohort Study.
Topics: Adult; Aged; Agranulocytosis; Amiodarone; Antithyroid Agents; Female; Humans; Male; Methimazole; Mid | 2019 |
Drugs, the Thyroid, and the Heart: A Lethal Cocktail.
Topics: Agranulocytosis; Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Atrial Fibrillation; Carbim | 2019 |
Thyrotoxicosis-facilitated bridge to recovery with a continuous-flow left ventricular assist device.
Topics: Amiodarone; Cardiomyopathies; Heart-Assist Devices; Humans; Male; Thyrotoxicosis; Ventricular Fibril | 2013 |
[Management of severe amiodarone-induced thyrotoxicosis after failure of standard medical treatment].
Topics: Amiodarone; Anti-Arrhythmia Agents; Humans; Male; Middle Aged; Severity of Illness Index; Thyrotoxic | 2013 |
[Amiodarone treatment and thyroid disorders].
Topics: Amiodarone; Anti-Arrhythmia Agents; Humans; Thyrotoxicosis | 2013 |
Amiodarone-induced thyrotoxicosis in adults with congenital heart disease--clinical presentation and response to therapy.
Topics: Adult; Amiodarone; Female; Heart Defects, Congenital; Humans; Male; Retrospective Studies; Thyrotoxi | 2014 |
How long should we check thyroid function after amiodarone withdrawal?
Topics: Amiodarone; Anti-Arrhythmia Agents; Female; Humans; Male; Thyrotoxicosis | 2013 |
Preoperative therapeutic apheresis for severe medically refractory amiodarone-induced thyrotoxicosis: a case report.
Topics: Amiodarone; Anti-Arrhythmia Agents; Blood Component Removal; Female; Humans; Middle Aged; Preoperati | 2014 |
Amiodarone-induced thyroid dysfunction in Taiwan: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Body Mass Index; Cohort Studies; | 2014 |
Amiodarone-induced thyrotoxicosis in a case of Eisenmenger's syndrome.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Eisenmenger Complex; Humans; Iodine | 2013 |
An audit of amiodarone-induced thyrotoxicosis--do anti-thyroid drugs alone provide adequate treatment?
Topics: Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Female; Glucocorticoids; Humans; Medical Aud | 2014 |
An adverse reaction to a medication given to treat an adverse reaction: a teachable moment.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Atrial Fibrillation; Febrile Neutropen | 2014 |
The onset time of amiodarone-induced thyrotoxicosis (AIT) depends on AIT type.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Female; Humans; Male; Middle Aged; Retrospective Studies | 2014 |
Amiodarone-related thyroid dysfunction.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Heart Failure; Humans; Hypothyroidism; Thyr | 2014 |
Amiodarone-induced thyrotoxicosis: type 1 or type 2?
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Atrial Fibrillation; Carbimazole; Gluc | 2014 |
Radioiodine therapy in patients with type II amiodarone-induced thyrotoxicosis.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Dose-Response Relationship, Radiation; Female; Humans; I | 2014 |
Quantitative assessment of thyroid-to-background ratio improves the interobserver reliability of technetium-99m sestamibi thyroid scintigraphy for investigation of amiodarone-induced thyrotoxicosis.
Topics: Aged; Aged, 80 and over; Amiodarone; Diagnosis, Differential; Female; Humans; Male; Middle Aged; Obs | 2015 |
Incidence, Clinical Course, and Risk Factors of Amiodarone-Induced Thyroid Dysfunction in Japanese Adults With Congenital Heart Disease.
Topics: Adolescent; Adult; Amiodarone; Asian People; Female; Follow-Up Studies; Heart Defects, Congenital; H | 2015 |
Iodine-induced hyperthyroidism as combination of different etiologies: an overlooked entity in the elderly.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Heart Failure; Humans; H | 2016 |
Total Thyroidectomy for Amiodarone-induced Thyrotoxicosis in the Hyperthyroid State.
Topics: Adult; Aged; Amiodarone; Female; Humans; Male; Middle Aged; Plasmapheresis; Retrospective Studies; T | 2016 |
The presence of anti-thyroglobulin (TgAb) and/or anti-thyroperoxidase antibodies (TPOAb) does not exclude the diagnosis of type 2 amiodarone-induced thyrotoxicosis.
Topics: Adult; Amiodarone; Autoantibodies; Autoantigens; Case-Control Studies; Female; Humans; Iodide Peroxi | 2016 |
Amiodarone-Induced Thyrotoxicosis Recurrence After Amiodarone Reintroduction.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Humans; Male; Middle | 2016 |
Dabigatran malabsorption in amiodarone-induced thyrotoxicosis: a clinical report.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dabigatran; Echocardiography; Humans; | 2016 |
Hyperpigmentation on face and arms and thyrotoxicosis induced by amiodarone treatment.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arm; Arrhythmias, Cardiac; Face; Humans; Hyperpigmentation | 2017 |
99mTc Sestamibi Thyroid Scan in Amiodarone-Induced Thyrotoxicosis Type I.
Topics: Aged; Amiodarone; Antithyroid Agents; Graves Disease; Humans; Male; Methimazole; Potassium Channel B | 2016 |
[Iodine excess induced thyroid dysfunction].
Topics: Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Contrast Media; Humans; Hyperthyroidism; Hyp | 2016 |
Safety and efficacy of early radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation complicated with amiodarone-induced thyrotoxicosis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Electrocardiography; Ele | 2016 |
Evaluation of
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Female; Humans; Iodine Radioisotopes; M | 2017 |
Unilateral facial swelling in a thyrotoxic patient.
Topics: Aged; Agranulocytosis; Amiodarone; Anti-Arrhythmia Agents; Diagnosis, Differential; Edema; Face; Fev | 2017 |
Radioactive iodine in the treatment of type-2 amiodarone-induced thyrotoxicosis.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Female; Humans; Iodine Radioisotopes; M | 2008 |
Atrial fibrillation due to late amiodarone-induced thyrotoxicosis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Humans; Male; | 2008 |
Recombinant human TSH as an adjuvant to radioiodine for the treatment of type 1 amiodarone-induced thyrotoxicosis (AIT).
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Chemotherapy, Adjuvant; Female; Humans; Iodine Radi | 2009 |
Thyrotoxicosis-induced ventricular arrhythmias.
Topics: Adult; Aged; Amiodarone; Fatal Outcome; Female; Humans; Male; Middle Aged; Tachycardia, Ventricular; | 2008 |
Amiodarone-induced thyrotoxicosis is a predictor of adverse cardiovascular outcome.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiovascular Diseases; Female; Humans; Male; Midd | 2009 |
Pharmacodynamic effect of iopanoic acid on free T(3) and T(4) levels in amiodarone-induced thyrotoxicosis.
Topics: Amiodarone; Atrial Fibrillation; Contrast Media; Humans; Iopanoic Acid; Male; Middle Aged; Thyroidec | 2008 |
Amiodarone-induced thyrotoxicosis in a patient with autonomously functioning nodular goiter.
Topics: Amiodarone; Anti-Arrhythmia Agents; Female; Goiter, Nodular; Humans; Middle Aged; Thyrotoxicosis | 2009 |
Recombinant human TSH as an adjuvant to radioiodine for the treatment of type 1 amiodarone-induced thyrotoxicosis: a cautionary note.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Chemotherapy, Adjuvant; Female; Humans; | 2010 |
Glucocorticoids are preferable to thionamides as first-line treatment for amiodarone-induced thyrotoxicosis due to destructive thyroiditis: a matched retrospective cohort study.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Antith | 2009 |
Radioiodine therapy in patients with amiodarone-induced thyrotoxicosis (AIT).
Topics: Aged; Aged, 80 and over; Amiodarone; Female; Follow-Up Studies; Goiter; Humans; Hypothyroidism; Iodi | 2009 |
Thyroid gland: use of glucocorticoids in amiodarone-induced thyrotoxicosis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Glucocorticoids; Humans; Thyroid Gland; Thyrotoxicosis | 2009 |
[Selective pituitary resistance to thyroid hormone in a patient treated with amiodarone].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diabetes Mellitus, Type 2; Feedback, Physio | 2009 |
Amiodarone-induced thyrotoxicosis in children and adolescents is a possible outcome in patients with low iodine intake.
Topics: Adolescent; Amiodarone; Anti-Arrhythmia Agents; Child; Female; Humans; Male; Thyrotoxicosis; Thyroxi | 2010 |
[A rare cause of thyreotoxicosis].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Arrhythmias, Cardiac; Dyspnea; Glucoco | 2010 |
Preservation of echogenicity in type II amiodarone-induced thyrotoxicosis: possible histopathological basis.
Topics: Amiodarone; Humans; Thyroid Gland; Thyrotoxicosis; Ultrasonography | 2010 |
Amiodarone-induced thyroid dysfunction in the Hong Kong Chinese population.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; China; Female; Humans; Hypothyro | 2010 |
Amiodarone and thyrotoxicosis: case reports.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Fatal Outcome; Female; Humans; Male; Middle Aged; Thyroid | 2010 |
Determinants and outcome of amiodarone-associated thyroid dysfunction.
Topics: Adult; Age Factors; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Databases, Factu | 2011 |
Amiodarone-induced thyrotoxicosis with thyroid papillary cancer in multinodular goiter: case report.
Topics: Amiodarone; Anti-Arrhythmia Agents; Carcinoma; Carcinoma, Papillary; Goiter, Nodular; Humans; Male; | 2012 |
Importance of (99)mTc-sestaMIBI thyroid scan in a case of amiodarone-induced thyrotoxicosis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diagnosis, Differential; Humans; Male; Midd | 2011 |
Propylthiouracil-induced interstitial pneumonia in a Caucasian woman with amiodarone-induced thyrotoxicosis.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Atrial Fibrillation; Cryptogenic Organ | 2012 |
Amiodarone-induced thyroid dysfunction in an iodine-replete area: epidemiological and clinical data.
Topics: Aged; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Female; Goiter; Humans; Hypothyroidi | 2012 |
Therapy-resistant ventricular tachycardia caused by amiodarone-induced thyrotoxicosis: a case report of electrical storm.
Topics: Amiodarone; Anti-Arrhythmia Agents; Electrocardiography; Emergency Service, Hospital; Heart; Humans; | 2012 |
Amiodarone-induced thyrotoxicosis, an overview of UK management.
Topics: Amiodarone; Anti-Arrhythmia Agents; Humans; Thyrotoxicosis; United Kingdom | 2012 |
Images in endocrine pathology: thyrotoxicosis associated with destructive thyroiditis.
Topics: Amiodarone; Heart Diseases; Humans; Male; Middle Aged; Thyroidectomy; Thyroiditis; Thyrotoxicosis; T | 2012 |
Total thyroidectomy for amiodarone-associated thyrotoxicosis: should surgery always be delayed for pre-operative medical preparation?
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Arrhythmias, | 2012 |
Total thyroidectomy in patients with amiodarone-induced thyrotoxicosis and severe left ventricular systolic dysfunction.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Female; Heart Diseases; Humans; Male; Middle Aged; Postope | 2012 |
[Drug induced thyrotoxicosis].
Topics: Amiodarone; Anti-HIV Agents; Antiviral Agents; Gonadotropin-Releasing Hormone; Humans; Interferon-al | 2012 |
Amiodarone-induced thyrotoxicosis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Humans; Thyrotoxicosis; Vasodilator Agents | 2002 |
[Thyrotoxicosis in heart recipients].
Topics: Adult; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Female; Heart Failure; Heart Transplantation; | 2002 |
Thyrotoxic periodic paralysis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Humans; Paralysis, Hyperkalemic Periodic; Thyrotoxicosis | 2002 |
Amiodarone-induced thyrotoxicosis presenting as hypokalemic periodic paralysis.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Humans; Male; Paralysis, Hyperkalemic Periodic; Thyrotoxi | 2002 |
Pathologic quiz case: a 66-year-old man with thyrotoxicosis.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Humans; Male; Thyroid Gland; Thyroidectomy; Thyrotoxicosis | 2003 |
Differential diagnosis and clinical course of amiodarone-induced thyroid dysfunction.
Topics: Adult; Aged; Amiodarone; Antithyroid Agents; Atrial Fibrillation; Diagnosis, Differential; Female; H | 2003 |
The prevalence of elevated serum C-reactive protein levels in inflammatory and noninflammatory thyroid disease.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; C-Reactive Protein; Case-Control Studie | 2003 |
Men are at increased risk of amiodarone-associated thyrotoxicosis in the UK.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Child; Female; Human | 2003 |
Radioiodine ablation of the thyroid to allow the reintroduction of amiodarone treatment in patients with a prior history of amiodarone-induced thyrotoxicosis.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Female; Humans; Iodine Radioisotopes; Male; Middle | 2004 |
Radioiodine ablation of the thyroid to prevent recurrence of amiodarone-induced thyrotoxicosis in patients with resistant tachyarrhythmias.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Iodine Radioisotopes; Male; | 2004 |
Can amiodarone be restarted after amiodarone-induced thyrotoxicosis?
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Humans; Male; Medical Records; Recurrence; Tachycardia, Ve | 2004 |
Plasmapheresis as a potential treatment option for amiodarone-induced thyrotoxicosis.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Humans; Male; Middle Aged; Plasmapheresis; Thyrotoxicosis | 2004 |
Diagnosis and management of amiodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association.
Topics: Amiodarone; Europe; Humans; Iodine Radioisotopes; Radionuclide Imaging; Sensitivity and Specificity; | 2004 |
Surgical management of amiodarone-associated thyrotoxicosis: Mayo Clinic experience.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Fatal Outc | 2004 |
[Thyroid dysfunction in long-term amiodarone administration. Correlation of the antiarrhythmic activity of amiodarone with its effect on thyroid function].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Female; Heart Rate; Humans; Hypothyroidism; Male; Middle A | 2005 |
[The specific features of thyrotoxicosis and euthyroid hyperthyroxinemia developed due to the use of cordarone].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Autoantibodies; Blood Flow Velocity; Elect | 2004 |
Amiodarone-induced thyrotoxicosis due to destructive thyroiditis: therapeutic recommendations.
Topics: Adult; Aged; Amiodarone; Antithyroid Agents; Carbimazole; Drug Therapy, Combination; Female; Glucoco | 2005 |
Amiodarone-induced thyroid dysfunction.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Female; Humans; Hyperthyroidism; | 2005 |
[Amiodarone-induced thyrotoxicosis: a diagnostic and therapeutic challenge].
Topics: Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Atrial Fibrillation; Atrial Flutter; Carbima | 2005 |
[Incidence and predictors of thyroid dysfunction caused by long-term intake of amiodaron].
Topics: Age Factors; Amiodarone; Anti-Arrhythmia Agents; Female; Heart Failure; Humans; Hypothyroidism; Inci | 2005 |
Amiodarone-induced thyroid dysfunction in cardiac patients from areas with iodine deficiency.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Hu | 2004 |
Amiodarone-induced hyperthyroidism in a patient with functioning papillary carcinoma of the thyroid and extensive hepatic metastases.
Topics: Aged; Amiodarone; Carcinoma, Papillary; Humans; Hyperthyroidism; Liver Neoplasms; Male; Thyroid Neop | 2005 |
Pulmonary hypertension and predominant right heart failure in thyrotoxicosis.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Hypertension, Pulmon | 2006 |
Continuation of amiodarone therapy despite type II amiodarone-induced thyrotoxicosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Databases, Factual; | 2006 |
[Use of lithium carbonate for the treatment of amiodarone-induced thyrotoxicosis].
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Cardiomyopathy, Dilated; Heart Transp | 2005 |
Amiodarone-induced thyrotoxicosis: left ventricular dysfunction is associated with increased mortality.
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Female; Goiter, Nodular; Graves Disease; Humans; Male | 2006 |
Paroxysmal atrial fibrillation precipitated by amiodarone-induced thyrotoxicosis five months after cessation of therapy.
Topics: Amiodarone; Atrial Fibrillation; Cardiomyopathy, Dilated; Electrocardiography; Humans; Male; Middle | 2006 |
Mild and short recurrence of type II amiodarone-induced thyrotoxicosis in three patients receiving amiodarone continuously for more than 10 years.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Autoantibodies; Humans; Immunoglobulins, Thyroid-Stimulati | 2006 |
Management of amiodarone-induced thyrotoxicosis in Latin America: an electronic survey.
Topics: Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Arrhythmias, Cardiac; Drug Administration Sc | 2006 |
[The effects of amiodaron on the thyroid function].
Topics: Amiodarone; Anti-Arrhythmia Agents; Humans; Hyperthyroidism; Hypothyroidism; Iodine; Thyroid Disease | 2006 |
Long-term outcome of thyroid function after amiodarone-induced thyrotoxicosis, as compared to subacute thyroiditis.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pr | 2006 |
Combination of minimally invasive thyroid surgery and local anesthesia associated to iopanoic acid for patients with amiodarone-induced thyrotoxicosis and severe cardiac disorders: a pilot study.
Topics: Aged; Amiodarone; Anesthesia, Local; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Autonomic Nerve B | 2007 |
Drug-induced thyrotoxicosis: the surgical option.
Topics: Aged; Aged, 80 and over; Amiodarone; Angiogenesis Inhibitors; Anti-Arrhythmia Agents; Benzofurans; F | 2007 |
Differentiation between the two types of amiodarone-associated thyrotoxicosis using duplex and amplitude Doppler sonography.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Area Under Curve; Atrial Fibrill | 2007 |
Amiodarone for atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Thyrotoxicosis | 2007 |
Amiodarone for atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Humans; International Norma | 2007 |
Proportion of type 1 and type 2 amiodarone-induced thyrotoxicosis has changed over a 27-year period in Italy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Chi-Square Distribution; Female; Humans; Italy; Male; Midd | 2007 |
Amiodarone-induced thyrotoxicosis: clinical course and predictors of outcome.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Diagnosis, Differential; Female; Glucocorticoids; Humans; | 2007 |
Color-flow Doppler sonography in the differential diagnosis and management of amiodarone-induced thyrotoxicosis.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Diagnosis, Differential; Female; Goiter, Nodular; Graves D | 2007 |
Treatment of amiodarone-associated thyrotoxicosis.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Carbimazole; Hormone Replacement Therapy; Humans; Hypothyr | 2007 |
Impact of thyroid metabolism on the course of INR levels in a patient with systemic anticoagulation suffering from amiodarone-induced thyrotoxicosis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Coumarins; Female; Humans; International Normali | 2007 |
[Difficult treatment of amiodarone-induced thyrotoxicosis: a case report].
Topics: Aged; Amiodarone; Humans; Male; Thyrotoxicosis | 2007 |
Fatal outcome during anaesthesia induction in a patient with amiodarone-induced thyrotoxicosis.
Topics: Amiodarone; Androstanols; Anesthetics, Intravenous; Anti-Arrhythmia Agents; Etomidate; Fatal Outcome | 2008 |
Diagnosis and management of amiodarone-induced thyrotoxicosis: similarities and differences between North American and European thyroidologists.
Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Competence; Endocrinology; Europe; Health Care Surveys; | 2008 |
Differential diagnosis and appropriate treatment of four thyrotoxic patients with Graves' disease required to take amiodarone due to life-threatening arrhythmia.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Arrhythmias, Cardiac; Diagnosis, Diff | 2008 |
Percutaneous ethanol injection therapy of autonomous nodule and amiodarone-induced thyrotoxicosis.
Topics: Amiodarone; Ethanol; Humans; Injections, Intradermal; Iodine; Male; Middle Aged; Thyroid Nodule; Thy | 1994 |
Nongoitrous (type I) amiodarone-associated thyrotoxicosis: evidence of follicular disruption in vitro and in vivo.
Topics: Adult; Aged; Amiodarone; Cell Line; Chromium Radioisotopes; Cytotoxins; Dexamethasone; Female; Gluco | 1995 |
[Ablation of the hyperconducting atrioventricular node in a patient with thyrotoxicosis induced by amiodarone].
Topics: Adult; Amiodarone; Atrial Fibrillation; Atrioventricular Node; Catheter Ablation; Female; Humans; Th | 1995 |
Thyroid ultrasonography in patients with a previous episode of amiodarone induced thyrotoxicosis.
Topics: Adult; Aged; Amiodarone; Evaluation Studies as Topic; Female; Humans; Male; Middle Aged; Thyroid Gla | 1994 |
Two cases of amiodarone-induced thyrotoxicosis successfully treated with a short course of antithyroid drugs while amiodarone was continued.
Topics: Adolescent; Amiodarone; Carbimazole; Humans; Male; Middle Aged; Perchlorates; Potassium Compounds; T | 1994 |
Serum interleukin-6 in amiodarone-induced thyrotoxicosis.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Cross-Sectional Studies; Diagnosis, Differential; Goiter | 1994 |
Treatment of amiodarone iodine-induced thyrotoxicosis with plasmapheresis and methimazole.
Topics: Aged; Amiodarone; Combined Modality Therapy; Female; Humans; Male; Methimazole; Middle Aged; Plasmap | 1993 |
The paradox of treating thyrotoxicosis with amiodarone.
Topics: Amiodarone; Angina Pectoris; Atrial Fibrillation; Humans; Thyroid Gland; Thyrotoxicosis | 1993 |
Amiodarone-induced thyrotoxicosis: clinical presentation and expanded indications for thyroidectomy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Female; Humans; Male; Middle Aged; Postoperative Complicat | 1993 |
Thyrotoxicosis followed by hypothyroidism in patients treated with amiodarone. A possible consequence of a destructive process in the thyroid.
Topics: Adult; Aged; Amiodarone; Biopsy; Female; Humans; Hypothyroidism; Male; Middle Aged; Thyroiditis; Thy | 1993 |
Amiodarone and the thyroid: pharmacological, toxic and therapeutic effects.
Topics: Amiodarone; Humans; Hypothyroidism; Iodine; Thyroid Gland; Thyroid Hormones; Thyrotoxicosis | 1993 |
[Subtotal thyroidectomy. A treatment to keep in mind in amiodarone-induced thyrotoxicosis].
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Humans; Hyperthyroidism; Male; Thyroidectomy; Thyrotoxico | 1996 |
Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study.
Topics: Adult; Aged; Amiodarone; Drug Therapy, Combination; Female; Humans; Interleukin-6; Male; Methimazole | 1996 |
Ultrastructural evidence of thyroid damage in amiodarone-induced thyrotoxicosis.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Biopsy, Needle; Humans; Male; Microscopy, Electron; Myocar | 1995 |
[Amiodarone and the thyroid].
Topics: Amiodarone; Anti-Arrhythmia Agents; Humans; Hypothyroidism; Thyroid Diseases; Thyroid Gland; Thyroto | 1995 |
A case of amiodarone-induced thyrotoxicosis successfully treated with prednisolone.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Humans; Male; Prednisolone; Tac | 1997 |
[Amiodarone-induced thyrotoxicosis cured by thyroidectomy].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Cardiomyopathy, Hypertrophic; Humans; Male; Midd | 1996 |
Lithium treatment in amiodarone-induced thyrotoxicosis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Drug Therapy, Combination; Humans; Lithium C | 1997 |
Color flow Doppler sonography rapidly differentiates type I and type II amiodarone-induced thyrotoxicosis.
Topics: Adult; Aged; Amiodarone; Antithyroid Agents; Diagnosis, Differential; Female; Glucocorticoids; Goite | 1997 |
Amiodarone and thyroid function.
Topics: Amiodarone; Humans; Thyrotoxicosis | 1997 |
Surgical management of amiodarone-associated thyrotoxicosis: too risky or too effective?
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Female; Humans; Male; Middle Aged; Thyr | 1998 |
Heart failure in thyrotoxicosis, an approach to management.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amiodarone; Antithyroid Agents; Carbimazole; C | 1998 |
Amiodarone-induced thyrotoxicosis associated with thyrotropin receptor antibody.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; Autoantibodie | 1998 |
Potentiation of warfarin sodium by amiodarone-induced thyrotoxicosis.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Drug Synergism; Humans; International Norm | 1999 |
[Thyrotoxicosis induced by amiodarone].
Topics: Amiodarone; Anti-Arrhythmia Agents; Female; Hematoma; Humans; Middle Aged; Postoperative Complicatio | 1998 |
[Thyrotoxicosis induced by amiodarone].
Topics: Amiodarone; Anti-Arrhythmia Agents; Female; Hematoma; Humans; Middle Aged; Postoperative Complicatio | 1998 |
High prevalence of thyroid dysfunction in adult patients with beta-thalassemia major submitted to amiodarone treatment.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; beta-Thalassemia; Female; Humans; Hypothyroidism; Male; T | 1999 |
Plasmapheresis in thyrotoxicosis.
Topics: Adult; Amiodarone; Cardiovascular Diseases; Contraindications; Humans; Male; Middle Aged; Plasmapher | 1999 |
[Iodine-induced hyperthyroidism (iodine-induced Basedow's disease): a current disease picture].
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Contrast Med | 1999 |
Clinical characteristics of amiodarone-induced thyrotoxicosis and hypothyroidism in Japan.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Female; Humans; Hypothyroidism; | 1999 |
Hyperthyroidism in an elderly patient.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Female; Humans; Hyperthyroidism; Thyrotoxicosis | 2000 |
Type II amiodarone-induced thyrotoxicosis and concomitant papillary cancer of the thyroid.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Carcinoma, Papillary; Cardiomyopathy, | 2000 |
Thyroidectomy for selected patients with thyrotoxicosis.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Female; Graves Disease; Humans; Hypocalcemia; Male; Medi | 2001 |
Anaesthesia for amiodarone-induced thyrotoxicosis: a case review.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anesthesia, General; Anesthetics, Intravenous; Anti-Arrh | 2001 |
Electrical storm due to amiodarone induced thyrotoxicosis in a young adult with dilated cardiomyopathy: thyroidectomy as the treatment of choice.
Topics: Adult; Amiodarone; Cardiomyopathy, Dilated; Defibrillators, Implantable; Female; Humans; Tachycardia | 2001 |
Amiodarone-induced thyrotoxicosis: a difficult diagnostic and therapeutic challenge.
Topics: Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Glucocorticoids; Humans; Interleukin-6; Iodi | 2002 |
Clinical experience of amiodarone-induced thyrotoxicosis over a 3-year period: role of colour-flow Doppler sonography.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Antith | 2002 |
Successful treatment of amiodarone-induced thyrotoxicosis.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Autoantibodies; Carbimazole; Cohort Studies; Female; Humans; | 2002 |
Iopanoic acid rapidly controls type I amiodarone-induced thyrotoxicosis prior to thyroidectomy.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Drug Resistance; Enzyme Inhibitors; Female; Humans; Iodide P | 2002 |
Surgical management of amiodarone-associated thyrotoxicosis.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Female; Humans; Male; Middle Age | 2002 |
Subclinical hypothyroidism, overt thyrotoxicosis and subclinical hypothyroidism: the subsequent phases of thyroid function in a patient chronically treated with amiodarone.
Topics: Amiodarone; Antibodies; Humans; Hypothyroidism; Male; Methimazole; Methylprednisolone; Middle Aged; | 1992 |
Iodine-induced subclinical hypothyroidism in euthyroid subjects with a previous episode of amiodarone-induced thyrotoxicosis.
Topics: Amiodarone; Female; Humans; Hypothyroidism; Iodine; Iodine Radioisotopes; Middle Aged; Perchlorates; | 1992 |
Treatment of amiodarone induced thyrotoxicosis with carbimazole alone and continuation of amiodarone.
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Carbimazole; Humans; Male; Middle Aged; Thyrotoxicosi | 1992 |
Life-threatening thyrotoxicosis induced by amiodarone in patients with benign heart disease.
Topics: Aged; Amiodarone; Atrial Fibrillation; Chronic Disease; Female; Humans; Male; Middle Aged; Thyrotoxi | 1992 |
Amiodarone-induced thyrotoxicosis responding to oral steroid therapy.
Topics: Administration, Oral; Amiodarone; Humans; Male; Middle Aged; Prednisolone; Thyrotoxicosis | 1992 |
[Kordaron and functional disorders of the thyroid gland].
Topics: Adult; Amiodarone; Atrial Fibrillation; Humans; Male; Middle Aged; Thyroid Function Tests; Thyroid G | 1991 |
Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Analysis of Variance; Female; Follow-Up Studies; Humans; | 1991 |
Goiter and hypothyroidism during re-treatment with amiodarone in a patient who previously experienced amiodarone-induced thyrotoxicosis.
Topics: Amiodarone; Female; Goiter; Humans; Hypothyroidism; Middle Aged; Tachycardia, Supraventricular; Thyr | 1991 |
The effects of plasmapheresis on thyroid hormone and plasma drug concentrations in amiodarone-induced thyrotoxicosis.
Topics: Aged; Amiodarone; Humans; Male; Pharmaceutical Preparations; Plasmapheresis; Thyroid Hormones; Thyro | 1991 |
Amiodarone-induced thyrotoxicosis suggestive of thyroid damage.
Topics: Adult; Amiodarone; Humans; Male; Middle Aged; Thyroglobulin; Thyroid Gland; Thyrotoxicosis; Thyrotro | 1990 |
Thyroidectomy for amiodarone-induced thyrotoxicosis.
Topics: Amiodarone; Humans; Male; Middle Aged; Thyroid Function Tests; Thyroidectomy; Thyrotoxicosis | 1990 |
Amiodarone-related cyclic thyroid dysfunction.
Topics: Adolescent; Amiodarone; Humans; Hyperthyroidism; Hypothyroidism; Male; Recurrence; Thyroiditis, Auto | 1989 |
Rapid effectiveness of prednisone and thionamides combined therapy in severe amiodarone iodine-induced thyrotoxicosis. Comparison of two groups of patients with apparently normal thyroid glands.
Topics: Adult; Aged; Amiodarone; Carbimazole; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; | 1989 |
Anaplastic carcinoma of the thyroid in a patient receiving radio-iodine therapy for amiodarone-induced thyrotoxicosis.
Topics: Amiodarone; Carcinoma; Humans; Iodine Radioisotopes; Male; Middle Aged; Neoplasms, Radiation-Induced | 1989 |
Dexamethasone treatment of amiodarone-induced thyrotoxicosis (AIT) with or without persistent administration of the drug.
Topics: Amiodarone; Dexamethasone; Humans; Male; Middle Aged; Propylthiouracil; Tachycardia; Thyrotoxicosis | 1989 |
Thionamides and iodide in iodine-induced thyrotoxicosis.
Topics: Amiodarone; Humans; Iodine; Thyrotoxicosis | 1989 |
More on KCl0(4) and amiodarone associated thyrotoxicosis.
Topics: Aged; Amiodarone; Humans; Male; Perchlorates; Potassium; Potassium Compounds; Thyrotoxicosis | 1988 |
Amiodarone: a common source of iodine-induced thyrotoxicosis.
Topics: Adult; Aged; Amiodarone; Drug Therapy, Combination; Female; Humans; Immunoglobulin G; Immunoglobulin | 1987 |
Amiodarone and the thyroid: the Janus response.
Topics: Amiodarone; Humans; Thyroid Gland; Thyrotoxicosis | 1987 |
Treatment of amiodarone associated thyrotoxicosis by simultaneous administration of potassium perchlorate and methimazole.
Topics: Adult; Aged; Amiodarone; Drug Synergism; Drug Therapy, Combination; Female; Goiter; Humans; Male; Me | 1986 |
[Worsening of asthma in amiodarone-induced thyrotoxicosis].
Topics: Aged; Amiodarone; Asthma; Female; Humans; Thyrotoxicosis | 1988 |
Serum thyroglobulin concentration may be a clue to the mechanism of amiodarone-induced thyrotoxicosis.
Topics: Amiodarone; Humans; Middle Aged; Thyroglobulin; Thyrotoxicosis | 1988 |
Suppression of thyroglobulin secretion in amiodarone iodine-induced thyrotoxicosis.
Topics: Adult; Amiodarone; Humans; Male; Thyroglobulin; Thyrotoxicosis; Ventricular Fibrillation | 1988 |
Diagnosis of amiodarone-iodine-induced thyrotoxicosis(AIIT) associated with severe nonthyroidal illness.
Topics: Aged; Amiodarone; Diagnosis, Differential; Humans; Hyperthyroidism; Iodine; Male; Sex Hormone-Bindin | 1987 |
Amiodarone-associated thyrotoxicosis masquerading as painful thyroiditis.
Topics: Amiodarone; Diagnosis, Differential; Humans; Male; Middle Aged; Pain; Thyroiditis, Subacute; Thyroto | 1987 |
Serum sex hormone-binding globulin in amiodarone-treated patients. A marker for tissue thyrotoxicosis.
Topics: Aged; Amiodarone; Female; Humans; Male; Middle Aged; Sex Hormone-Binding Globulin; Thyrotoxicosis; T | 1987 |
Amiodarone-associated thyrotoxicosis (AAT): experience with surgical management.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Female; Humans; Male; Middle Aged; Thyroidectomy; T | 1987 |
Is humoral thyroid autoimmunity relevant in amiodarone iodine-induced thyrotoxicosis (AIIT)?
Topics: Adult; Aged; Amiodarone; Antibody Formation; Autoantibodies; Female; Humans; Male; Middle Aged; Thyr | 1986 |
Amiodarone-induced thyroid gland dysfunction.
Topics: Amiodarone; Female; Humans; Hypothyroidism; Iodine; Male; Tachycardia; Thyroid Diseases; Thyroid Gla | 1987 |
Pathology of the thyroid in amiodarone-associated thyrotoxicosis.
Topics: Adult; Aged; Amiodarone; Female; Humans; Male; Microscopy, Electron; Middle Aged; Thyroid Gland; Thy | 1987 |